[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Inion Ltd.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":329},{"warningLetters":4,"total":328},[5,31,54,76,99,117,138,160,181,199,218,237,256,275,295,311],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},21724,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-09-22T04:00:00Z\">09\u002F22\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-27T04:00:00Z\">08\u002F27\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funion-trade-inc-729071-08272026\">Union Trade Inc.\u003C\u002Fa>","Office of Inspections and Investigations","Foreign Supplier Verification Program (FSVP)","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Xu Chen\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Union Trade Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>333 City Blvd W Ste 1210\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Orange\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92868-5908\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Inspections and Investigations\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 27, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS # 729071\u003C\u002Fp>\u003Cp>Dear Mr. Chen:\u003C\u002Fp>\u003Cp>On April 06, 2026 and April 07, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Union Trade Inc. located at 333 City Blvd W Ste 1210, Orange CA 92868-5908. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable United States food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplierverification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods from foreign suppliers indicated in the attached list. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\u003C\u002Fp>\u003Cp>We acknowledge receipt of your response, dated April 9, 2026, in which you described intended corrective actions for all six observations noted on the FDA 483a. You stated that you will revise the FSVP program, update supplier evaluation forms and risk classification matrix, complete hazard analyses and evaluations within 60 days, and have an FSVP for all products within 90 days. You also committed to developing hazard analyses for crisp radish and dried mushrooms within 5 business days, completing hazard analyses for all products within 2 months, revising FSVP written procedures for verification activities within 10 business days, and pausing importation of any products that do not have a hazard analysis. You promised to conduct a supplier evaluation for \u003Cstrong>(b)(4)\u003C\u002Fstrong> within 5 business days, and to document corrective actions for the dried mushrooms within 3 business days. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your planned or completed corrective actions. To date, no additional FSVP documents have been received by FDA.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cp>1. You did not develop, maintain, and follow an FSVP, as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for the foods you import from the foreign suppliers indicated in the attached list, including each of the following foods:\u003C\u002Fp>\u003Cul>\u003Cli>crisp radish imported from \u003Cstrong>(b)(4) \u003C\u002Fstrong>located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>peanut, in shell imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> (subtropical and tropical fruit) from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>2. You did not document that you took appropriate corrective actions after you determined that a foreign supplier of food you import does not produce the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the FD&amp;C Act, if either is applicable, and the implementing regulations or produced food that is adulterated under section 402 or misbranded under section 403(w) (if applicable) of the FD&amp;C Act, as required by 21 CFR 1.508(a). Specifically, dried mushrooms manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were found to contain undeclared sulfites, which resulted in two Class 2 recalls, but you did not provide any documentation to show that you took corrective actions as a result of this finding. We note that your FSVP Program Overview states that if a supplier or product is found to present a food safety concern, appropriate corrective actions will be taken and all actions will be documented. Under 21 CFR 1.508(a), the appropriate corrective actions will depend on the circumstances but could include discontinuing use of the foreign supplier until the cause or causes of noncompliance, adulteration, or misbranding have been adequately addressed.\u003C\u002Fp>\u003Cp>Your response indicates that for your dried mushrooms from \u003Cstrong>(b)(4)\u003C\u002Fstrong> you would document your corrective actions within three business days. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your corrective actions.\u003C\u002Fp>\u003Cp>3. You did not conduct a hazard analysis for each type of food you import to determine whether there are any hazards requiring a control, as required by 21 CFR 1.504(a). Although you may meet this requirement by reviewing and assessing the hazard analysis conducted by another entity using a qualified individual, you must document your review and assessment of the hazard analysis, including documenting that the hazard analysis was conducted by a qualified individual (21 CFR 1.504(d)). During the inspection, you provided FSVP documents for your dried mushrooms imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, that included a supplier evaluation, supplier compliance statement, HACCP System Certificate, \u003Cstrong>(b)(4) \u003C\u002Fstrong>Certificate and \u003Cstrong>(b)(4)\u003C\u002Fstrong> analytical report. Although your written response indicates that you will develop a hazard analysis for dried mushrooms within five business days, you did not provide documentation during the inspection or in your response that you have conducted a hazard analysis or reviewed and assessed a hazard analysis conducted by another entity, as required by 21 CFR 1.504(d).\u003C\u002Fp>\u003Cp>4. You did not meet the requirements to perform foreign supplier verification activities in accordance with 21 CFR 1.506(e) for the products you import. Specifically, you did not document your determination or performance of appropriate supplier verification activities for your dried mushrooms imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. During the inspection, you provided FSVP documents that included a supplier evaluation, supplier compliance statement, a HACCP System Certificate, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Certification and \u003Cstrong>(b)(4) \u003C\u002Fstrong>heavy metal analytical report, as well as an FSVP Program Overview that includes a Risk Classification and Verification Matrix, that are listed as documentation of your approval of the supplier. To the extent these records that could be used to satisfy the requirements to perform verification activities, you did not determine and document which verification activity or activities, as well as the frequency with which the activity or activities must be conducted, are needed to provide adequate assurances that the food you obtain from the foreign supplier is produced in accordance with 21 CFR 1.506(c), as required by 21 CFR 1.506(d). Furthermore, you did not establish written procedures for ensuring that appropriate supplier verification activities are conducted in accordance with 21 CFR 1.506(b).\u003C\u002Fp>\u003Cp>While your written response dated April 9, 2026, indicated that you will revise your FSVP written procedures for verification activities within 10 business days and develop verification activities for dried mushrooms from \u003Cstrong>(b)(4)\u003C\u002Fstrong> within five business days, you did provide any supporting documentation demonstrating your corrective actions.\u003C\u002Fp>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>Additionally, we offer the following comment:\u003C\u002Fp>\u003Cp>Your supplier evaluation for dried mushrooms from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated June 5, 2025, included records that include a HACCP System Certificate and \u003Cstrong>(b)(4) \u003C\u002Fstrong>Certification. However, these documents alone do not demonstrate that you have approved your foreign suppliers on the basis of an evaluation of your foreign supplier’s performance and the risk posed by the food, in accordance with 21 CFR 1.505(a), for the products you import. In approving your foreign suppliers and determining the appropriate supplier verification activities, you must consider the hazard analysis of the food conducted per 21 CFR 1.504, including the nature of the hazard requiring a control, as required by 21 CFR 1.505(a)(1)(i). You must also consider the foreign supplier’s procedures, processes, and practices related to the safety of the food, as required by 1.505(a)(1)(iii)(A), and the applicable FDA food safety regulations and information relevant to the foreign supplier’s compliance with those regulations, as required by 21 CFR 1.505(a)(1)(iii)(B).\u003C\u002Fp>\u003Cp>In your written response dated April 9, 2026, you stated that you had already decided not to purchase any dried mushrooms from \u003Cstrong>(b)(4)\u003C\u002Fstrong> upon being notified of the two Class 2 recalls for undeclared sulfites. We note that if you resume importing food from this foreign supplier, under 21 CFR 1.505(c), you must promptly reevaluate the concerns associated with the factors under 21 CFR 1.505(a)(1), regarding the foreign supplier's performance, including applicable FDA food safety regulations and information relevant to the foreign supplier's compliance with those regulations, including whether the foreign supplier is the subject of an FDA warning letter, import alert, recalls, or other FDA compliance action related to food safety, per 21 CFR 1.505(a)(ii)(B). You must also document any investigations, corrective actions, and changes to your FSVP that you undertake (21 CFR 1.508(b)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Celena Ngo, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, or wish to send your response electronically, you may contact Celena Ngo via email at celena.ngo@fda.hhs.gov. Please reference CMS # 729071 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Dr. Kathleen Turner\u003Cbr>Program Division Director\u003Cbr>Division of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nXu Chen\n\nRecipient Title\n\nChief Executive Officer\n\nUnion Trade Inc.\n\n333 City Blvd W Ste 1210\n\nOrange, CA 92868-5908\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nOffice of Inspections and Investigations\n\nUnited States\n\nAugust 27, 2026\nWARNING LETTER\nRe: CMS # 729071\nDear Mr. Chen:\nOn April 06, 2026 and April 07, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Union Trade Inc. located at 333 City Blvd W Ste 1210, Orange CA 92868-5908. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable United States food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplierverification-programs-fsvp-importers-food-humans-and-animals.\nDuring the inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods from foreign suppliers indicated in the attached list. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\nWe acknowledge receipt of your response, dated April 9, 2026, in which you described intended corrective actions for all six observations noted on the FDA 483a. You stated that you will revise the FSVP program, update supplier evaluation forms and risk classification matrix, complete hazard analyses and evaluations within 60 days, and have an FSVP for all products within 90 days. You also committed to developing hazard analyses for crisp radish and dried mushrooms within 5 business days, completing hazard analyses for all products within 2 months, revising FSVP written procedures for verification activities within 10 business days, and pausing importation of any products that do not have a hazard analysis. You promised to conduct a supplier evaluation for (b)(4) within 5 business days, and to document corrective actions for the dried mushrooms within 3 business days. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your planned or completed corrective actions. To date, no additional FSVP documents have been received by FDA.\nYour significant violations of the FSVP regulation are as follows:\n1. You did not develop, maintain, and follow an FSVP, as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for the foods you import from the foreign suppliers indicated in the attached list, including each of the following foods:\ncrisp radish imported from (b)(4) located in (b)(4).\npeanut, in shell imported from (b)(4), located in (b)(4)\n(b)(4) (subtropical and tropical fruit) from (b)(4), located in (b)(4)\n2. You did not document that you took appropriate corrective actions after you determined that a foreign supplier of food you import does not produce the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the FD&C Act, if either is applicable, and the implementing regulations or produced food that is adulterated under section 402 or misbranded under section 403(w) (if applicable) of the FD&C Act, as required by 21 CFR 1.508(a). Specifically, dried mushrooms manufactured by (b)(4), were found to contain undeclared sulfites, which resulted in two Class 2 recalls, but you did not provide any documentation to show that you took corrective actions as a result of this finding. We note that your FSVP Program Overview states that if a supplier or product is found to present a food safety concern, appropriate corrective actions will be taken and all actions will be documented. Under 21 CFR 1.508(a), the appropriate corrective actions will depend on the circumstances but could include discontinuing use of the foreign supplier until the cause or causes of noncompliance, adulteration, or misbranding have been adequately addressed.\nYour response indicates that for your dried mushrooms from (b)(4) you would document your corrective actions within three business days. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your corrective actions.\n3. You did not conduct a hazard analysis for each type of food you import to determine whether there are any hazards requiring a control, as required by 21 CFR 1.504(a). Although you may meet this requirement by reviewing and assessing the hazard analysis conducted by another entity using a qualified individual, you must document your review and assessment of the hazard analysis, including documenting that the hazard analysis was conducted by a qualified individual (21 CFR 1.504(d)). During the inspection, you provided FSVP documents for your dried mushrooms imported from (b)(4), that included a supplier evaluation, supplier compliance statement, HACCP System Certificate, (b)(4) Certificate and (b)(4) analytical report. Although your written response indicates that you will develop a hazard analysis for dried mushrooms within five business days, you did not provide documentation during the inspection or in your response that you have conducted a hazard analysis or reviewed and assessed a hazard analysis conducted by another entity, as required by 21 CFR 1.504(d).\n4. You did not meet the requirements to perform foreign supplier verification activities in accordance with 21 CFR 1.506(e) for the products you import. Specifically, you did not document your determination or performance of appropriate supplier verification activities for your dried mushrooms imported from (b)(4), located in (b)(4). During the inspection, you provided FSVP documents that included a supplier evaluation, supplier compliance statement, a HACCP System Certificate, (b)(4) Certification and (b)(4) heavy metal analytical report, as well as an FSVP Program Overview that includes a Risk Classification and Verification Matrix, that are listed as documentation of your approval of the supplier. To the extent these records that could be used to satisfy the requirements to perform verification activities, you did not determine and document which verification activity or activities, as well as the frequency with which the activity or activities must be conducted, are needed to provide adequate assurances that the food you obtain from the foreign supplier is produced in accordance with 21 CFR 1.506(c), as required by 21 CFR 1.506(d). Furthermore, you did not establish written procedures for ensuring that appropriate supplier verification activities are conducted in accordance with 21 CFR 1.506(b).\nWhile your written response dated April 9, 2026, indicated that you will revise your FSVP written procedures for verification activities within 10 business days and develop verification activities for dried mushrooms from (b)(4) within five business days, you did provide any supporting documentation demonstrating your corrective actions.\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nAdditionally, we offer the following comment:\nYour supplier evaluation for dried mushrooms from (b)(4), dated June 5, 2025, included records that include a HACCP System Certificate and (b)(4) Certification. However, these documents alone do not demonstrate that you have approved your foreign suppliers on the basis of an evaluation of your foreign supplier’s performance and the risk posed by the food, in accordance with 21 CFR 1.505(a), for the products you import. In approving your foreign suppliers and determining the appropriate supplier verification activities, you must consider the hazard analysis of the food conducted per 21 CFR 1.504, including the nature of the hazard requiring a control, as required by 21 CFR 1.505(a)(1)(i). You must also consider the foreign supplier’s procedures, processes, and practices related to the safety of the food, as required by 1.505(a)(1)(iii)(A), and the applicable FDA food safety regulations and information relevant to the foreign supplier’s compliance with those regulations, as required by 21 CFR 1.505(a)(1)(iii)(B).\nIn your written response dated April 9, 2026, you stated that you had already decided not to purchase any dried mushrooms from (b)(4) upon being notified of the two Class 2 recalls for undeclared sulfites. We note that if you resume importing food from this foreign supplier, under 21 CFR 1.505(c), you must promptly reevaluate the concerns associated with the factors under 21 CFR 1.505(a)(1), regarding the foreign supplier's performance, including applicable FDA food safety regulations and information relevant to the foreign supplier's compliance with those regulations, including whether the foreign supplier is the subject of an FDA warning letter, import alert, recalls, or other FDA compliance action related to food safety, per 21 CFR 1.505(a)(ii)(B). You must also document any investigations, corrective actions, and changes to your FSVP that you undertake (21 CFR 1.508(b)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Celena Ngo, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, or wish to send your response electronically, you may contact Celena Ngo via email at celena.ngo@fda.hhs.gov. Please reference CMS # 729071 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nDr. Kathleen Turner\nProgram Division Director\nDivision of West Coast Imports","Union Trade Inc.","union-trade-inc-729071-08272026","2026-10-14T12:31:16.41489+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funion-trade-inc-729071-08272026","2026-11-03T01:02:17.615107+00:00","Warning Letter","Issued","2026-09-22","729071","Food & Beverages","Xu Chen","2026-10-14T12:37:04.147+00:00","Via Express Delivery","2026-08-27",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":49,"recipient_name":50,"body_fetched_at":51,"delivery_method":52,"recipient_title":19,"reference_number":19,"action_taken_date":53,"medical_device_id":19,"response_letter_date":19},1967,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2023-08-01T13:20:00Z\">08\u002F01\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-07-18T04:00:00Z\">07\u002F18\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Favlon-industries-inc-652903-07182023\">Avlon Industries, Inc.\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations III","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS Next Day\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Ali N. Syed\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Co-President\u002FChairman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Avlon Industries, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1999 N. 15th Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Melrose Park\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60160\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>July 18, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nWL #652903\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Dr. Syed:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Avlon Industries, Inc., FEI 3007090726, at 1999 N. 15th Avenue, Melrose Park, from January 17 to 24, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your February 13, 2023 response and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to test your incoming components for identity prior to manufacturing your over-the-counter (OTC) drug products (e.g., active ingredients, glycerin, and water as a component). Additionally, you relied on certificates of analysis (COAs) from unqualified suppliers for specifications such as purity, strength, and quality. By not adequately analyzing your components for identity, purity, strength, and quality, you failed to ensure your incoming components meet appropriate specifications.\u003C\u002Fp>\n\n\u003Cp>Identity testing for each shipment of each lot of components used in drug product manufacturing is required, and you may only rely on COA for other component attributes by validating the suppliers’ test results at appropriate intervals.\u003C\u002Fp>\n\n\u003Cp>Glycerin and propylene glycol are ingredients used in some of your drug products, including Keracare® Dry &amp; Itchy Scalp Anti-Dandruff Moisturizing Conditioner and As I Am Dry &amp; Itchy Scalp Care Dandruff Conditioner, and are examples of components with higher risk of DEG or EG contamination compared to other drug components. The identity testing of glycerin and other high-risk components such as propylene glycol may include a limit test per the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for the levels of diethylene glycol (DEG) or ethylene glycol (EG). Because you did not perform the identity testing on each container on each shipment of each high-risk drug component lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of the high-risk components used in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>The use of glycerin or propylene glycol contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at risk for DEG or EG contamination, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Results of tests for DEG and EG in retain samples of all glycerin lots or any other high-risk components (such as propylene glycol) used to manufacture your drug products.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including but not limited to glycerin). Take prompt and appropriate actions to determine the safety of all lots of the ingredient(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures. (21 CFR 211.100(a) and 211.100(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Lack of Process Validation\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You failed to provide data to demonstrate that you adequately validate your manufacturing processes used to manufacture your OTC drug products and demonstrate that your processes are reproducible and controlled to consistently yield drugs of uniform character and quality.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>See FDA's guidance for industry, \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Lack of Cleaning Validation\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You failed to provide evidence that you performed cleaning validation for the equipment (e.g., mixing tanks, hoses, filling lines, and packaging lines) used to manufacture your OTC drug products. This is a repeat observation from the 2017 FDA inspection. Additionally, you lacked cleaning and usage logs for production tanks (i.e., kettles), or any holding tanks used in manufacturing your bulk drug products.\u003C\u002Fp>\n\n\u003Cp>You manufacture drug products using the same equipment that you use to manufacture nonpharmaceutical products such as cosmetics. Chemical and microbiological residues on equipment from previous manufacturing activities can adversely impact the purity, quality, and safety of drug products also manufactured on that equipment.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate Water System\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm uses water as a component to manufacture your OTC drug products. You failed to provide documentation that you performed a qualification of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water system. You also failed to show that your water system is monitored adequately to ensure it consistently produces water that meets appropriate microbial limits. Routine monitoring of microbial counts and identity of contamination in the system is integral to ensuring oversight of ongoing state of control and suitability of water for use in manufacturing operations. These are repeat observations from the 2017 FDA inspection.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\n\t\u003Cli>A timeline for performing appropriate process performance qualification for each of your marketed drug products.\u003C\u002Fli>\n\t\u003Cli>Include your process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\n\t\u003Cli>Provide a detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\n\t\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Drugs with higher toxicities\u003Cbr>\n&nbsp; &nbsp; o Drugs with higher drug potencies\u003Cbr>\n&nbsp; &nbsp; o Drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; &nbsp; o Drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Maximum hold times before cleaning\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\n\t\u003Cli>A comprehensive remediation plan for the design, control, and maintenance of the water system, including a \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\u003C\u002Fli>\n\t\u003Cli>A procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\n\t\u003Cli>The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water system. Ensure that the total count limits for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water are appropriately stringent in view of the intended use of each of the products produced by your firm.\u003C\u002Fli>\n\t\u003Cli>A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces water that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity. (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) did not provide adequate oversight for the manufacture of your OTC drug products. FDA investigators observed multiple documents related to CGMP activities that had not been completed, such as:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>CGMP-related policies\u003C\u002Fli>\n\t\u003Cli>Standard operating procedures (SOPs)\u003C\u002Fli>\n\t\u003Cli>Validation plans\u003C\u002Fli>\n\t\u003Cli>Stability program\u003C\u002Fli>\n\t\u003Cli>Corrective actions and preventive actions (CAPA)\u003C\u002Fli>\n\t\u003Cli>Annual product review (APR)\u003C\u002Fli>\n\t\u003Cli>CGMP training\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>An adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003Cbr>\n\u003Cbr>\nIn response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A complete assessment of documentation systems used throughout your manufacturing operations, to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices, to ensure you retain attributable, legible, complete, original, accurate, and contemporaneous records throughout your operation.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Russell K. Riley\u003Cbr>\nCompliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Case Number above (#652903). If you have questions regarding the contents of the letter, please contact Mr. Riley at (630) 277-1908.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CDR Jeffrey D. Meng\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>_______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e. Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS Next Day\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDr. Ali N. Syed\n\nRecipient Title\n\nCo-President\u002FChairman\n\nAvlon Industries, Inc.\n\n1999 N. 15th Avenue\n\nMelrose Park, IL 60160\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations III\n\nUnited States\n\nJuly 18, 2023\n\nWARNING LETTER\n\nWL #652903\n\nDear Dr. Syed:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Avlon Industries, Inc., FEI 3007090726, at 1999 N. 15th Avenue, Melrose Park, from January 17 to 24, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your February 13, 2023 response and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nYour firm failed to test your incoming components for identity prior to manufacturing your over-the-counter (OTC) drug products (e.g., active ingredients, glycerin, and water as a component). Additionally, you relied on certificates of analysis (COAs) from unqualified suppliers for specifications such as purity, strength, and quality. By not adequately analyzing your components for identity, purity, strength, and quality, you failed to ensure your incoming components meet appropriate specifications.\n\nIdentity testing for each shipment of each lot of components used in drug product manufacturing is required, and you may only rely on COA for other component attributes by validating the suppliers’ test results at appropriate intervals.\n\nGlycerin and propylene glycol are ingredients used in some of your drug products, including Keracare® Dry & Itchy Scalp Anti-Dandruff Moisturizing Conditioner and As I Am Dry & Itchy Scalp Care Dandruff Conditioner, and are examples of components with higher risk of DEG or EG contamination compared to other drug components. The identity testing of glycerin and other high-risk components such as propylene glycol may include a limit test per the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for the levels of diethylene glycol (DEG) or ethylene glycol (EG). Because you did not perform the identity testing on each container on each shipment of each high-risk drug component lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of the high-risk components used in the manufacture of your drug products.\n\nThe use of glycerin or propylene glycol contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at risk for DEG or EG contamination, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nIn response to this letter, provide:\n\nResults of tests for DEG and EG in retain samples of all glycerin lots or any other high-risk components (such as propylene glycol) used to manufacture your drug products.\n\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including but not limited to glycerin). Take prompt and appropriate actions to determine the safety of all lots of the ingredient(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\n\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\n\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures. (21 CFR 211.100(a) and 211.100(b)).\n\nLack of Process Validation\n\nYou failed to provide data to demonstrate that you adequately validate your manufacturing processes used to manufacture your OTC drug products and demonstrate that your processes are reproducible and controlled to consistently yield drugs of uniform character and quality.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nSee FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\nLack of Cleaning Validation\n\nYou failed to provide evidence that you performed cleaning validation for the equipment (e.g., mixing tanks, hoses, filling lines, and packaging lines) used to manufacture your OTC drug products. This is a repeat observation from the 2017 FDA inspection. Additionally, you lacked cleaning and usage logs for production tanks (i.e., kettles), or any holding tanks used in manufacturing your bulk drug products.\n\nYou manufacture drug products using the same equipment that you use to manufacture nonpharmaceutical products such as cosmetics. Chemical and microbiological residues on equipment from previous manufacturing activities can adversely impact the purity, quality, and safety of drug products also manufactured on that equipment.\n\nInadequate Water System\n\nYour firm uses water as a component to manufacture your OTC drug products. You failed to provide documentation that you performed a qualification of your (b)(4) Water system. You also failed to show that your water system is monitored adequately to ensure it consistently produces water that meets appropriate microbial limits. Routine monitoring of microbial counts and identity of contamination in the system is integral to ensuring oversight of ongoing state of control and suitability of water for use in manufacturing operations. These are repeat observations from the 2017 FDA inspection.\n\n(b)(4) water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\n\nIn response to this letter, provide:\n\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\nA timeline for performing appropriate process performance qualification for each of your marketed drug products.\n\nInclude your process performance protocol(s), and written procedures for qualification of equipment and facilities.\n\nProvide a detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\n\no Drugs with higher toxicities\n\no Drugs with higher drug potencies\n\no Drugs of lower solubility in their cleaning solvents\n\no Drugs with characteristics that make them difficult to clean\n\no Swabbing locations for areas that are most difficult to clean\n\no Maximum hold times before cleaning\n\nA summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\nA comprehensive remediation plan for the design, control, and maintenance of the water system, including a (b)(4) water system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\n\nA procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\n\nThe current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4) Water system. Ensure that the total count limits for your (b)(4) water are appropriately stringent in view of the intended use of each of the products produced by your firm.\n\nA procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces water that meets (b)(4) Water, USP monograph specifications and appropriate microbial limits.\n\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity. (21 CFR 211.22).\n\nYour quality unit (QU) did not provide adequate oversight for the manufacture of your OTC drug products. FDA investigators observed multiple documents related to CGMP activities that had not been completed, such as:\n\nCGMP-related policies\n\nStandard operating procedures (SOPs)\n\nValidation plans\n\nStability program\n\nCorrective actions and preventive actions (CAPA)\n\nAnnual product review (APR)\n\nCGMP training\n\nAn adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nA complete assessment of documentation systems used throughout your manufacturing operations, to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices, to ensure you retain attributable, legible, complete, original, accurate, and contemporaneous records throughout your operation.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\n\nAttention: Russell K. Riley\n\nCompliance Officer\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations III\n\nYour written notification should refer to the Warning Letter Case Number above (#652903). If you have questions regarding the contents of the letter, please contact Mr. Riley at (630) 277-1908.\n\nSincerely,\n\n\u002FS\u002F\n\nCDR Jeffrey D. Meng\n\nProgram Division Director\n\nDivision of Pharmaceutical Quality Operations III\n\n_______________________\n\n1 i.e. Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Avlon Industries, Inc.","avlon-industries-inc-652903-07182023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Favlon-industries-inc-652903-07182023","2026-10-26T08:07:59.687766+00:00","2023-08-01","652903","Drugs","Division of Pharmaceutical Quality Operations III","Dr. Ali N. Syed","2026-08-20T00:49:39.857+00:00","UPS Next Day","2023-07-18",{"id":55,"raw":56,"subject":61,"body_html":63,"body_text":64,"firm_name":65,"letter_id":66,"created_at":67,"fei_number":19,"letter_url":68,"updated_at":69,"action_type":22,"case_status":70,"posted_date":71,"marcs_cms_no":72,"product_type":26,"closeout_date":71,"issuing_office":60,"recipient_name":73,"body_fetched_at":74,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":75,"medical_device_id":19,"response_letter_date":19},2396,[57,58,59,60,61,13,62,13],"\u003Ctime datetime=\"2022-10-18T13:20:00Z\">10\u002F18\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-04-20T04:00:00Z\">04\u002F20\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthai-union-group-plc-630100-04202022\">Thai Union Group PLC\u003C\u002Fa>","Center for Food Safety and Applied Nutrition","Seafood HACCP\u002FCGMP for Foods\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthai-union-group-plc-630100-09082022\">\u003Ctime datetime=\"2022-10-18T04:00:00Z\">10\u002F18\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Wachira Katueang-Ngan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Quality Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Thai Union Group PLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>72\u002F1 Moo 7 Sethakit 1 Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tambon Tarsrai\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Amphoe\u003C\u002Fspan>, \u003Cspan>Mueang\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Samut Sakhon\u003C\u002Fspan> \u003Cspan>74000\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Thailand\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 20, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Reference # 630100\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Wachira Katueang-Ngan:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted a Foreign Remote Regulatory Assessment (FRRA) of your seafood processing facility, Thai Union Group PLC, located at 72\u002F1 Moo 7 Sethakit 1 Road, Tambon Tarsrai, Amphoe Mueang Samutsakhon, Samutsakhon, 74000, Thailand on January 18-20 &amp; 25, 2022. An on-site inspection was not possible due to travel restrictions during the COVID-19 pandemic. During the remote assessment, we found that you had serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations (21 CFR Part 123). At the conclusion of the assessment, the FDA investigator discussed items of concern. We acknowledge your email responses dated, February 1, 2022, and March 1, 2022, to the discussion items identified during the FRRA.\u003C\u002Fp>\n\n\u003Cp>In accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your frozen, pre-cooked tuna loin products are adulterated, in that they have been prepared, packed, or held under conditions whereby they may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation and the 4th Edition of the Fish and Fisheries Products Hazards and Controls Guidance (the Hazards Guide) through links in FDA's home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Your significant deviations are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You must have a HACCP plan that at minimum lists the critical limits that must be met, to comply with 21 CFR 123.6 (c)(3). A critical limit is defined in 21 CFR 123.3 (c) as the “the maximum or minimum value to which a physical, biological, or chemical parameter must be controlled at a critical control point to prevent, eliminate, or reduce to an acceptable level the occurrence of the identified food safety hazard. However, your firm’s HACCP Plan for frozen precooked tuna loins lists a critical limit of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” at the Precooking critical control point (CCP 11) that is not adequate to control scombrotoxin (histamine) formation. FDA recommends you establish critical limits for the minimum or maximum values for the critical factors established by a scientific study, which may include length of the cook cycle, speed of the belt for a continuous cooker, temperature of the steam or water used for cooking, initial temperature of the product, product form (loin, whole fish, etc.), and any other critical factors that affect the rate of heating the product. Alternatively, you may establish a value for the end product internal product temperature (EPIPT), established by a scientific study.\u003C\u002Fp>\n\n\u003Cp>Your Temperature Distribution Testing Report and Heat Penetration Testing Report provided during the inspection do not support the listed critical limit of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003Cbr>\na. The Temperature Distribution Testing Report documents the result of temperature distribution within “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” located at “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” but the Heat Penetration Testing Report documents results for “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” located at “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” In order to scientifically validate the cooking process, the scientific studies used to establish critical limits should be conducted for and applied to each individual cook tunnel.\u003Cbr>\nb. Although the “Test Procedure” section of the Heat Penetration Testing Report states that the thermocouples (TC) should be placed in the geometric center of the product at the thickest point near the backbone,” the photos on page 3 of the report show temperature sensors placed in tuna loins and not in whole, headed and gutted or any tunas with backbones. It does not appear that the heat penetration study is representative of the whole tuna processed under the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” HACCP plan, which lists the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” step as occurring after the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” step.\u003C\u002Fp>\n\n\u003Cp>Additionally, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” is identified as the scheduled process of precooked tuna (For USA) and includes Skipjack, Bigeye, Yellowfin, and Albacore tuna. The document lists multiple sizes for each species and a corresponding “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” It is unclear how this document relates to the listed critical limit of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” or how it relates to the Heat Penetration Testing Report. Since multiple sized batches are processed, the critical limit should include ensuring each fish of each batch weighs less than a specific maximum size to ensure that all fish are processed to achieve a uniform heat penetration with a minimum internal temperature of 60°C.\u003C\u002Fp>\n\n\u003Cp>2. You must have a HACCP Plan that at minimum lists monitoring procedures and their frequency for each critical control point, to comply with 21 CFR 123.6(c)(4). However, your firm’s HACCP plan for frozen precooked tuna loins lists a monitoring frequency at the following critical control points that is not adequate. Specifically:\u003Cbr>\n\u003Cbr>\na. The unrefrigerated processing critical control points for steps “3-19” (CCP 10) lists a monitoring frequency of “-Every bin of raw material -Every trolley of precooked fish” that is not adequate to control scombrotoxin (histamine) formation because it does not include a unit of time between measurements. FDA recommends monitoring cumulative exposure time at a frequency of every 2 hours.\u003Cbr>\nb. The unrefrigerated processing critical control point for steps “19-33, 44” (CCP 12) lists a monitoring frequency of “-Every precooked fish trolley” that is not adequate to control scombrotoxin (histamine) formation because it does not include a unit of time between measurements. FDA recommends monitoring cumulative exposure time at a frequency of every 2 hours.\u003Cbr>\nc. The unrefrigerated processing critical control point for steps “22-33,40” (CCP13) lists a monitoring frequency of “-Every precooked fish trolley” that is not adequate to control \u003Cem>Staphylococcus aureus\u003C\u002Fem> growth and toxin formation because it does not include a unit of time between measurements. FDA recommends monitoring cumulative exposure time at a frequency of every 2 hours.\u003C\u002Fp>\n\n\u003Cp>3. You must implement the monitoring procedures and frequency that you have listed in your HACCP Plan, to comply with 21 CFR 123.6(b) and (c)(4). However, your firm did not follow the monitoring procedure of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” at the unrefrigerated processing critical control point for steps “3-19” (CCP 10) to control scombrotoxin (histamine) formation. FDA recommends continuous ambient temperature monitoring (air and water surrounding fish) from the time a lot of fish exits cold storage until the time a lot of fish enters the \u003Cstrong>(b)(4)\u003C\u002Fstrong> step.\u003C\u002Fp>\n\n\u003Cp>According to your submitted Corrective Action report, [the] “production department has designated PD Staffs to check temperature of water in the fish tank by thermometer at the end of \u003Cstrong>(b)(4)\u003C\u002Fstrong> step. PD staffs has recorded its temperature for monitoring the temperature control at \u003Cstrong>(b)(4)\u003C\u002Fstrong> step.” Monitoring the water temperature at the end of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> step is not consistent with your listed monitoring procedure of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and does not ensure that the fish were not exposed to temperatures above 4.4°C (40°F) during tempering (or thawing).\u003C\u002Fp>\n\n\u003Cp>Your “Attach No.3 – Validation of temperature from the each step.xlsx,” document showed that the total time fish are exposed to temperatures above 4.4°C (40°F) between the start of step 3 until step 19 (raw material transportation to precooking) take over 19 hours (1166 minutes). We acknowledge that the water temperature during tempering and thawing varies. It appears you are using thermocouples to monitor the water temperature during tempering and thawing. If the thermocouples are connected to continuous temperature monitoring device that produces a history of the water temperature during these steps, this would allow for continuous monitoring and documentation of the actual amount of time fish are exposed to water temperatures above 4.4°C (40°F) (see “Attach No.1 – Temperature control at \u003Cstrong>(b)(4)\u003C\u002Fstrong> step.pdf”).\u003C\u002Fp>\n\n\u003Cp>4. Since you chose to include corrective actions in your HACCP Plan, your described corrective actions must be appropriate, to comply with 21 CFR 123.7(b). However, your corrective action plan listed at the following critical control points are not appropriate. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. The metal detecting critical control point (CCP 2) lists a corrective actions of “If any product was rejected by metal detector, action shall be taken one as following: 1) the fish shall be rejected, or 2) the fish shall be separated for sorting out the metal fragments and after removed the metal fragment, re-pass the fish through metal detector again before releasing” is not adequate because it does not address the cause of the critical limit deviation. In order to regain control over the operation, FDA also recommends you attempt to locate and correct the source of the fragments found in the product by the metal detector.\u003Cbr>\nb. The unrefrigerated processing critical control point for steps 3-19 (CCP 10) does not ensure unsafe product doesn’t reach the consumer or correct the cause of the critical limit deviation. To ensure unsafe product does not reach the consumer, in addition to your listed corrective action of “perform histamine analysis on the fish lot by analyzing minimum of 60 fish, including all fish that show evidence of decomposition,” FDA recommends you also add instructions to destroy the lot or divert it to a non-food use if any fish is found with histamine greater than or equal to 50ppm. To correct the cause of the critical limit deviation, FDA recommends you modify the process as needed to reduce exposure time. Note that the listed corrective action to “reject the lot which is all raw material bins that take longer than control time and greater than control temperature at each step” is not appropriate because it represents an action taken for a critical limit deviation for processing temperatures, but the CCP does not contain a temperature critical limit.\u003Cbr>\nc. The unrefrigerated processing critical control point for steps 19-33,40 (CCP 12) lists a corrective action of “If cumulative time from after precooking until start of freezing exceeds 12 hours, then specifically identify the involved trolley of tuna, segregate and immediately expedite processing, then conduct histamine analysis at cleaning for 60 tuna randomly selected from the identified racks based on composites from 3 tuna (20 composites) If any composite exceeds 10ppm histamine, then reject all identified rack.- Depending on evidence, each of the 60 individual fish can be analyzed whereby all identified tuna are rejected if any one fish exceeds 30ppm. – Determine and correct cause for the excessive exposure time”. This corrective action is not adequate to ensure unsafe product does not reach the consumer or correct the cause of the critical limit deviation.\u003C\u002Fp>\n\n\u003Cp>To ensure unsafe product does not reach the consumer, FDA recommends you:\u003Cbr>\n• chill and hold the affected product until histamine analysis is performed on a minimum of 60 fish representatively collected from throughout the affected lot and destroy the lot or divert it to a non-food use if any fish is found with histamine greater than or equal to 50 ppm. The fish collected for analysis may be composited if the action plan is reduced accordingly. For example, a sample of 60 fish may be composited into 20 units of 3 fish each, provided the action point is reduced from 50 ppm to 17 ppm for each unit;\u003Cbr>\nOR\u003Cbr>\n• Destroy the product;\u003Cbr>\nOR\u003Cbr>\n• Divert the product to a non-food use.\u003Cbr>\nAND: to regain control over the operation and correct the cause of the critical limit deviation, FDA recommends you:\u003Cbr>\n• Add ice to the product;\u003Cbr>\nOR\u003Cbr>\n• Return the affected product to the cooler;\u003Cbr>\nAND\u003Cbr>\n• Modify the process as needed to reduce the time and temperature exposure.\u003Cbr>\nd. The Unrefrigerated Processing critical control point for steps 22-33,40 (CCP 13) lists a corrective action of “If the accumulated time is more than the critical limits reject the products” that is not adequate to ensure unsafe product does not reach the consumer or correct the cause of the critical limit deviation.\u003Cbr>\nTo ensure unsafe product does not reach the consumer, FDA recommends you:\u003Cbr>\n• Chill and hold the affected product until an evaluation of total time and temperature exposures is performed;\u003Cbr>\nOR\u003Cbr>\n• Destroy the product;\u003Cbr>\nOR\u003Cbr>\n• Divert the product to a non-food use.\u003Cbr>\nAND: to regain control over the operation and correct the cause of the critical limit deviation, FDA recommends you:\u003Cbr>\n• Determine cause of deviation\u003Cbr>\nAND\u003Cbr>\n• Modify the process as needed to reduce time and temperature exposure.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your revised HACCP plan dated “22\u002F02\u002F22”. This HACCP plan outlines a process where tuna is loined after the \u003Cstrong>(b)(4)\u003C\u002Fstrong> step. The technical review conducted was based upon the updated flowchart provided with the updated HACCP Plan. However, your description of the traditional process for vacuum-packed frozen tuna loins outlines processing steps that conflict with the steps outlined in the updated HACCP plan dated 22\u002F02\u002F22. Clarification is needed to determine which is utilized during production, the actual process outlined in the updated flowchart and updated HACCP plan dated “22\u002F02\u002F22”. If the actual process, the updated flowchart, and updated HACCP plan do not align with actual processing taking place, hazards might not be identified and\u002For adequately controlled during processing.\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific steps you are taking to correct these deviations. More specifically, your response should include documentation reflecting the changes you made, such as a copy of your revised HACCP plan or plans, five (5) consecutive days of completed monitoring records (i.e., complete sets of monitoring records for the production of 5 production date codes of products) to demonstrate implementation of the plan, and any additional information that you wish to supply that provides assurance of your intent to fully comply now and in the future with the seafood HACCP regulation. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported fish or fishery products under Section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the seafood HACCP regulation is Import Alert #16-120. You may view this alert at: \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. This letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the seafood HACCP regulation and the Current Good Manufacturing Practice regulation (21 CFR Part 117, Subpart B). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>You should direct your written reply to Rosemary Sexton, Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835. If you have any questions regarding this letter, you may contact Rosemary Sexton via email at Rosemary.Sexton@fda.hhs.gov. Please reference CMS #630100 on any submissions and on the subject line of any emails to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMs. Wachira Katueang-Ngan\n\nRecipient Title\n\nQuality Manager\n\nThai Union Group PLC\n\n72\u002F1 Moo 7 Sethakit 1 Road\n\nTambon Tarsrai\n\nAmphoe, Mueang\n\nSamut Sakhon 74000\n\nThailand\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition\n\nUnited States\n\nApril 20, 2022\n\nWARNING LETTER\n\nReference # 630100\n\nDear Ms. Wachira Katueang-Ngan:\n\nThe United States Food and Drug Administration (FDA) conducted a Foreign Remote Regulatory Assessment (FRRA) of your seafood processing facility, Thai Union Group PLC, located at 72\u002F1 Moo 7 Sethakit 1 Road, Tambon Tarsrai, Amphoe Mueang Samutsakhon, Samutsakhon, 74000, Thailand on January 18-20 & 25, 2022. An on-site inspection was not possible due to travel restrictions during the COVID-19 pandemic. During the remote assessment, we found that you had serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations (21 CFR Part 123). At the conclusion of the assessment, the FDA investigator discussed items of concern. We acknowledge your email responses dated, February 1, 2022, and March 1, 2022, to the discussion items identified during the FRRA.\n\nIn accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your frozen, pre-cooked tuna loin products are adulterated, in that they have been prepared, packed, or held under conditions whereby they may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation and the 4th Edition of the Fish and Fisheries Products Hazards and Controls Guidance (the Hazards Guide) through links in FDA's home page at www.fda.gov.\n\nYour significant deviations are as follows:\n\n1. You must have a HACCP plan that at minimum lists the critical limits that must be met, to comply with 21 CFR 123.6 (c)(3). A critical limit is defined in 21 CFR 123.3 (c) as the “the maximum or minimum value to which a physical, biological, or chemical parameter must be controlled at a critical control point to prevent, eliminate, or reduce to an acceptable level the occurrence of the identified food safety hazard. However, your firm’s HACCP Plan for frozen precooked tuna loins lists a critical limit of “(b)(4)” at the Precooking critical control point (CCP 11) that is not adequate to control scombrotoxin (histamine) formation. FDA recommends you establish critical limits for the minimum or maximum values for the critical factors established by a scientific study, which may include length of the cook cycle, speed of the belt for a continuous cooker, temperature of the steam or water used for cooking, initial temperature of the product, product form (loin, whole fish, etc.), and any other critical factors that affect the rate of heating the product. Alternatively, you may establish a value for the end product internal product temperature (EPIPT), established by a scientific study.\n\nYour Temperature Distribution Testing Report and Heat Penetration Testing Report provided during the inspection do not support the listed critical limit of “(b)(4).”\n\na. The Temperature Distribution Testing Report documents the result of temperature distribution within “(b)(4)” located at “(b)(4)” but the Heat Penetration Testing Report documents results for “(b)(4)” and “(b)(4)” located at “(b)(4).” In order to scientifically validate the cooking process, the scientific studies used to establish critical limits should be conducted for and applied to each individual cook tunnel.\n\nb. Although the “Test Procedure” section of the Heat Penetration Testing Report states that the thermocouples (TC) should be placed in the geometric center of the product at the thickest point near the backbone,” the photos on page 3 of the report show temperature sensors placed in tuna loins and not in whole, headed and gutted or any tunas with backbones. It does not appear that the heat penetration study is representative of the whole tuna processed under the “(b)(4)” HACCP plan, which lists the “(b)(4)” step as occurring after the “(b)(4)” step.\n\nAdditionally, your “(b)(4)” is identified as the scheduled process of precooked tuna (For USA) and includes Skipjack, Bigeye, Yellowfin, and Albacore tuna. The document lists multiple sizes for each species and a corresponding “(b)(4).” It is unclear how this document relates to the listed critical limit of “(b)(4)” or how it relates to the Heat Penetration Testing Report. Since multiple sized batches are processed, the critical limit should include ensuring each fish of each batch weighs less than a specific maximum size to ensure that all fish are processed to achieve a uniform heat penetration with a minimum internal temperature of 60°C.\n\n2. You must have a HACCP Plan that at minimum lists monitoring procedures and their frequency for each critical control point, to comply with 21 CFR 123.6(c)(4). However, your firm’s HACCP plan for frozen precooked tuna loins lists a monitoring frequency at the following critical control points that is not adequate. Specifically:\n\na. The unrefrigerated processing critical control points for steps “3-19” (CCP 10) lists a monitoring frequency of “-Every bin of raw material -Every trolley of precooked fish” that is not adequate to control scombrotoxin (histamine) formation because it does not include a unit of time between measurements. FDA recommends monitoring cumulative exposure time at a frequency of every 2 hours.\n\nb. The unrefrigerated processing critical control point for steps “19-33, 44” (CCP 12) lists a monitoring frequency of “-Every precooked fish trolley” that is not adequate to control scombrotoxin (histamine) formation because it does not include a unit of time between measurements. FDA recommends monitoring cumulative exposure time at a frequency of every 2 hours.\n\nc. The unrefrigerated processing critical control point for steps “22-33,40” (CCP13) lists a monitoring frequency of “-Every precooked fish trolley” that is not adequate to control Staphylococcus aureus growth and toxin formation because it does not include a unit of time between measurements. FDA recommends monitoring cumulative exposure time at a frequency of every 2 hours.\n\n3. You must implement the monitoring procedures and frequency that you have listed in your HACCP Plan, to comply with 21 CFR 123.6(b) and (c)(4). However, your firm did not follow the monitoring procedure of “(b)(4)” at the unrefrigerated processing critical control point for steps “3-19” (CCP 10) to control scombrotoxin (histamine) formation. FDA recommends continuous ambient temperature monitoring (air and water surrounding fish) from the time a lot of fish exits cold storage until the time a lot of fish enters the (b)(4) step.\n\nAccording to your submitted Corrective Action report, [the] “production department has designated PD Staffs to check temperature of water in the fish tank by thermometer at the end of (b)(4) step. PD staffs has recorded its temperature for monitoring the temperature control at (b)(4) step.” Monitoring the water temperature at the end of the (b)(4) step is not consistent with your listed monitoring procedure of “(b)(4)” and does not ensure that the fish were not exposed to temperatures above 4.4°C (40°F) during tempering (or thawing).\n\nYour “Attach No.3 – Validation of temperature from the each step.xlsx,” document showed that the total time fish are exposed to temperatures above 4.4°C (40°F) between the start of step 3 until step 19 (raw material transportation to precooking) take over 19 hours (1166 minutes). We acknowledge that the water temperature during tempering and thawing varies. It appears you are using thermocouples to monitor the water temperature during tempering and thawing. If the thermocouples are connected to continuous temperature monitoring device that produces a history of the water temperature during these steps, this would allow for continuous monitoring and documentation of the actual amount of time fish are exposed to water temperatures above 4.4°C (40°F) (see “Attach No.1 – Temperature control at (b)(4) step.pdf”).\n\n4. Since you chose to include corrective actions in your HACCP Plan, your described corrective actions must be appropriate, to comply with 21 CFR 123.7(b). However, your corrective action plan listed at the following critical control points are not appropriate. Specifically:\n\na. The metal detecting critical control point (CCP 2) lists a corrective actions of “If any product was rejected by metal detector, action shall be taken one as following: 1) the fish shall be rejected, or 2) the fish shall be separated for sorting out the metal fragments and after removed the metal fragment, re-pass the fish through metal detector again before releasing” is not adequate because it does not address the cause of the critical limit deviation. In order to regain control over the operation, FDA also recommends you attempt to locate and correct the source of the fragments found in the product by the metal detector.\n\nb. The unrefrigerated processing critical control point for steps 3-19 (CCP 10) does not ensure unsafe product doesn’t reach the consumer or correct the cause of the critical limit deviation. To ensure unsafe product does not reach the consumer, in addition to your listed corrective action of “perform histamine analysis on the fish lot by analyzing minimum of 60 fish, including all fish that show evidence of decomposition,” FDA recommends you also add instructions to destroy the lot or divert it to a non-food use if any fish is found with histamine greater than or equal to 50ppm. To correct the cause of the critical limit deviation, FDA recommends you modify the process as needed to reduce exposure time. Note that the listed corrective action to “reject the lot which is all raw material bins that take longer than control time and greater than control temperature at each step” is not appropriate because it represents an action taken for a critical limit deviation for processing temperatures, but the CCP does not contain a temperature critical limit.\n\nc. The unrefrigerated processing critical control point for steps 19-33,40 (CCP 12) lists a corrective action of “If cumulative time from after precooking until start of freezing exceeds 12 hours, then specifically identify the involved trolley of tuna, segregate and immediately expedite processing, then conduct histamine analysis at cleaning for 60 tuna randomly selected from the identified racks based on composites from 3 tuna (20 composites) If any composite exceeds 10ppm histamine, then reject all identified rack.- Depending on evidence, each of the 60 individual fish can be analyzed whereby all identified tuna are rejected if any one fish exceeds 30ppm. – Determine and correct cause for the excessive exposure time”. This corrective action is not adequate to ensure unsafe product does not reach the consumer or correct the cause of the critical limit deviation.\n\nTo ensure unsafe product does not reach the consumer, FDA recommends you:\n\n• chill and hold the affected product until histamine analysis is performed on a minimum of 60 fish representatively collected from throughout the affected lot and destroy the lot or divert it to a non-food use if any fish is found with histamine greater than or equal to 50 ppm. The fish collected for analysis may be composited if the action plan is reduced accordingly. For example, a sample of 60 fish may be composited into 20 units of 3 fish each, provided the action point is reduced from 50 ppm to 17 ppm for each unit;\n\nOR\n\n• Destroy the product;\n\nOR\n\n• Divert the product to a non-food use.\n\nAND: to regain control over the operation and correct the cause of the critical limit deviation, FDA recommends you:\n\n• Add ice to the product;\n\nOR\n\n• Return the affected product to the cooler;\n\nAND\n\n• Modify the process as needed to reduce the time and temperature exposure.\n\nd. The Unrefrigerated Processing critical control point for steps 22-33,40 (CCP 13) lists a corrective action of “If the accumulated time is more than the critical limits reject the products” that is not adequate to ensure unsafe product does not reach the consumer or correct the cause of the critical limit deviation.\n\nTo ensure unsafe product does not reach the consumer, FDA recommends you:\n\n• Chill and hold the affected product until an evaluation of total time and temperature exposures is performed;\n\nOR\n\n• Destroy the product;\n\nOR\n\n• Divert the product to a non-food use.\n\nAND: to regain control over the operation and correct the cause of the critical limit deviation, FDA recommends you:\n\n• Determine cause of deviation\n\nAND\n\n• Modify the process as needed to reduce time and temperature exposure.\n\nWe acknowledge your revised HACCP plan dated “22\u002F02\u002F22”. This HACCP plan outlines a process where tuna is loined after the (b)(4) step. The technical review conducted was based upon the updated flowchart provided with the updated HACCP Plan. However, your description of the traditional process for vacuum-packed frozen tuna loins outlines processing steps that conflict with the steps outlined in the updated HACCP plan dated 22\u002F02\u002F22. Clarification is needed to determine which is utilized during production, the actual process outlined in the updated flowchart and updated HACCP plan dated “22\u002F02\u002F22”. If the actual process, the updated flowchart, and updated HACCP plan do not align with actual processing taking place, hazards might not be identified and\u002For adequately controlled during processing.\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific steps you are taking to correct these deviations. More specifically, your response should include documentation reflecting the changes you made, such as a copy of your revised HACCP plan or plans, five (5) consecutive days of completed monitoring records (i.e., complete sets of monitoring records for the production of 5 production date codes of products) to demonstrate implementation of the plan, and any additional information that you wish to supply that provides assurance of your intent to fully comply now and in the future with the seafood HACCP regulation. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nIf you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported fish or fishery products under Section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the seafood HACCP regulation is Import Alert #16-120. You may view this alert at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. This letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the seafood HACCP regulation and the Current Good Manufacturing Practice regulation (21 CFR Part 117, Subpart B). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\n\nYou should direct your written reply to Rosemary Sexton, Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835. If you have any questions regarding this letter, you may contact Rosemary Sexton via email at Rosemary.Sexton@fda.hhs.gov. Please reference CMS #630100 on any submissions and on the subject line of any emails to us.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition","Thai Union Group PLC","thai-union-group-plc-630100-04202022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthai-union-group-plc-630100-04202022","2026-10-26T08:10:10.946439+00:00","Closed Out","2022-10-18","630100","Ms. Wachira Katueang-Ngan","2026-08-20T01:30:24.318+00:00","2022-04-20",{"id":77,"raw":78,"subject":83,"body_html":84,"body_text":85,"firm_name":86,"letter_id":87,"created_at":88,"fei_number":19,"letter_url":89,"updated_at":90,"action_type":22,"case_status":23,"posted_date":91,"marcs_cms_no":92,"product_type":93,"closeout_date":19,"issuing_office":82,"recipient_name":94,"body_fetched_at":95,"delivery_method":96,"recipient_title":19,"reference_number":97,"action_taken_date":98,"medical_device_id":19,"response_letter_date":19},138,[79,80,81,82,83,13,13,13],"\u003Ctime datetime=\"2026-06-02T04:00:00Z\">06\u002F02\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-26T04:00:00Z\">05\u002F26\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fblue-horizon-international-llc-728085-05262026\">Blue Horizon International, LLC \u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Unapproved New Drugs\u002FUnlicensed Biological Product Violations","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via UPS and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 26-728085\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Brian Mehling\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Medical Officer and Founder \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Blue Horizon International, LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>214 State Street Suite 101\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hackensack\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07601\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:bmehling@bluehorizoninternational.com\"> bmehling@bluehorizoninternational.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>May 26, 2026\u003C\u002Fp>\u003Cp>CBER 26-728085\u003C\u002Fp>\u003Cp>Dear Dr. Mehling:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) reviewed your company’s website at https:\u002F\u002Fbluehorizonstemcells.com (last visited May 2026), through which your company markets “Stem Cell Therapy” derived from umbilical cord blood and “Exosome Therapy”\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> derived from Wharton’s Jelly Mesenchymal Stem Cells (“WJ-MSC[s]”) for allogeneic use (hereafter, “your products”). This letter is to advise you that your misbranding of your products while held for sale after shipment in interstate commerce violates section 301(k) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 331(k).\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Unlicensed Biological Product Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, including your website, https:\u002F\u002Fbluehorizonstemcells.com, (last visited May 2026), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example,\u003C\u002Fp>\u003Cul>\u003Cli>After identifying your products, and under the heading “What Can We Treat,” your homepage lists various diseases and conditions, including:\u003Cbr>o Digestive System Diseases, including Hepatic steatosis and Chronic pancreatitis\u003Cbr>o Respiratory Diseases, including Allergic rhinitis, Rhinitis, and Sinusitis\u003Cbr>o Rheumatic Diseases, including Lupus\u003Cbr>o Endocrine Diseases, including Hashimoto’s thyroiditis and Hypothyroidism\u003Cbr>o Musculoskeletal Diseases, including Myositis, and Sports-related injury complications\u003Cbr>o Cardiovascular Diseases, including Coronary artery disease\u003C\u002Fli>\u003Cli>Your home page states, “Our stem cell treatments use ethically sourced cells from umbilical cord blood and adipose tissue to treat chronic conditions, injuries, and degenerative diseases.” This statement is followed by a link to your stem cell treatment webpage and a list of uses for stem cells: “Tissue regeneration[;] Immune modulation[;] Anti-inflammatory effects[; and] Pain reduction”.\u003C\u002Fli>\u003Cli>Under the heading “Revolutionary Stem Cell Therapy,” your stem cell treatment webpage states, “Explore the power of stem cells in treating various medical conditions[,]” followed by, among other conditions and diseases:\u003Cbr>o Neurological Marvels\u003Cbr> …Spinal Cord Regeneration\u003Cbr> Stroke Recovery\u003Cbr> Multiple Sclerosis Relief\u003Cbr>o Cardiovascular Miracles\u003Cbr> …Myocardial Rejuvenation\u003Cbr> …Cardiomyopathy Triumph\u003Cbr> Reversing Atherosclerosis\u003Cbr>o Musculoskeletal Wonders\u003Cbr> …Osteoarthritis Solutions\u003Cbr> Rheumatoid Arthritis Breakthrough\u003Cbr>o Lung Restoration\u003Cbr> … Defying COPD\u003Cbr>o Liver Regeneration\u003Cbr> Reviving Liver Function\u003Cbr> Cirrhosis Reversal\u003Cbr>o Bowel Revolution\u003Cbr> Conquering Crohn’s Disease\u003Cbr>o Metabolic Transformation\u003Cbr> Diabetes Remissions\u003C\u002Fli>\u003Cli>Under the heading “Our Results” on your exosome webpage, “These exosomes demonstrate strong regenerative and anti-inflammatory properties…”\u003C\u002Fli>\u003Cli>Under the heading “Our Exosomes” on your homepage: “These next generation therapies enhance tissue regeneration, reduce inflammation, and support natural healing processes through the body.”\u003C\u002Fli>\u003Cli>Under the heading “What Are Exosomes” on your exosome webpage, “Functionally, exosomes are pivotal in regulating immune responses, promoting tissue repair, and facilitating cellular regeneration.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your umbilical cord blood derived stem cell product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Blue Horizon International does not qualify for any exception in 21 CFR 1271.15, and your umbilical cord blood derived stem cell product fails to meet all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>Your umbilical cord blood derived stem cell product fails to meet the criterion that the HCT\u002FPs be “intended for homologous use only.” Homologous use means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). Your umbilical cord blood derived stem cell product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., forming and replenishing the lymphohematopoietic system). Rather, your umbilical cord blood derived stem cell product is intended for use in the treatment of several diseases and conditions, including multiple sclerosis, rheumatoid arthritis, cardiovascular and musculoskeletal conditions, which is not a basic function of umbilical cord blood in the donor.\u003C\u002Fp>\u003Cp>Moreover, your umbilical cord blood derived stem cell product fails to meet the criterion in 21 CFR 1271.10(a)(4) because it is manufactured from allogeneic umbilical cord blood, is dependent on the metabolic activity of living cells for their primary function, and is not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.\u003C\u002Fp>\u003Cp>Therefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your umbilical cord derived product is regulated as a drug as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>To lawfully market a drug that is also a biological product, a valid biologics license must be in effect. 42 U.S.C. § 262(a). Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations. 21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312. Neither of your products are the subject of an approved biologics license application (BLA) nor is there an IND in effect for either of them.\u003C\u002Fp>\u003Cp>Both your products, the umbilical cord blood derived stem cell product and the WJ-MSC\u002FUC exosome product, are misbranded drugs under section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. § 352(f)(1). A drug is misbranded under section 502(f)(1) if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. 21 CFR 201.5. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&amp;C Act, 21 U.S.C. § 353(b)(1)(A), can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>Your products are intended for use in the treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, your products fail to bear adequate directions for its intended uses and, therefore, is misbranded under section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. § 352(f)(1). Misbranding your products while they are held for sale after shipment of the drug or one or more of its components in interstate commerce is prohibited under section 301(k) of the FD&amp;C Act, 21 U.S.C. § 331(k).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Vincent Amatrudo\u003Cbr>Director (Acting)\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We direct your attention to FDA’s Public Safety Notification on Exosome Products, available at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia UPS and EMAIL\n\nReference #:\n\nCBER 26-728085\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nDr. Brian Mehling\n\nRecipient Title\n\nChief Medical Officer and Founder\n\nBlue Horizon International, LLC\n\n214 State Street Suite 101\n\nHackensack, NJ 07601\n\nUnited States\n\nbmehling@bluehorizoninternational.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nMay 26, 2026\nCBER 26-728085\nDear Dr. Mehling:\nThe United States Food and Drug Administration (FDA) reviewed your company’s website at https:\u002F\u002Fbluehorizonstemcells.com (last visited May 2026), through which your company markets “Stem Cell Therapy” derived from umbilical cord blood and “Exosome Therapy”1 derived from Wharton’s Jelly Mesenchymal Stem Cells (“WJ-MSC[s]”) for allogeneic use (hereafter, “your products”). This letter is to advise you that your misbranding of your products while held for sale after shipment in interstate commerce violates section 301(k) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 331(k).\nUnapproved New Drug and Unlicensed Biological Product Violations\nBased on information and records reviewed by FDA, including your website, https:\u002F\u002Fbluehorizonstemcells.com, (last visited May 2026), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example,\nAfter identifying your products, and under the heading “What Can We Treat,” your homepage lists various diseases and conditions, including:\no Digestive System Diseases, including Hepatic steatosis and Chronic pancreatitis\no Respiratory Diseases, including Allergic rhinitis, Rhinitis, and Sinusitis\no Rheumatic Diseases, including Lupus\no Endocrine Diseases, including Hashimoto’s thyroiditis and Hypothyroidism\no Musculoskeletal Diseases, including Myositis, and Sports-related injury complications\no Cardiovascular Diseases, including Coronary artery disease\nYour home page states, “Our stem cell treatments use ethically sourced cells from umbilical cord blood and adipose tissue to treat chronic conditions, injuries, and degenerative diseases.” This statement is followed by a link to your stem cell treatment webpage and a list of uses for stem cells: “Tissue regeneration[;] Immune modulation[;] Anti-inflammatory effects[; and] Pain reduction”.\nUnder the heading “Revolutionary Stem Cell Therapy,” your stem cell treatment webpage states, “Explore the power of stem cells in treating various medical conditions[,]” followed by, among other conditions and diseases:\no Neurological Marvels\n …Spinal Cord Regeneration\n Stroke Recovery\n Multiple Sclerosis Relief\no Cardiovascular Miracles\n …Myocardial Rejuvenation\n …Cardiomyopathy Triumph\n Reversing Atherosclerosis\no Musculoskeletal Wonders\n …Osteoarthritis Solutions\n Rheumatoid Arthritis Breakthrough\no Lung Restoration\n … Defying COPD\no Liver Regeneration\n Reviving Liver Function\n Cirrhosis Reversal\no Bowel Revolution\n Conquering Crohn’s Disease\no Metabolic Transformation\n Diabetes Remissions\nUnder the heading “Our Results” on your exosome webpage, “These exosomes demonstrate strong regenerative and anti-inflammatory properties…”\nUnder the heading “Our Exosomes” on your homepage: “These next generation therapies enhance tissue regeneration, reduce inflammation, and support natural healing processes through the body.”\nUnder the heading “What Are Exosomes” on your exosome webpage, “Functionally, exosomes are pivotal in regulating immune responses, promoting tissue repair, and facilitating cellular regeneration.”\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nYour umbilical cord blood derived stem cell product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Blue Horizon International does not qualify for any exception in 21 CFR 1271.15, and your umbilical cord blood derived stem cell product fails to meet all criteria in 21 CFR 1271.10(a).\nYour umbilical cord blood derived stem cell product fails to meet the criterion that the HCT\u002FPs be “intended for homologous use only.” Homologous use means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). Your umbilical cord blood derived stem cell product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., forming and replenishing the lymphohematopoietic system). Rather, your umbilical cord blood derived stem cell product is intended for use in the treatment of several diseases and conditions, including multiple sclerosis, rheumatoid arthritis, cardiovascular and musculoskeletal conditions, which is not a basic function of umbilical cord blood in the donor.\nMoreover, your umbilical cord blood derived stem cell product fails to meet the criterion in 21 CFR 1271.10(a)(4) because it is manufactured from allogeneic umbilical cord blood, is dependent on the metabolic activity of living cells for their primary function, and is not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.\nTherefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.2 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your umbilical cord derived product is regulated as a drug as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nTo lawfully market a drug that is also a biological product, a valid biologics license must be in effect. 42 U.S.C. § 262(a). Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations. 21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312. Neither of your products are the subject of an approved biologics license application (BLA) nor is there an IND in effect for either of them.\nBoth your products, the umbilical cord blood derived stem cell product and the WJ-MSC\u002FUC exosome product, are misbranded drugs under section 502(f)(1) of the FD&C Act, 21 U.S.C. § 352(f)(1). A drug is misbranded under section 502(f)(1) if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. 21 CFR 201.5. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act, 21 U.S.C. § 353(b)(1)(A), can only be used safely at the direction, and under the supervision, of a licensed practitioner.\nYour products are intended for use in the treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, your products fail to bear adequate directions for its intended uses and, therefore, is misbranded under section 502(f)(1) of the FD&C Act, 21 U.S.C. § 352(f)(1). Misbranding your products while they are held for sale after shipment of the drug or one or more of its components in interstate commerce is prohibited under section 301(k) of the FD&C Act, 21 U.S.C. § 331(k).\nConclusion\nThis letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you with an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nVincent Amatrudo\nDirector (Acting)\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n_______________________\n1 We direct your attention to FDA’s Public Safety Notification on Exosome Products, available at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\n2 Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).","Blue Horizon International, LLC","blue-horizon-international-llc-728085-05262026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fblue-horizon-international-llc-728085-05262026","2026-10-26T08:08:06.70821+00:00","2026-06-02","728085","Biologics","Dr. Brian Mehling","2026-08-19T04:38:45.672+00:00","Via UPS and EMAIL","CBER 26-728085","2026-05-26",{"id":100,"raw":101,"subject":12,"body_html":105,"body_text":106,"firm_name":107,"letter_id":108,"created_at":88,"fei_number":19,"letter_url":109,"updated_at":110,"action_type":22,"case_status":23,"posted_date":111,"marcs_cms_no":112,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":113,"body_fetched_at":114,"delivery_method":115,"recipient_title":19,"reference_number":19,"action_taken_date":116,"medical_device_id":19,"response_letter_date":19},220,[102,103,104,11,12,13,13,13],"\u003Ctime datetime=\"2026-04-21T04:00:00Z\">04\u002F21\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-03-26T04:00:00Z\">03\u002F26\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feaglelionton-intl-trading-co-inc-724560-03262026\">Eaglelionton Int&#039;l Trading Co Inc\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Perry Sproul\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Eaglelionton Int'l Trading Co Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>306 E 48th St.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Brooklyn\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11203-3304\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:perrytheowl@optonline.net\"> perrytheowl@optonline.net\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Inspections and Investigations\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>RE: CMS# 724560\u003C\u002Fp>\u003Cp>Dear Mr. Sproul,\u003C\u002Fp>\u003Cp>On January 29, 2026, through February 12, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Eaglelionton Int'l Trading Co Inc located at 306 E 48th St, Brooklyn, NY 11203-3304. We also conducted an inspection from May 01, 2023, through May 17, 2023. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\u003C\u002Fp>\u003Cp>We have not received your response to the Form FDA 483a issued on February 12, 2026.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cul>\u003Cli>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Actand 21 CFR part 1.502(a). Specifically, you did not develop an FSVP for any of the foods youimport, including each of the following foods:\u003Cbr>o &nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Coconut Milk imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>o &nbsp;Canned \u003Cstrong>(b)(4)\u003C\u002Fstrong> imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>o &nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States from the identified foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Stanley Nelson, Compliance Officer, Division of Northeast Imports: oiioiodneiwlresponses@fda.hhs.gov. Please also cc (carbon copy) Stanley. Nelson@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Nelson via email at Stanley.Nelson@fda.hhs.gov. Please reference CMS # 724560 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,&nbsp;\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>CDR Joseph S. Tomao\u003Cbr>Program Division Director\u003Cbr>Division of Northeast Importer\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nPerry Sproul\n\nRecipient Title\n\nOwner\n\nEaglelionton Int'l Trading Co Inc\n\n306 E 48th St.\n\nBrooklyn, NY 11203-3304\n\nUnited States\n\nperrytheowl@optonline.net\n\nIssuing Office:\n\nOffice of Inspections and Investigations\n\nUnited States\n\nWARNING LETTER\nRE: CMS# 724560\nDear Mr. Sproul,\nOn January 29, 2026, through February 12, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Eaglelionton Int'l Trading Co Inc located at 306 E 48th St, Brooklyn, NY 11203-3304. We also conducted an inspection from May 01, 2023, through May 17, 2023. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\nWe have not received your response to the Form FDA 483a issued on February 12, 2026.\nYour significant violations of the FSVP regulation are as follows:\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Actand 21 CFR part 1.502(a). Specifically, you did not develop an FSVP for any of the foods youimport, including each of the following foods:\no (b)(4) Coconut Milk imported from (b)(4) located in (b)(4).\no Canned (b)(4) imported from (b)(4) located in (b)(4).\no (b)(4) imported from (b)(4) located in (b)(4).\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States from the identified foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Stanley Nelson, Compliance Officer, Division of Northeast Imports: oiioiodneiwlresponses@fda.hhs.gov. Please also cc (carbon copy) Stanley. Nelson@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Nelson via email at Stanley.Nelson@fda.hhs.gov. Please reference CMS # 724560 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nCDR Joseph S. Tomao\nProgram Division Director\nDivision of Northeast Importer","Eaglelionton Int'l Trading Co Inc","eaglelionton-intl-trading-co-inc-724560-03262026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feaglelionton-intl-trading-co-inc-724560-03262026","2026-10-26T08:08:29.927551+00:00","2026-04-21","724560","Perry Sproul","2026-08-19T04:46:14.905+00:00","Via Email","2026-03-26",{"id":118,"raw":119,"subject":124,"body_html":125,"body_text":126,"firm_name":127,"letter_id":128,"created_at":129,"fei_number":19,"letter_url":130,"updated_at":131,"action_type":22,"case_status":23,"posted_date":132,"marcs_cms_no":133,"product_type":134,"closeout_date":19,"issuing_office":123,"recipient_name":135,"body_fetched_at":136,"delivery_method":115,"recipient_title":19,"reference_number":19,"action_taken_date":137,"medical_device_id":19,"response_letter_date":19},627,[120,121,122,123,124,13,13,13],"\u003Ctime datetime=\"2025-09-16T04:00:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-17T04:00:00Z\">07\u002F17\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmericon-industries-inc-692733-07172025\">Mericon Industries, Inc. \u003C\u002Fa>","Human Foods Program","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Brian Connelly\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Mericon Industries, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8819 N Pioneer Rd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Peoria\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>61615-1519\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Brian.Connelly@mericonindustries.com\"> Brian.Connelly@mericonindustries.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>July 17, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS #692733\u003C\u002Fp>\u003Cp>Dear Mr. Connelly:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your facility, located at 8819 N Pioneer Rd, Peoria, IL, from August 12 through 21, 2024. Based on inspectional findings and review of product labels collected during the inspections, as well as review of your website, www.mericonindustries.com, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection on August 21, 2024, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your response dated September 5, 2024, and we address your response below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drugs\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA reviewed your website at the Internet address www.mericonindustries.com in February, 2025, and has determined that you take orders there for the products Florical 100 capsules, Florical 500 capsules, and Meribin 120 capsules. The claims on your website establish that the products are drugs under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\u003C\u002Fp>\u003Cp>Examples of some of the claims on your website www.mericonindustries.com that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cu>Florical 100 Capsules\u003C\u002Fu>\u003Cbr>“Prevention and remediation of osteoporosis.”\u003C\u002Fli>\u003Cli>\u003Cu>Florical 500 Capsules\u003C\u002Fu>\u003Cbr>“Prevention and remediation of osteoporosis.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Drugs\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>Your products Florical 100 Capsules and Florical 500 Capsules are intended for treatment or prevention of one or more diseases that are not amenable to self-diagnosis, treatment, or prevention without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Florical 100 Capsules and Florical 500 Capsules fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Adulterated Dietary Supplements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The inspection of your facility on August 12 through 21, 2024, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the dietary supplements manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. Thus, in addition to being unapproved new drugs and\u002For misbranded drugs, your Florical 100 capsules, Florical 500 capsules, and Meribin 120 capsules are also adulterated dietary supplements under section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)].\u003C\u002Fp>\u003Cp>Your significant violations of the CGMP requirements are as follows:\u003C\u002Fp>\u003Cp>1. You failed to establish product specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contaminants that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). Specifically, you have not established identity specifications for your finished Florical and Meribin products. The identification test described in your batch records for these products are not adequate because they only include visual examination. Visual examination of the encapsulated powder is not be an appropriate identity test due to decreased reliability in confirming the identity of the product, potentially resulting in misidentification.\u003C\u002Fp>\u003Cp>In your response to the FDA Form 483, you did not provide finished product specifications. You also stated that, due to increased costs, it is difficult to accommodate private laboratory testing of your finished dietary supplement products. As required by 21 CFR 111.75(c), you must verify that your finished batch of the dietary supplement meets product specifications for identity, purity, strength, composition, and for limits on those types of contaminants that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement. To date, you have not submitted any evidence of corrective action for this violation.\u003C\u002Fp>\u003Cp>2. You failed to establish and follow written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any reprocessing, as required by 21 CFR 111.103. Specifically, during the inspection, when our investigator requested your written procedures for quality control operations, you were not able to provide any written procedures for quality control operations that are used to ensure the quality of the dietary supplements. On 05\u002F28\u002F2024, you manufactured Florical Lot#240528A and distributed the finished product on 08\u002F08\u002F2024.\u003C\u002Fp>\u003Cp>In your response to the FDA Form 483, you stated that you have quality controls in the form of a manual of Standard Operating Procedures. You did not provide any documentation to demonstrate that you have established and follow written procedures for the responsibilities of the quality control operations. To date, you have not submitted any evidence of corrective action.\u003C\u002Fp>\u003Cp>3. Your batch production records failed to include complete information relating to the production and control of each batch, as required by 21 CFR 111.255(b) and 21 CFR 111.260. Specifically, your batch production records for the Florical and Meribin dietary supplement products that you manufacture failed to include:\u003C\u002Fp>\u003Cul>\u003Cli>The identity of the equipment and processing lines used in producing the batch (21 CFR 111.260(b));\u003C\u002Fli>\u003Cli>Documentation that the finished dietary supplement meets specifications established in accordance with 21 CFR 111.70(e) and (g) (21 CFR 111.260(i));\u003C\u002Fli>\u003Cli>Documentation at the time of performance that quality control personnel reviewed the batch production record (21 CFR 111.260(l)(1)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response to the FDA Form 483, you stated that you plan to create an SOP to address the batch production record deficiencies. To date, you have not submitted any evidence of corrective action.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Dietary Supplements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, we reviewed your product labels collected during the inspection and have determined the Florical 100 Capsules, Florical 500 Capsules, and Meribin 120 Capsules products you manufacture are misbranded under section 403 of the Act [21 U.S.C. 343] because they do not comply with the labeling requirements for dietary supplements. Thus, in addition to being unapproved new drugs and misbranded drugs, your Florical 100 Capsules, Florical 500 Capsules, and Meribin 120 Capsules are also misbranded dietary supplements under section 403 of the Act [21 U.S.C. 343].] Specifically, we identified the following:\u003C\u002Fp>\u003Cp>1. Your Florical 100 Capsules, Florical 500 Capsules, and Meribin 120 Capsules, dietary supplement products are misbranded within the meaning of section 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] in that the presentation of the nutrition information on the labeling of your products does not comply with 21 CFR 101.36 and 21 CFR 101.9, and 21 CFR 101.4. For example, the calculated % Daily Value for all (b)(2)-dietary ingredients must be the quantitative amount by weight per serving divided by the RDI for each respective nutrient established in 21 CFR 101.9(c)(8)(iv), and expressed to the nearest whole percent in accordance with 21 CFR 101.36(b)(2)(C).\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written reply should be directed to Rebecca Allen, Compliance Officer, via email at HFPOCE-DietarySupplements@fda.hhs.gov. Please reference CMS #692733 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCEDietarySupplements@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, JD, MBA\u003Cbr>Acting Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nBrian Connelly\n\nRecipient Title\n\nOwner\n\nMericon Industries, Inc.\n\n8819 N Pioneer Rd.\n\nPeoria, IL 61615-1519\n\nUnited States\n\nBrian.Connelly@mericonindustries.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nJuly 17, 2025\nWARNING LETTER\nCMS #692733\nDear Mr. Connelly:\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your facility, located at 8819 N Pioneer Rd, Peoria, IL, from August 12 through 21, 2024. Based on inspectional findings and review of product labels collected during the inspections, as well as review of your website, www.mericonindustries.com, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\nAt the conclusion of the inspection on August 21, 2024, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your response dated September 5, 2024, and we address your response below.\nUnapproved New Drugs\nFDA reviewed your website at the Internet address www.mericonindustries.com in February, 2025, and has determined that you take orders there for the products Florical 100 capsules, Florical 500 capsules, and Meribin 120 capsules. The claims on your website establish that the products are drugs under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\nExamples of some of the claims on your website www.mericonindustries.com that provide evidence that your products are intended for use as drugs include:\nFlorical 100 Capsules\n“Prevention and remediation of osteoporosis.”\nFlorical 500 Capsules\n“Prevention and remediation of osteoporosis.”\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\nMisbranded Drugs\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\nYour products Florical 100 Capsules and Florical 500 Capsules are intended for treatment or prevention of one or more diseases that are not amenable to self-diagnosis, treatment, or prevention without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Florical 100 Capsules and Florical 500 Capsules fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\nAdulterated Dietary Supplements\nThe inspection of your facility on August 12 through 21, 2024, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the dietary supplements manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. Thus, in addition to being unapproved new drugs and\u002For misbranded drugs, your Florical 100 capsules, Florical 500 capsules, and Meribin 120 capsules are also adulterated dietary supplements under section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)].\nYour significant violations of the CGMP requirements are as follows:\n1. You failed to establish product specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contaminants that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). Specifically, you have not established identity specifications for your finished Florical and Meribin products. The identification test described in your batch records for these products are not adequate because they only include visual examination. Visual examination of the encapsulated powder is not be an appropriate identity test due to decreased reliability in confirming the identity of the product, potentially resulting in misidentification.\nIn your response to the FDA Form 483, you did not provide finished product specifications. You also stated that, due to increased costs, it is difficult to accommodate private laboratory testing of your finished dietary supplement products. As required by 21 CFR 111.75(c), you must verify that your finished batch of the dietary supplement meets product specifications for identity, purity, strength, composition, and for limits on those types of contaminants that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement. To date, you have not submitted any evidence of corrective action for this violation.\n2. You failed to establish and follow written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any reprocessing, as required by 21 CFR 111.103. Specifically, during the inspection, when our investigator requested your written procedures for quality control operations, you were not able to provide any written procedures for quality control operations that are used to ensure the quality of the dietary supplements. On 05\u002F28\u002F2024, you manufactured Florical Lot#240528A and distributed the finished product on 08\u002F08\u002F2024.\nIn your response to the FDA Form 483, you stated that you have quality controls in the form of a manual of Standard Operating Procedures. You did not provide any documentation to demonstrate that you have established and follow written procedures for the responsibilities of the quality control operations. To date, you have not submitted any evidence of corrective action.\n3. Your batch production records failed to include complete information relating to the production and control of each batch, as required by 21 CFR 111.255(b) and 21 CFR 111.260. Specifically, your batch production records for the Florical and Meribin dietary supplement products that you manufacture failed to include:\nThe identity of the equipment and processing lines used in producing the batch (21 CFR 111.260(b));\nDocumentation that the finished dietary supplement meets specifications established in accordance with 21 CFR 111.70(e) and (g) (21 CFR 111.260(i));\nDocumentation at the time of performance that quality control personnel reviewed the batch production record (21 CFR 111.260(l)(1)).\nIn your response to the FDA Form 483, you stated that you plan to create an SOP to address the batch production record deficiencies. To date, you have not submitted any evidence of corrective action.\nMisbranded Dietary Supplements\nIn addition, we reviewed your product labels collected during the inspection and have determined the Florical 100 Capsules, Florical 500 Capsules, and Meribin 120 Capsules products you manufacture are misbranded under section 403 of the Act [21 U.S.C. 343] because they do not comply with the labeling requirements for dietary supplements. Thus, in addition to being unapproved new drugs and misbranded drugs, your Florical 100 Capsules, Florical 500 Capsules, and Meribin 120 Capsules are also misbranded dietary supplements under section 403 of the Act [21 U.S.C. 343].] Specifically, we identified the following:\n1. Your Florical 100 Capsules, Florical 500 Capsules, and Meribin 120 Capsules, dietary supplement products are misbranded within the meaning of section 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] in that the presentation of the nutrition information on the labeling of your products does not comply with 21 CFR 101.36 and 21 CFR 101.9, and 21 CFR 101.4. For example, the calculated % Daily Value for all (b)(2)-dietary ingredients must be the quantitative amount by weight per serving divided by the RDI for each respective nutrient established in 21 CFR 101.9(c)(8)(iv), and expressed to the nearest whole percent in accordance with 21 CFR 101.36(b)(2)(C).\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nYour written reply should be directed to Rebecca Allen, Compliance Officer, via email at HFPOCE-DietarySupplements@fda.hhs.gov. Please reference CMS #692733 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCEDietarySupplements@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, JD, MBA\nActing Director, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","Mericon Industries, Inc.","mericon-industries-inc-692733-07172025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmericon-industries-inc-692733-07172025","2026-10-26T08:09:24.060729+00:00","2025-09-16","692733","DrugsFood & Beverages","Brian Connelly","2026-08-19T16:23:51.686+00:00","2025-07-17",{"id":139,"raw":140,"subject":145,"body_html":146,"body_text":147,"firm_name":148,"letter_id":149,"created_at":150,"fei_number":19,"letter_url":151,"updated_at":152,"action_type":22,"case_status":23,"posted_date":153,"marcs_cms_no":154,"product_type":155,"closeout_date":19,"issuing_office":144,"recipient_name":156,"body_fetched_at":157,"delivery_method":158,"recipient_title":19,"reference_number":19,"action_taken_date":159,"medical_device_id":19,"response_letter_date":19},1115,[141,142,143,144,145,13,13,13],"\u003Ctime datetime=\"2024-12-24T14:20:00Z\">12\u002F24\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-17T05:00:00Z\">12\u002F17\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fannes-daye-ltd-dba-tampon-innovations-696362-12172024\">Anne’s Daye Ltd dba Tampon Innovations\u003C\u002Fa>","Center for Devices and Radiological Health","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Valentina Milanova \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder &amp; CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Anne’s Daye Ltd dba Tampon Innovations\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>The Biscuit Factory, 100 Drummond Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bermondsey\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>London\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>SE16 4DG\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United Kingdom\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 17, 2024\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 696362\u003C\u002Fp>\u003Cp>Dear Valentina Milanova:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Oblast Sofia Grad, Bulgaria on July 8, 2024, through July 11, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Cannabinoid (CBD) coated tampons (“CBD Daye Tampons”) and vaginal microbiome screening kits. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>We received a response from Valentina Milanova, Founder and CEO, dated July 30, 2024, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We have also previously received additional correspondence from your firm related to marketing authorization requirements for your products. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>UNAPPROVED DEVICE VIOLATIONS\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>1. Our inspection and review of your website (www.yourdaye.com) determined that the CBD Daye Tampon is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device. The CBD Daye Tampon is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution this device with major changes or modifications to the intended use without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(ii). The device is further misbranded because your firm did not notify FDA regarding changes and modifications in the device that could significantly affect the safety or effectiveness of the device, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(i).\u003C\u002Fp>\u003Cp>Specifically, the Daye Tampon was cleared under K223883 with the following indications “The Daye Tampons are indicated for insertion into the vagina to absorb menstrual discharge.” However, your firm’s labeling and promotion of the device provides evidence that the device is intended for relief of period related pain, which would constitute a major change or modification to its intended use, for which your firm lacks clearance or approval. Examples include:\u003C\u002Fp>\u003Cp>• Images of your package label and other statements on the Walmart Web Site at: https:\u002F\u002Fwww.walmart.com\u002Fip\u002FDaye-Mixed-Pack-Tampons-Sugarcane-Applicator-No-Shed-Sleeve-Ocean-Safe-Flushable-Wrapper-100-Organic-Cotton-9-Comfort-Coated-Super-Absorbency-18-Coun\u002F5551535956?classType=REGULARhttps\u003Cbr>&nbsp; o “CBD is known for its soothing and anti-inflammatory properties, which makes it your period’s perfect partner in crime.”\u003Cbr>&nbsp; o “…, each featuring a special comfort coating that ensures a mellow period experience.”\u003C\u002Fp>\u003Cp>• Trustpilot Web Site: https:\u002F\u002Fwww.trustpilot.com\u002Freview\u002Fyourdaye.com\u003Cbr>&nbsp; o “We're really sorry to hear that the CBD tampons didn’t work for you. Research shows that different bodies have different responses to CBD, and just as other forms of pain relief, annoyingly it won’t work for everyone.”\u003C\u002Fp>\u003Cp>• YourDaye Web Site: https:\u002F\u002Fwww.yourdaye.com\u002Fproducts\u002Forganic-cbd-tampons\u002F\u003Cbr>&nbsp; o “Fully-sustainable organic tampons with a no-shed protective sleeve and a CBD coating for the days when period pain is cramping your style.”\u003C\u002Fp>\u003Cp>• Interview of your CEO: https:\u002F\u002Ftherecursive.com\u002Fbreaking-feminine-health-taboos-the-startup-story-of-daye-and-their-cbd-tampons\u002F\u003Cbr>&nbsp; o “She found it interesting that industrial hemp has two main properties - its extracts act as a pain reliever while its fiber is super absorbent. These two properties stuck in my mind and as you can tell, that is how the idea of our pain-relieving tampon was born,’ Valentina says.”\u003C\u002Fp>\u003Cp>Additionally, as noted above, and as you were advised in the It Has Come to Our Attention (IHCTOA) Letter of April 5, 2024, the CBD coating raises significant concerns regarding the safety and effectiveness of your device. The letter addressed FDA’s having previously notified you in our written feedback to pre-submission Q200187 that “the inclusion of a drug product (CBD) as part of the subject device (tampon) represents a different technological characteristic and raises different questions of safety and effectiveness as compared to the proposed predicate devices and other previously cleared tampons. Therefore, the 510(k) pathway is not appropriate for your product.”\u003C\u002Fp>\u003Cp>As a related matter, FDA evaluated the regulatory decision form that you provided the investigator to support not needing a 510(k) for the CBD Coated Daye Tampons and found the assessment was inadequate because the CBD coating raises significant concerns regarding safety and effectiveness of the devices due to the potential for local and systemic exposure of CBD, potential adverse events (e.g., reproductive\u002Fdevelopmental toxicity) associated with CBD, and potential effects due to the uncertainty of the potency and quality of the CBD (e.g., psychoactive effects from possible contaminants like Delta-9-tetrahydrocannabinol).\u003C\u002Fp>\u003Cp>Although FDA has repeatedly identified your product as being marketed without the necessary premarket authorization, you continue to market the device. Your firm currently imports Cannabidiol (CBD) Coated Daye Tampons into the United States under K223883. As we have communicated to you, the K223883 clearance is for only the Daye Tampon and not for a CBD coated Daye Tampon.\u003C\u002Fp>\u003Cp>Please provide copies of all labeling and advertisements for the CBD Coated Daye Tampons.\u003C\u002Fp>\u003Cp>2. Our inspection and review of your website (www.yourdaye.com) determined that the Vaginal Microbiome Screening Kit is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device. The Vaginal Microbiome Screening Kit is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\u003Cp>Your firm’s promotion of the Vaginal Microbiome Screening Kit provides evidence that the device is intended for diagnosing yeast infections, BV, STIs, fertility implications, and other gynecological health complications, indications for which your firm lacks clearance or approval. Examples include your company’s materials shown on:\u003C\u002Fp>\u003Cp>• Your Web Site: https:\u002F\u002Fwww.yourdaye.com\u002Fproducts\u002Fvaginal-testing\u002F\u003Cbr>&nbsp; o “Understand your risk of vaginal infections like yeast infection or BV, STIs, fertility implications, and other gynecological health complications using a non-invasive at-home tampon test.”\u003Cbr>&nbsp; o “Understand if you are at a higher risk for STIs and UTIs”\u003Cbr>&nbsp; o “Detect bacteria that can cause vaginal infections like thrush &amp; BV” via\u003C\u002Fp>\u003Cp>• Trustpilot Web Site: https:\u002F\u002Fwww.trustpilot.com\u002Freview\u002Fyourdaye.com\u003Cbr>&nbsp; o “Our diagnostic tool enables improved accuracy compared to traditional methods, increasing the sensitivity and specificity of existing diagnostic assays.”\u003Cbr>&nbsp; o “For anyone who tests positive for STIs or HPV, we always provide a free consultation with our nurses to ensure they get the support they need.”\u003C\u002Fp>\u003Cp>• Amazon Web Site: https:\u002F\u002Fwww.amazon.com\u002Fstores\u002FDaye\u003Cbr>&nbsp; o “Detect bacteria that cause vaginal infections like yeast infections &amp; BV, understand your risk of contracting STIs and UTIs, check for microbes that affect your fertility using a non-invasive at-home tampon screen.”\u003Cbr>&nbsp; o “Daye Tampons take highly accurate samples &amp; allow for comfortable, at-home testing, complete with an applicator designed for pain-free and smooth insertion.”\u003Cbr>&nbsp; o “Daye Microbiome Screening tests for bacteria and pathogens such as lactobacilli, bacterial vaginosis, candida, mycoplasma &amp; ureaplasma.”\u003Cbr>&nbsp; o “Getting screened with us means never having to face dead-end results as we offer specialist aftercare, tailored to you. Get personalized lifestyle hacks based on your results to boost your health as well.”\u003Cbr>&nbsp; o “Screen the population of good and bad bacteria in your microflora with an increased diagnostic accuracy. Understand what's actually causing your symptoms.”\u003Cbr>&nbsp; o “Tampons take better, more accurate samples then a standard swab”.\u003C\u002Fp>\u003Cp>You have been importing and distributing Vaginal Microbiome Screening Kits into interstate commerce under K223883, which did not include a clearance for diagnostic purposes for the Daye tampons. The FDA evaluated the regulatory decision form you provided to the investigator to support that the Vaginal Microbiome Screening Kit is a general wellness device. However, the FDA has determined that your assessment is inadequate because your firm markets the device with diagnostic claims that are outside the scope of a general wellness device as described in the FDA guidance document “General Wellness: Policy for Low Risk Devices” at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fgeneral-wellness-policy-low-risk-devices; and therefore, your device would need to be submitted for premarket review by the FDA.\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for these devices is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>In addition, we offer the following comment:\u003C\u002Fp>\u003Cp>During our inspection, FDA determined that your firm failed to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required 21 CFR 820.198(a). Complaints related to the addition of CBD to Daye Tampons that were listed in Trustpilot or third party systems were given responses by your firm, but not logged and evaluated appropriately in your complaint handling system. The complaints indicate CBD Daye Tampons may have an impact on the patients’ health (e.g. CBD drug interactions) that exceed the expected risks associated with regular (non-CBD) tampons.\u003C\u002Fp>\u003Cp>Given the serious nature of the violations of the Act, the CBD Daye Tampons and Vaginal Microbiome Screening Kits manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations are addressed. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violations described in this letter. We will notify you regarding the adequacy of your firm’s responses and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS # 696362 when replying. If you have any questions about the contents of this letter, please contact: Jason Roberts at (240) 402-6400 or jason.roberts@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Michael J. Hoffmann\u003Cbr>Office Director\u003Cbr>OHT3: Office of GastroRenal, ObGyn,\u003Cbr>General Hospital and Urology Devices\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003Cbr>\u003Cbr>CC:\u003Cbr>Valentina Milanova\u003Cbr>Tampon Innovations\u003Cbr>Nadezhda Dist, Bulevard Rozhen 41a\u003Cbr>Iliyantsi, Oblast Sofia Grad, 1271 Bulgaria\u003C\u002Fp>\u003Cp>David Lennarz&nbsp;&nbsp;\u003Cbr>Registrar Corp\u003Cbr>144 Research Drive\u003Cbr>Hampton, VA US 23666\u003Cbr>Phone: (757) 224-0177\u003Cbr>Email: david.lennarz@registrarcorp.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nValentina Milanova\n\nRecipient Title\n\nFounder & CEO\n\nAnne’s Daye Ltd dba Tampon Innovations\n\nThe Biscuit Factory, 100 Drummond Road\n\nBermondsey\n\nLondon\n\nSE16 4DG\n\nUnited Kingdom\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nDecember 17, 2024\nWARNING LETTER\nCMS # 696362\nDear Valentina Milanova:\nDuring an inspection of your firm located in Oblast Sofia Grad, Bulgaria on July 8, 2024, through July 11, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Cannabinoid (CBD) coated tampons (“CBD Daye Tampons”) and vaginal microbiome screening kits. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nWe received a response from Valentina Milanova, Founder and CEO, dated July 30, 2024, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We have also previously received additional correspondence from your firm related to marketing authorization requirements for your products. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\nUNAPPROVED DEVICE VIOLATIONS\n1. Our inspection and review of your website (www.yourdaye.com) determined that the CBD Daye Tampon is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device. The CBD Daye Tampon is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution this device with major changes or modifications to the intended use without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(ii). The device is further misbranded because your firm did not notify FDA regarding changes and modifications in the device that could significantly affect the safety or effectiveness of the device, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(i).\nSpecifically, the Daye Tampon was cleared under K223883 with the following indications “The Daye Tampons are indicated for insertion into the vagina to absorb menstrual discharge.” However, your firm’s labeling and promotion of the device provides evidence that the device is intended for relief of period related pain, which would constitute a major change or modification to its intended use, for which your firm lacks clearance or approval. Examples include:\n• Images of your package label and other statements on the Walmart Web Site at: https:\u002F\u002Fwww.walmart.com\u002Fip\u002FDaye-Mixed-Pack-Tampons-Sugarcane-Applicator-No-Shed-Sleeve-Ocean-Safe-Flushable-Wrapper-100-Organic-Cotton-9-Comfort-Coated-Super-Absorbency-18-Coun\u002F5551535956?classType=REGULARhttps\no “CBD is known for its soothing and anti-inflammatory properties, which makes it your period’s perfect partner in crime.”\no “…, each featuring a special comfort coating that ensures a mellow period experience.”\n• Trustpilot Web Site: https:\u002F\u002Fwww.trustpilot.com\u002Freview\u002Fyourdaye.com\no “We're really sorry to hear that the CBD tampons didn’t work for you. Research shows that different bodies have different responses to CBD, and just as other forms of pain relief, annoyingly it won’t work for everyone.”\n• YourDaye Web Site: https:\u002F\u002Fwww.yourdaye.com\u002Fproducts\u002Forganic-cbd-tampons\u002F\no “Fully-sustainable organic tampons with a no-shed protective sleeve and a CBD coating for the days when period pain is cramping your style.”\n• Interview of your CEO: https:\u002F\u002Ftherecursive.com\u002Fbreaking-feminine-health-taboos-the-startup-story-of-daye-and-their-cbd-tampons\u002F\no “She found it interesting that industrial hemp has two main properties - its extracts act as a pain reliever while its fiber is super absorbent. These two properties stuck in my mind and as you can tell, that is how the idea of our pain-relieving tampon was born,’ Valentina says.”\nAdditionally, as noted above, and as you were advised in the It Has Come to Our Attention (IHCTOA) Letter of April 5, 2024, the CBD coating raises significant concerns regarding the safety and effectiveness of your device. The letter addressed FDA’s having previously notified you in our written feedback to pre-submission Q200187 that “the inclusion of a drug product (CBD) as part of the subject device (tampon) represents a different technological characteristic and raises different questions of safety and effectiveness as compared to the proposed predicate devices and other previously cleared tampons. Therefore, the 510(k) pathway is not appropriate for your product.”\nAs a related matter, FDA evaluated the regulatory decision form that you provided the investigator to support not needing a 510(k) for the CBD Coated Daye Tampons and found the assessment was inadequate because the CBD coating raises significant concerns regarding safety and effectiveness of the devices due to the potential for local and systemic exposure of CBD, potential adverse events (e.g., reproductive\u002Fdevelopmental toxicity) associated with CBD, and potential effects due to the uncertainty of the potency and quality of the CBD (e.g., psychoactive effects from possible contaminants like Delta-9-tetrahydrocannabinol).\nAlthough FDA has repeatedly identified your product as being marketed without the necessary premarket authorization, you continue to market the device. Your firm currently imports Cannabidiol (CBD) Coated Daye Tampons into the United States under K223883. As we have communicated to you, the K223883 clearance is for only the Daye Tampon and not for a CBD coated Daye Tampon.\nPlease provide copies of all labeling and advertisements for the CBD Coated Daye Tampons.\n2. Our inspection and review of your website (www.yourdaye.com) determined that the Vaginal Microbiome Screening Kit is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device. The Vaginal Microbiome Screening Kit is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\nYour firm’s promotion of the Vaginal Microbiome Screening Kit provides evidence that the device is intended for diagnosing yeast infections, BV, STIs, fertility implications, and other gynecological health complications, indications for which your firm lacks clearance or approval. Examples include your company’s materials shown on:\n• Your Web Site: https:\u002F\u002Fwww.yourdaye.com\u002Fproducts\u002Fvaginal-testing\u002F\no “Understand your risk of vaginal infections like yeast infection or BV, STIs, fertility implications, and other gynecological health complications using a non-invasive at-home tampon test.”\no “Understand if you are at a higher risk for STIs and UTIs”\no “Detect bacteria that can cause vaginal infections like thrush & BV” via\n• Trustpilot Web Site: https:\u002F\u002Fwww.trustpilot.com\u002Freview\u002Fyourdaye.com\no “Our diagnostic tool enables improved accuracy compared to traditional methods, increasing the sensitivity and specificity of existing diagnostic assays.”\no “For anyone who tests positive for STIs or HPV, we always provide a free consultation with our nurses to ensure they get the support they need.”\n• Amazon Web Site: https:\u002F\u002Fwww.amazon.com\u002Fstores\u002FDaye\no “Detect bacteria that cause vaginal infections like yeast infections & BV, understand your risk of contracting STIs and UTIs, check for microbes that affect your fertility using a non-invasive at-home tampon screen.”\no “Daye Tampons take highly accurate samples & allow for comfortable, at-home testing, complete with an applicator designed for pain-free and smooth insertion.”\no “Daye Microbiome Screening tests for bacteria and pathogens such as lactobacilli, bacterial vaginosis, candida, mycoplasma & ureaplasma.”\no “Getting screened with us means never having to face dead-end results as we offer specialist aftercare, tailored to you. Get personalized lifestyle hacks based on your results to boost your health as well.”\no “Screen the population of good and bad bacteria in your microflora with an increased diagnostic accuracy. Understand what's actually causing your symptoms.”\no “Tampons take better, more accurate samples then a standard swab”.\nYou have been importing and distributing Vaginal Microbiome Screening Kits into interstate commerce under K223883, which did not include a clearance for diagnostic purposes for the Daye tampons. The FDA evaluated the regulatory decision form you provided to the investigator to support that the Vaginal Microbiome Screening Kit is a general wellness device. However, the FDA has determined that your assessment is inadequate because your firm markets the device with diagnostic claims that are outside the scope of a general wellness device as described in the FDA guidance document “General Wellness: Policy for Low Risk Devices” at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fgeneral-wellness-policy-low-risk-devices; and therefore, your device would need to be submitted for premarket review by the FDA.\nFor a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for these devices is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nIn addition, we offer the following comment:\nDuring our inspection, FDA determined that your firm failed to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required 21 CFR 820.198(a). Complaints related to the addition of CBD to Daye Tampons that were listed in Trustpilot or third party systems were given responses by your firm, but not logged and evaluated appropriately in your complaint handling system. The complaints indicate CBD Daye Tampons may have an impact on the patients’ health (e.g. CBD drug interactions) that exceed the expected risks associated with regular (non-CBD) tampons.\nGiven the serious nature of the violations of the Act, the CBD Daye Tampons and Vaginal Microbiome Screening Kits manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations are addressed. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violations described in this letter. We will notify you regarding the adequacy of your firm’s responses and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS # 696362 when replying. If you have any questions about the contents of this letter, please contact: Jason Roberts at (240) 402-6400 or jason.roberts@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nMichael J. Hoffmann\nOffice Director\nOHT3: Office of GastroRenal, ObGyn,\nGeneral Hospital and Urology Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\n\nCC:\nValentina Milanova\nTampon Innovations\nNadezhda Dist, Bulevard Rozhen 41a\nIliyantsi, Oblast Sofia Grad, 1271 Bulgaria\nDavid Lennarz\nRegistrar Corp\n144 Research Drive\nHampton, VA US 23666\nPhone: (757) 224-0177\nEmail: david.lennarz@registrarcorp.com","Anne’s Daye Ltd dba Tampon Innovations","annes-daye-ltd-dba-tampon-innovations-696362-12172024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fannes-daye-ltd-dba-tampon-innovations-696362-12172024","2026-10-26T08:07:56.086586+00:00","2024-12-24","696362","Medical Devices","Valentina Milanova","2026-08-19T17:06:30.931+00:00","VIA UNITED PARCEL SERVICE","2024-12-17",{"id":161,"raw":162,"subject":167,"body_html":168,"body_text":169,"firm_name":170,"letter_id":171,"created_at":129,"fei_number":19,"letter_url":172,"updated_at":173,"action_type":22,"case_status":23,"posted_date":174,"marcs_cms_no":175,"product_type":48,"closeout_date":19,"issuing_office":166,"recipient_name":176,"body_fetched_at":177,"delivery_method":178,"recipient_title":19,"reference_number":179,"action_taken_date":180,"medical_device_id":19,"response_letter_date":19},551,[163,164,165,166,167,13,13,13],"\u003Ctime datetime=\"2025-10-07T04:00:00Z\">10\u002F07\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-17T04:00:00Z\">09\u002F17\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdixon-investments-inc-dba-ari-710087-09172025\">Dixon Investments Inc. dba ARI\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-15-111\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. John Gordon Dixon\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Dixon Investments Inc. dba ARI\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2523 South McDonough Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Orchard Hill\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>30266\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-15-111\u003C\u002Fp>\u003Cp>September 17, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Dixon:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Dixon Investments Inc. dba ARI, FEI 1037559, at 2523 South McDonough Road, Orchard Hill, from March 5 to 11, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>In addition, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). Additionally, \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are misbranded under sections 502(f)(1) and 502(f)(2) of the FD&amp;C Act, 21 U.S.C. 352(f)(1) and 352(f)(2). Furthermore, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>We reviewed your March 27, 2025 response to our Form FDA-483 in detail.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm had not performed process validation for your over-the-counter (OTC) aerosol drug products. This is a repeat violation noted in previous inspections.\u003C\u002Fp>\u003Cp>In your response, you state that you will outline the control procedures to ensure that manufacturing processes are properly validated. You also state that you will follow your current standard operating procedure (SOP) for data collection on the drug products you manufacture.\u003C\u002Fp>\u003Cp>Your response is inadequate because it lacks specific timelines, including details of your interim plans, while working toward full and complete process validation.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluates batches to determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\u003Cp>See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing appropriate PPQ for each of your marketed drug products.\u003C\u002Fli>\u003Cli>Process performance protocols, and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to test an adequate number of drug product batches as defined by your written stability procedure. This is a repeat violation noted in previous inspections.\u003C\u002Fp>\u003Cp>In your response, you state that you will continue placing batches of drug product on stability and commit to updating your stability procedure based on market demands.\u003C\u002Fp>\u003Cp>Your response is inadequate because you failed to address the lack of appropriate stability data to support the expiry dates of your drug products that are currently on the market. Further, you failed to provide sufficient details on the interim measures you will take to ensure product maintains its critical quality attributes throughout its shelf life.\u003C\u002Fp>\u003Cp>Without appropriate stability studies, you do not have scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\u003C\u002Fp>\u003Cp>In response to this letter please provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability-indicating methods.\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003Cbr>o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint).\u003Cbr>o All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not adequately exercise its authority and responsibilities, including but not limited to, implementing effective procedures and conducting adequate oversight of the drug products you manufacture. For example, your QU failed to ensure:\u003C\u002Fp>\u003Cul>\u003Cli>Adequate procedures for change controls, batch record release and CAPA.\u003C\u002Fli>\u003Cli>Adequate review of control records (i.e., finished product testing) prior to release and distribution.\u003C\u002Fli>\u003Cli>Appropriate procedures are established and followed for the cleaning and maintenance of your drug manufacturing equipment.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision. Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drug and Misbranding Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are “drugs” as defined by section 201(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> product labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” ; [from the product label]\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” [from the product label]\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” [from the product label]\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” [from the product label]\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” [from the product label]\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, \u003Cstrong>(b)(4)\u003C\u002Fstrong> are intended for use as combination topical first aid antiseptic and external analgesic drug products, among other intended uses. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\u003C\u002Fp>\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"over-the-counter (OTC) monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to nonprescription combination first aid antiseptic and external analgesic drug products, such as your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monographs, here M003: First Aid Antiseptic Drug Products for Over-the-Counter Human Use (henceforth “M003”) and M017: External Analgesic Drug Products for Over-the-Counter Human Use (henceforth “M017”).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, \u003Cstrong>(b)(4)\u003C\u002Fstrong> do not conform to the conditions specified in M003 and M017 for the reasons described below.\u003C\u002Fp>\u003Cp>The name of \u003Cstrong>(b)(4)\u003C\u002Fstrong> includes “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and the label contains statements such as, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and the “Uses” section of the drug facts panel includes the statement, “for help in control of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” Likewise, the name of \u003Cstrong>(b)(4)\u003C\u002Fstrong> includes “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and the label contains statements such as, “Aids in control of \u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and the “Uses” section of the drug facts panel includes the statement, “for help in control of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” These intended use claims are not permitted under either M003 or M017 and go beyond describing the general intended uses for a first aid antiseptic or an external analgesic drug product.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> is labeled to contain the active ingredients \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> in its formulation. However, this product does not conform to the conditions in M003 or M017, whether as a first aid antiseptic or as an external analgesic drug product. Specifically, this combination of active ingredients is not permitted under either M003.20 nor M017.20. Furthermore, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which you label as topical anesthetic in your Drug Facts, is not a permitted external analgesic active ingredient under M017.10(a). In addition, the concentration of the active ingredient of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which is labeled at \u003Cstrong>(b)(4)\u003C\u002Fstrong>, is more than the allowed concentration of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for a first aid antiseptic drug product under M003.10(d).\u003C\u002Fp>\u003Cp>Thus, your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> products do not comply with the applicable conditions specified in M003 and M017 and have not otherwise been found GRASE.2 Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which these products would be legally marketed without an approved application. Because there is no application in effect for these products, they are unapproved new drugs.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of such unapproved new drug products into interstate commerce violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are misbranded under section 502(f)(1) of the FD&amp;C Act, 21U.S.C. 352(f)(1) because the product labels fail to include all applicable directions for use required under M003.50(d). For example, the directions section for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> do not include, “\u003Cstrong>(b)(4)\u003C\u002Fstrong> a small amount of this product on the area 1 to 3 times daily,” “May be covered with a sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and “If \u003Cstrong>(b)(4)\u003C\u002Fstrong>, let dry first,” as required by M003.50(d)(4),(5), and (6).\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are further misbranded under section 502(f)(2) of the FD&amp;C Act, 21U.S.C. 352(f)(2), because their labeling do not “\u003Cem>[bear]…such adequate warnings against use in those pathological conditions or by children where its use may be dangerous to health, or against unsafe dosage or methods or duration of administration or application, in such manner and form, as are necessary for the protection of users\u003C\u002Fem>….” Here, the warning described in M003.50(c)(1)(ii), “Stop use and ask a doctor if the condition persists or gets worse. Do not use longer than 1 week unless directed by a doctor,” is required for first aid antiseptic drug products, such as your \u003Cstrong>(b)(4)\u003C\u002Fstrong> products, to be legally marketed under section 505G of the FD&amp;C Act. This monograph warning also falls within the scope of the warnings described in section 502(f)(2) of the FD&amp;C Act. Thus, omission of this monograph warning from the products’ labeling renders the products misbranded under section 502(f)(2).\u003C\u002Fp>\u003Cp>Additionally, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Repeat Violations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In previous inspections, FDA cited similar CGMP violations. You proposed specific remediation for these violations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1037559 and ATTN: Yvette Johnson.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> M003 reflects the conditions set forth in the relevant final order(s) established and in effect under section 505G; see Order ID OTC000030, available at FDA’s website OTC Monographs@FDA [https:\u002F\u002Fdps.fda.gov\u002Fomuf\u002Fordersearch] M017 reflects the conditions set forth in the relevant final order(s) established and in effect under section 505G; see Order ID OTC000033, available at FDA’s website OTC Monographs@FDA [https:\u002F\u002Fdps.fda.gov\u002Fomuf\u002Fordersearch]\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-15-111\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. John Gordon Dixon\n\nRecipient Title\n\nPresident\n\nDixon Investments Inc. dba ARI\n\n2523 South McDonough Road\n\nOrchard Hill, GA 30266\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-15-111\nSeptember 17, 2025\nDear Mr. Dixon:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Dixon Investments Inc. dba ARI, FEI 1037559, at 2523 South McDonough Road, Orchard Hill, from March 5 to 11, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nIn addition, (b)(4), and (b)(4) are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). Additionally, (b)(4) and (b)(4) are misbranded under sections 502(f)(1) and 502(f)(2) of the FD&C Act, 21 U.S.C. 352(f)(1) and 352(f)(2). Furthermore, (b)(4), and (b)(4) are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\nWe reviewed your March 27, 2025 response to our Form FDA-483 in detail.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYour firm had not performed process validation for your over-the-counter (OTC) aerosol drug products. This is a repeat violation noted in previous inspections.\nIn your response, you state that you will outline the control procedures to ensure that manufacturing processes are properly validated. You also state that you will follow your current standard operating procedure (SOP) for data collection on the drug products you manufacture.\nYour response is inadequate because it lacks specific timelines, including details of your interim plans, while working toward full and complete process validation.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluates batches to determine whether an initial state of control has been established.\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing appropriate PPQ for each of your marketed drug products.\nProcess performance protocols, and written procedures for qualification of equipment and facilities.\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n2. Your firm failed to follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\nYour firm failed to test an adequate number of drug product batches as defined by your written stability procedure. This is a repeat violation noted in previous inspections.\nIn your response, you state that you will continue placing batches of drug product on stability and commit to updating your stability procedure based on market demands.\nYour response is inadequate because you failed to address the lack of appropriate stability data to support the expiry dates of your drug products that are currently on the market. Further, you failed to provide sufficient details on the interim measures you will take to ensure product maintains its critical quality attributes throughout its shelf life.\nWithout appropriate stability studies, you do not have scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\nIn response to this letter please provide:\nA comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability-indicating methods.\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\no Detailed definition of the specific attributes to be tested at each station (timepoint).\no All procedures that describe these and other elements of your remediated stability program.\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) did not adequately exercise its authority and responsibilities, including but not limited to, implementing effective procedures and conducting adequate oversight of the drug products you manufacture. For example, your QU failed to ensure:\nAdequate procedures for change controls, batch record release and CAPA.\nAdequate review of control records (i.e., finished product testing) prior to release and distribution.\nAppropriate procedures are established and followed for the cleaning and maintenance of your drug manufacturing equipment.\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision. Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nUnapproved New Drug and Misbranding Drug Violations\n(b)(4) and (b)(4) are “drugs” as defined by section 201(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples from the (b)(4) and (b)(4) product labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\n(b)(4)\n“(b)(4)” ; [from the product label]\n(b)(4)\n“(b)(4)” [from the product label]\n(b)(4)\n“(b)(4)” [from the product label]\n(b)(4)\n“(b)(4)” [from the product label]\n(b)(4)\n“(b)(4)” [from the product label]\nUnapproved New Drug Violations\nBased on the above labeling evidence, (b)(4) are intended for use as combination topical first aid antiseptic and external analgesic drug products, among other intended uses. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"over-the-counter (OTC) monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to nonprescription combination first aid antiseptic and external analgesic drug products, such as your (b)(4), in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monographs, here M003: First Aid Antiseptic Drug Products for Over-the-Counter Human Use (henceforth “M003”) and M017: External Analgesic Drug Products for Over-the-Counter Human Use (henceforth “M017”).1 However, (b)(4) do not conform to the conditions specified in M003 and M017 for the reasons described below.\nThe name of (b)(4) includes “(b)(4)” and the label contains statements such as, “(b)(4),” and the “Uses” section of the drug facts panel includes the statement, “for help in control of (b)(4).” Likewise, the name of (b)(4) includes “(b)(4)” and the label contains statements such as, “Aids in control of (b)(4),” and the “Uses” section of the drug facts panel includes the statement, “for help in control of (b)(4).” These intended use claims are not permitted under either M003 or M017 and go beyond describing the general intended uses for a first aid antiseptic or an external analgesic drug product.\n(b)(4) is labeled to contain the active ingredients (b)(4), and (b)(4) in its formulation. However, this product does not conform to the conditions in M003 or M017, whether as a first aid antiseptic or as an external analgesic drug product. Specifically, this combination of active ingredients is not permitted under either M003.20 nor M017.20. Furthermore, (b)(4), which you label as topical anesthetic in your Drug Facts, is not a permitted external analgesic active ingredient under M017.10(a). In addition, the concentration of the active ingredient of (b)(4), which is labeled at (b)(4), is more than the allowed concentration of (b)(4) for a first aid antiseptic drug product under M003.10(d).\nThus, your (b)(4), and (b)(4) products do not comply with the applicable conditions specified in M003 and M017 and have not otherwise been found GRASE.2 Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which these products would be legally marketed without an approved application. Because there is no application in effect for these products, they are unapproved new drugs.\nThe introduction or delivery for introduction of such unapproved new drug products into interstate commerce violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nMisbranded Drug Violations\n(b)(4) and (b)(4) are misbranded under section 502(f)(1) of the FD&C Act, 21U.S.C. 352(f)(1) because the product labels fail to include all applicable directions for use required under M003.50(d). For example, the directions section for (b)(4) and (b)(4) do not include, “(b)(4) a small amount of this product on the area 1 to 3 times daily,” “May be covered with a sterile (b)(4),” and “If (b)(4), let dry first,” as required by M003.50(d)(4),(5), and (6).\n(b)(4) and (b)(4) are further misbranded under section 502(f)(2) of the FD&C Act, 21U.S.C. 352(f)(2), because their labeling do not “[bear]…such adequate warnings against use in those pathological conditions or by children where its use may be dangerous to health, or against unsafe dosage or methods or duration of administration or application, in such manner and form, as are necessary for the protection of users….” Here, the warning described in M003.50(c)(1)(ii), “Stop use and ask a doctor if the condition persists or gets worse. Do not use longer than 1 week unless directed by a doctor,” is required for first aid antiseptic drug products, such as your (b)(4) products, to be legally marketed under section 505G of the FD&C Act. This monograph warning also falls within the scope of the warnings described in section 502(f)(2) of the FD&C Act. Thus, omission of this monograph warning from the products’ labeling renders the products misbranded under section 502(f)(2).\nAdditionally, (b)(4), and (b)(4) are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nRepeat Violations at Facility\nIn previous inspections, FDA cited similar CGMP violations. You proposed specific remediation for these violations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1037559 and ATTN: Yvette Johnson.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\u002FS\u002F\nTina Smith\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n____________________\n1 M003 reflects the conditions set forth in the relevant final order(s) established and in effect under section 505G; see Order ID OTC000030, available at FDA’s website OTC Monographs@FDA [https:\u002F\u002Fdps.fda.gov\u002Fomuf\u002Fordersearch] M017 reflects the conditions set forth in the relevant final order(s) established and in effect under section 505G; see Order ID OTC000033, available at FDA’s website OTC Monographs@FDA [https:\u002F\u002Fdps.fda.gov\u002Fomuf\u002Fordersearch]\n2 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that (b)(4), and (b)(4) are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).","Dixon Investments Inc. dba ARI","dixon-investments-inc-dba-ari-710087-09172025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdixon-investments-inc-dba-ari-710087-09172025","2026-10-26T08:08:25.54067+00:00","2025-10-07","710087","Mr. John Gordon Dixon","2026-08-19T16:14:46.422+00:00","VIA Electronic Mail","320-15-111","2025-09-17",{"id":182,"raw":183,"subject":167,"body_html":187,"body_text":188,"firm_name":189,"letter_id":190,"created_at":88,"fei_number":19,"letter_url":191,"updated_at":192,"action_type":22,"case_status":23,"posted_date":193,"marcs_cms_no":194,"product_type":48,"closeout_date":19,"issuing_office":166,"recipient_name":195,"body_fetched_at":196,"delivery_method":197,"recipient_title":19,"reference_number":19,"action_taken_date":198,"medical_device_id":19,"response_letter_date":19},127,[184,185,186,166,167,13,13,13],"\u003Ctime datetime=\"2026-06-09T04:00:00Z\">06\u002F09\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-29T04:00:00Z\">05\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmacau-union-pharmaceutical-limited-724506-05292026\">Macau-Union Pharmaceutical Limited\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Kin Va Choi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Macau-Union Pharmaceutical Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3 - 3A Rua Cinco Do Bairro Da Areia Preta\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Room B 1\u002FF, Industrial Veng Fong\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Macao SAR China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-83\u003C\u002Fp>\u003Cp>May 29, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Choi:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Macau-Union Pharmaceutical Limited, FEI 3011219786, at 3-3A Rua Cinco Do Bairro Da Areia Preta, Room B 1\u002FF, Industrial Veng Fong, from December 15 to 17, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>In addition, “Bamboo Pharmacy® Mobility penetrating muscle &amp; joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a), 331(d). Additionally, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under section 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>We reviewed your February 2, 2026, response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and for each batch of drug product required to be free of objectionable microorganisms, appropriate laboratory testing, as necessary (21 CFR 211.165(a) and 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm did not adequately test your over-the-counter (OTC) drug products prior to release and distribution to the U.S. market. Specifically, your firm failed to test the identity and strength of each active ingredient before releasing the drug products. Your firm also failed to perform adequate microbiological testing on each batch of your drug products prior to release. You confirmed to our investigator that you lacked procedures for testing your finished drug products, and you could only provide evidence of finished drug product testing for appearance and weight.\u003C\u002Fp>\u003Cp>In your response, you commit to requiring testing for all drug products for the U.S. market, including identity verification, assay, microbial limits, and critical quality attributes. You also included summary test reports for batches shipped to the U.S. These reports contained both chemical and microbial test results.\u003C\u002Fp>\u003Cp>Your response is inadequate because you failed to provide supporting documentation for corrective actions. Additionally, the analytical reports provided lack specifications and show results for your active ingredients \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The analyses found that these active ingredients were below the drug product labeled concentrations but offered no scientific justification or explanation. Sub potency versus the labeled concentration is also a violation of section 501(c) in that the drug product’s quality falls below that which it purports to possess. Further, your microbiological reports reference “Modified United States Pharmacopeia” (USP) methods (e.g. &lt;61&gt; and &lt;62&gt;); however, your response lacks adequate documentation describing the specific modifications made to the compendial USP methods.\u003C\u002Fp>\u003Cp>Testing is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Because your firm lacked adequate testing of each batch of your drug products, you do not know whether the drug products conform to all appropriate finished drug product specifications and are suitable for release to consumers.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A list of chemical and microbial specifications, including test methods used to analyze each batch of your drug products before a batch disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and drug product recalls.\u003Cbr>o Complete microbiological testing results per USP &lt;61&gt; and &lt;62&gt; as written. Provide justification for any modified microbiological test method with validation data.\u003Cbr>o A comprehensive objectionable organism testing panel appropriate for topical OTC drug products including scientific rationale for microbiological specifications\u003Cbr>o Corrective actions to ensure no drug product is released without complete finished drug product testing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to test incoming active pharmaceutical ingredients (APIs) (e.g. \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and other components used to manufacture your OTC drug products to determine their identity, purity, strength, and other appropriate quality attributes. Additionally, you relied on your suppliers’ certificates of analysis (COA) without verifying your supplier’s test results at appropriate intervals.\u003C\u002Fp>\u003Cp>In your response, you committed to implementing an identity testing program for all incoming components to align with USP requirements and to retrospectively verify the identity of the active ingredients \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, you will establish a supplier audit procedure to verify that suppliers’ test methods and COA results to ensure compliance with USP standards.\u003C\u002Fp>\u003Cp>Your response is inadequate because you failed to provide supporting documentation demonstrating adequate implementation of the proposed corrective actions. You also do not mention retrospective testing for the active ingredients \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, you did not include your interim plans to mitigate risks to drug products during the implementation of these corrective actions.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system including, but not limited to:\u003Cbr>o evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\u003Cbr>o an assessment of all materials to determine if they are consistently of acceptable quality\u003Cbr>o a review to ensure assigned expiration or retest dates are appropriate (supported by data)\u003Cbr>o adequacy of the supplier qualification program and its selection, qualification, and disqualification provisions.\u003C\u002Fli>\u003Cli>Based on a thorough review, provide a summary of your systems corrective action and preventive action (CAPA) plan to remediate the vendor qualification program and prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming batch of component for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each component batch for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component batch for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component batch.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the components and drug products you manufacture.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and your firm’s quality control unit did not review and approve those procedures, including any changes (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm lacks process validation studies to demonstrate reproducibility and control of your manufacturing processes to ensure uniform drug product quality. Additionally, your cleaning procedures for shared equipment are inadequate. You have not demonstrated that they enable operators to clean each equipment type reproducibly and effectively.\u003C\u002Fp>\u003Cp>In your response, you committed to conducting full process validation for U.S. drug products along with establishing a comprehensive in-process testing program. You will develop a shared equipment cleaning validation protocol to validate cleaning effectiveness. Additionally, you will install a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> system with monitoring capabilities and revise your \u003Cstrong>(b)(4)\u003C\u002Fstrong> management procedure to ensure that cleaning water meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP standards.\u003C\u002Fp>\u003Cp>Your response is inadequate because you failed to provide supporting documentation demonstrating adequate implementation of the proposed corrective actions. Additionally, you did not include a risk assessment of released drug products or provide any interim manufacturing plans to mitigate risks to drug products during the implementation of your corrective actions.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the drug product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing appropriate PPQ for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced without performing any process validation studies.\u003C\u002Fli>\u003Cli>Process performance protocol(s) and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that include vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003Cbr>o Drugs with higher toxicities\u003Cbr>o Drugs with higher drug potencies\u003Cbr>o Drugs of lower solubility in their cleaning solvents\u003Cbr>o Drugs with characteristics that make them difficult to clean\u003Cbr>o Swabbing locations for areas that are most difficult to clean\u003Cbr>o Maximum hold times before cleaning\u003C\u002Fli>\u003Cli>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new drug product.\u003C\u002Fli>\u003Cli>A summary of updated standard operating procedures that ensure an appropriate program is in place for verification and validation of cleaning procedures for drug products, processes, and equipment.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to assure that the drug product bore an expiration date that was supported by appropriate stability testing (21 CFR 211.137(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to establish an adequate stability testing program to support the labeled expiration date on your distributed drug products in the U.S. market. There is no assurance that your OTC drug products will remain acceptable throughout the labeled \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiry period without an ongoing stability program.\u003C\u002Fp>\u003Cp>In your response, you committed to establishing a stability testing program “in compliance with USP &lt;1150&gt;.” You also commit to test identity and strength of the active ingredients, related substances, microbial limits, appearance, and viscosity at designated time intervals.\u003C\u002Fp>\u003Cp>Your response is inadequate because your it lacked sufficient scientific evidence to ensure that your drug products will meet proposed specifications and retain their quality attributes throughout labeled expiry. Additionally, you did not conduct or provide a risk assessment for drug products currently on the market without adequate stability testing to support the labeled expiration date.\u003C\u002Fp>\u003Cp>Without appropriate stability data, you cannot ensure your drug products meet established specifications and all pre-determined quality criteria throughout their assigned shelf-life.\u003C\u002Fp>\u003Cp>In response to this letter, provide a comprehensive, independent assessment CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003C\u002Fp>\u003Cul>\u003Cli>Stability-indicating methods\u003C\u002Fli>\u003Cli>Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003C\u002Fli>\u003Cli>An ongoing program in which representative batches of each drug product are added each year to the program to determine if the shelf-life claim remains valid\u003C\u002Fli>\u003Cli>Detailed definition of the specific attributes to be tested at each station (timepoint)\u003C\u002Fli>\u003Cli>All procedures that describe these and other elements of your remediated stability program\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“Bamboo Pharmacy® Mobility penetrating muscle &amp; joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” are drugs as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C) because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from the product labels that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>“Bamboo Pharmacy® Mobility penetrating muscle &amp; joint rub”\u003C\u002Fu>\u003C\u002Fp>\u003Cul>\u003Cli>“\u003Cstrong>DRUG FACTS . . . Uses:\u003C\u002Fstrong> For the temporary relief of minor aches and pains of muscles and joints due to ■arthritis ■strains ■bruises ■sprains ■simple backache” [from the product label]\u003C\u002Fli>\u003Cli>“Natural herbs to Promote Healing Improve Circulation Reduce Inflammation” [from the product label]\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>“Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub”\u003C\u002Fu>\u003C\u002Fp>\u003Cul>\u003Cli>“\u003Cstrong>DRUG FACTS . . . Uses:\u003C\u002Fstrong> For the temporary relief of minor aches and pains of muscles and joints due to■¦arthritis ■strains ■bruises ■sprains ■simple backache” [from the product label]\u003C\u002Fli>\u003Cli>“Natural herbs to Promote Healing Improve Circulation Reduce Inflammation” [from the product label]\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, “Bamboo Pharmacy® Mobility penetrating muscle &amp; joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” are intended for use as external analgesic drug products, among other intended uses. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\u003C\u002Fp>\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to nonprescription external analgesic drug products, such as your “Bamboo Pharmacy® Mobility penetrating muscle &amp; joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub,” in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, here M017: External Analgesic Drug Products for Over-the-Counter Human Use.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, “Bamboo Pharmacy® Mobility penetrating muscle &amp; joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” do not conform to the conditions specified in M017 for the reasons described below.\u003C\u002Fp>\u003Cp>Specifically, the labeling for “Bamboo Pharmacy® Mobility penetrating muscle &amp; joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” includes intended use claims that are not permitted under M017. For example, claims that the products “…Promote Healing Improve Circulation Reduce Inflammation” go beyond the allowed general intended uses for an external analgesic drug product and do not conform with M017.50(b).\u003C\u002Fp>\u003Cp>Furthermore, as formulated “Bamboo Pharmacy® Mobility penetrating muscle &amp; joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” includes active ingredients that are not permitted by M017.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> For example, the product labels for “Bamboo Pharmacy® Mobility penetrating muscle &amp; joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” state that the products are formulated with “Natural herbs to Promote Healing Improve Circulation Reduce Inflammation.” While the products are labeled to contain \u003Cstrong>(b)(4)\u003C\u002Fstrong> as active ingredients, which are permitted by M017 to be active ingredients in counterirritant external analgesics, “natural herbs”; however, are not permitted as active ingredients in M017 in combination or as sole ingredients. Although the products’ Drug Facts Panel do not specifically list natural herb ingredients as active ingredients, the claim that the products are formulated with “Natural herbs to Promote Healing Improve Circulation Reduce Inflammation” purports the natural herbs furnish pharmacological activity, demonstrating that natural herbs are “active ingredients” as defined in 21 CFR 201.66(b)(2).\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Thus, as formulated and labeled, your “Bamboo Pharmacy® Mobility penetrating muscle &amp; joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” products do not comply with the applicable conditions specified in M017 and have not otherwise been found GRASE.\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which these products would be legally marketed without an approved application. Because there are no applications in effect for these products, these products are unapproved new drugs.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of these unapproved new drug products into interstate commerce violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Additionally, “Bamboo Pharmacy® Mobility penetrating muscle &amp; joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on March 24, 2026.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Macau-Union Pharmaceutical Limited, at 3-3A Rua Cinco Do Bairro Da Areia Preta, Room B 1\u002FF, Industrial Veng Fong, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B) and are misbranded under section 502 of the FD&amp;C Act, respectively.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3011219786 and ATTN: Rory Geyer.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>__________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> M017 reflects the conditions in the relevant final order established and in effect under Section 505G of the FD&amp;C Act; see Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002Findex.cfm?event=OrderDetail&amp;orderid=OTC000033.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 201.66(b)(2).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Under 21 CFR 201.66(b), an active ingredient is a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “Bamboo Pharmacy® Mobility penetrating muscle &amp; joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Return Receipt Requested\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Kin Va Choi\n\nRecipient Title\n\nGeneral Manager\n\nMacau-Union Pharmaceutical Limited\n\n3 - 3A Rua Cinco Do Bairro Da Areia Preta\n\nRoom B 1\u002FF, Industrial Veng Fong\n\nMacao SAR China\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-83\nMay 29, 2026\nDear Mr. Choi:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Macau-Union Pharmaceutical Limited, FEI 3011219786, at 3-3A Rua Cinco Do Bairro Da Areia Preta, Room B 1\u002FF, Industrial Veng Fong, from December 15 to 17, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nIn addition, “Bamboo Pharmacy® Mobility penetrating muscle & joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a), 331(d). Additionally, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under section 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\nWe reviewed your February 2, 2026, response to our Form FDA 483 in detail.\nCGMP Violations\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and for each batch of drug product required to be free of objectionable microorganisms, appropriate laboratory testing, as necessary (21 CFR 211.165(a) and 211.165(b)).\nYour firm did not adequately test your over-the-counter (OTC) drug products prior to release and distribution to the U.S. market. Specifically, your firm failed to test the identity and strength of each active ingredient before releasing the drug products. Your firm also failed to perform adequate microbiological testing on each batch of your drug products prior to release. You confirmed to our investigator that you lacked procedures for testing your finished drug products, and you could only provide evidence of finished drug product testing for appearance and weight.\nIn your response, you commit to requiring testing for all drug products for the U.S. market, including identity verification, assay, microbial limits, and critical quality attributes. You also included summary test reports for batches shipped to the U.S. These reports contained both chemical and microbial test results.\nYour response is inadequate because you failed to provide supporting documentation for corrective actions. Additionally, the analytical reports provided lack specifications and show results for your active ingredients (b)(4). The analyses found that these active ingredients were below the drug product labeled concentrations but offered no scientific justification or explanation. Sub potency versus the labeled concentration is also a violation of section 501(c) in that the drug product’s quality falls below that which it purports to possess. Further, your microbiological reports reference “Modified United States Pharmacopeia” (USP) methods (e.g. \u003C61> and \u003C62>); however, your response lacks adequate documentation describing the specific modifications made to the compendial USP methods.\nTesting is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Because your firm lacked adequate testing of each batch of your drug products, you do not know whether the drug products conform to all appropriate finished drug product specifications and are suitable for release to consumers.\nIn response to this letter, provide:\nA list of chemical and microbial specifications, including test methods used to analyze each batch of your drug products before a batch disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and drug product recalls.\no Complete microbiological testing results per USP \u003C61> and \u003C62> as written. Provide justification for any modified microbiological test method with validation data.\no A comprehensive objectionable organism testing panel appropriate for topical OTC drug products including scientific rationale for microbiological specifications\no Corrective actions to ensure no drug product is released without complete finished drug product testing.\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm failed to test incoming active pharmaceutical ingredients (APIs) (e.g. (b)(4)) and other components used to manufacture your OTC drug products to determine their identity, purity, strength, and other appropriate quality attributes. Additionally, you relied on your suppliers’ certificates of analysis (COA) without verifying your supplier’s test results at appropriate intervals.\nIn your response, you committed to implementing an identity testing program for all incoming components to align with USP requirements and to retrospectively verify the identity of the active ingredients (b)(4). In addition, you will establish a supplier audit procedure to verify that suppliers’ test methods and COA results to ensure compliance with USP standards.\nYour response is inadequate because you failed to provide supporting documentation demonstrating adequate implementation of the proposed corrective actions. You also do not mention retrospective testing for the active ingredients (b)(4). Additionally, you did not include your interim plans to mitigate risks to drug products during the implementation of these corrective actions.\nWithout adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\nIn response to this letter, provide:\nA comprehensive, independent review of your material system including, but not limited to:\no evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\no an assessment of all materials to determine if they are consistently of acceptable quality\no a review to ensure assigned expiration or retest dates are appropriate (supported by data)\no adequacy of the supplier qualification program and its selection, qualification, and disqualification provisions.\nBased on a thorough review, provide a summary of your systems corrective action and preventive action (CAPA) plan to remediate the vendor qualification program and prevent use of unsuitable components, containers, and closures.\nThe chemical and microbiological quality control specifications you use to test and release each incoming batch of component for use in manufacturing.\nA description of how you will test each component batch for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component batch for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component batch.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\nA summary of your program for qualifying and overseeing contract facilities that test the components and drug products you manufacture.\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and your firm’s quality control unit did not review and approve those procedures, including any changes (21 CFR 211.100(a)).\nYour firm lacks process validation studies to demonstrate reproducibility and control of your manufacturing processes to ensure uniform drug product quality. Additionally, your cleaning procedures for shared equipment are inadequate. You have not demonstrated that they enable operators to clean each equipment type reproducibly and effectively.\nIn your response, you committed to conducting full process validation for U.S. drug products along with establishing a comprehensive in-process testing program. You will develop a shared equipment cleaning validation protocol to validate cleaning effectiveness. Additionally, you will install a new (b)(4) system with monitoring capabilities and revise your (b)(4) management procedure to ensure that cleaning water meets (b)(4) USP standards.\nYour response is inadequate because you failed to provide supporting documentation demonstrating adequate implementation of the proposed corrective actions. Additionally, you did not include a risk assessment of released drug products or provide any interim manufacturing plans to mitigate risks to drug products during the implementation of your corrective actions.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nIn response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the drug product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing appropriate PPQ for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced without performing any process validation studies.\nProcess performance protocol(s) and written procedures for qualification of equipment and facilities.\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that include vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\no Drugs with higher toxicities\no Drugs with higher drug potencies\no Drugs of lower solubility in their cleaning solvents\no Drugs with characteristics that make them difficult to clean\no Swabbing locations for areas that are most difficult to clean\no Maximum hold times before cleaning\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new drug product.\nA summary of updated standard operating procedures that ensure an appropriate program is in place for verification and validation of cleaning procedures for drug products, processes, and equipment.\n4. Your firm failed to assure that the drug product bore an expiration date that was supported by appropriate stability testing (21 CFR 211.137(a)).\nYou failed to establish an adequate stability testing program to support the labeled expiration date on your distributed drug products in the U.S. market. There is no assurance that your OTC drug products will remain acceptable throughout the labeled (b)(4) expiry period without an ongoing stability program.\nIn your response, you committed to establishing a stability testing program “in compliance with USP \u003C1150>.” You also commit to test identity and strength of the active ingredients, related substances, microbial limits, appearance, and viscosity at designated time intervals.\nYour response is inadequate because your it lacked sufficient scientific evidence to ensure that your drug products will meet proposed specifications and retain their quality attributes throughout labeled expiry. Additionally, you did not conduct or provide a risk assessment for drug products currently on the market without adequate stability testing to support the labeled expiration date.\nWithout appropriate stability data, you cannot ensure your drug products meet established specifications and all pre-determined quality criteria throughout their assigned shelf-life.\nIn response to this letter, provide a comprehensive, independent assessment CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\nStability-indicating methods\nStability studies for each drug product in its marketed container-closure system before distribution is permitted\nAn ongoing program in which representative batches of each drug product are added each year to the program to determine if the shelf-life claim remains valid\nDetailed definition of the specific attributes to be tested at each station (timepoint)\nAll procedures that describe these and other elements of your remediated stability program\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nUnapproved New Drug and Misbranding Violations\n“Bamboo Pharmacy® Mobility penetrating muscle & joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” are drugs as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C) because they are intended to affect the structure or any function of the body.\nExamples from the product labels that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\n“Bamboo Pharmacy® Mobility penetrating muscle & joint rub”\n“DRUG FACTS . . . Uses: For the temporary relief of minor aches and pains of muscles and joints due to ■arthritis ■strains ■bruises ■sprains ■simple backache” [from the product label]\n“Natural herbs to Promote Healing Improve Circulation Reduce Inflammation” [from the product label]\n“Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub”\n“DRUG FACTS . . . Uses: For the temporary relief of minor aches and pains of muscles and joints due to■¦arthritis ■strains ■bruises ■sprains ■simple backache” [from the product label]\n“Natural herbs to Promote Healing Improve Circulation Reduce Inflammation” [from the product label]\nUnapproved New Drug Violations\nBased on the above labeling evidence, “Bamboo Pharmacy® Mobility penetrating muscle & joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” are intended for use as external analgesic drug products, among other intended uses. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to nonprescription external analgesic drug products, such as your “Bamboo Pharmacy® Mobility penetrating muscle & joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub,” in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, here M017: External Analgesic Drug Products for Over-the-Counter Human Use.1 However, “Bamboo Pharmacy® Mobility penetrating muscle & joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” do not conform to the conditions specified in M017 for the reasons described below.\nSpecifically, the labeling for “Bamboo Pharmacy® Mobility penetrating muscle & joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” includes intended use claims that are not permitted under M017. For example, claims that the products “…Promote Healing Improve Circulation Reduce Inflammation” go beyond the allowed general intended uses for an external analgesic drug product and do not conform with M017.50(b).\nFurthermore, as formulated “Bamboo Pharmacy® Mobility penetrating muscle & joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” includes active ingredients that are not permitted by M017.2 For example, the product labels for “Bamboo Pharmacy® Mobility penetrating muscle & joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” state that the products are formulated with “Natural herbs to Promote Healing Improve Circulation Reduce Inflammation.” While the products are labeled to contain (b)(4) as active ingredients, which are permitted by M017 to be active ingredients in counterirritant external analgesics, “natural herbs”; however, are not permitted as active ingredients in M017 in combination or as sole ingredients. Although the products’ Drug Facts Panel do not specifically list natural herb ingredients as active ingredients, the claim that the products are formulated with “Natural herbs to Promote Healing Improve Circulation Reduce Inflammation” purports the natural herbs furnish pharmacological activity, demonstrating that natural herbs are “active ingredients” as defined in 21 CFR 201.66(b)(2).3\nThus, as formulated and labeled, your “Bamboo Pharmacy® Mobility penetrating muscle & joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” products do not comply with the applicable conditions specified in M017 and have not otherwise been found GRASE.4 Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which these products would be legally marketed without an approved application. Because there are no applications in effect for these products, these products are unapproved new drugs.\nThe introduction or delivery for introduction of these unapproved new drug products into interstate commerce violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nMisbranded Drug Violations\nAdditionally, “Bamboo Pharmacy® Mobility penetrating muscle & joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on March 24, 2026.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Macau-Union Pharmaceutical Limited, at 3-3A Rua Cinco Do Bairro Da Areia Preta, Room B 1\u002FF, Industrial Veng Fong, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B) and are misbranded under section 502 of the FD&C Act, respectively.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3011219786 and ATTN: Rory Geyer.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\u002FS\u002F\nTina Smith\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n__________________________\n1 M017 reflects the conditions in the relevant final order established and in effect under Section 505G of the FD&C Act; see Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002Findex.cfm?event=OrderDetail&orderid=OTC000033.\n2 See 21 CFR 201.66(b)(2).\n3 Under 21 CFR 201.66(b), an active ingredient is a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n4 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “Bamboo Pharmacy® Mobility penetrating muscle & joint rub” and “Bamboo Pharmacy® Relief + Recovery deep tissue pain relieving rub” are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).","Macau-Union Pharmaceutical Limited","macau-union-pharmaceutical-limited-724506-05292026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmacau-union-pharmaceutical-limited-724506-05292026","2026-10-26T08:09:18.024742+00:00","2026-06-09","724506","Mr. Kin Va Choi","2026-08-19T04:38:02.357+00:00","Via Electronic Mail - Return Receipt Requested","2026-05-29",{"id":200,"raw":201,"subject":205,"body_html":206,"body_text":207,"firm_name":208,"letter_id":209,"created_at":210,"fei_number":19,"letter_url":211,"updated_at":212,"action_type":22,"case_status":23,"posted_date":213,"marcs_cms_no":214,"product_type":26,"closeout_date":19,"issuing_office":123,"recipient_name":215,"body_fetched_at":216,"delivery_method":178,"recipient_title":19,"reference_number":19,"action_taken_date":217,"medical_device_id":19,"response_letter_date":19},22115,[202,203,204,123,205,13,13,13],"\u003Ctime datetime=\"2026-11-03T05:00:00Z\">11\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-09-29T04:00:00Z\">09\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fif-co-pack-llc-dba-initiative-foods-732244-09292026\">IF Co-Pack, LLC dba Initiative Foods\u003C\u002Fa>","CGMP\u002FHazard Analysis\u002FRisk-Based Preventive Controls for Food\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Roy D. Ephgrave\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>IF Co-Pack, LLC dba Initiative Foods\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1912 Industrial Way\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sanger\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>93657-9508\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 29, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS # 732244\u003C\u002Fp>\u003Cp>Dear Mr. Ephgrave:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your ready-to-eat (RTE) food manufacturing facility, located at 1912 Industrial Way, Sanger, California from March 31 to April 9, 2026. Your firm manufactures high-acid, acidified, and low-acid canned (LACF) fruit and vegetable baby food products. The inspection revealed significant violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117).\u003C\u002Fp>\u003Cp>The failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP &amp; PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and further information about FDA’s regulations through links in FDA’s home page at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, FDA investigators issued an FDA Form 483 (FDA-483), Inspectional Observations, listing the violations observed at your facility. As of the date of this letter, we have not received a response to the FDA-483 issued to you at the close of the inspection on April 9, 2026. Based on our review of the inspectional findings, FDA is issuing this letter to advise you of our concerns and to provide detailed information describing the findings at your facility.\u003C\u002Fp>\u003Cp>Your significant violations were as follows:\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Hazard Analysis and Risk-Based Preventive Controls (21 CFR Part 117, Subpart C)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>1. You did not identify and evaluate known or reasonably foreseeable hazards to determine whether they required preventive controls, as required by 21 CFR 117.130(a)(1).\u003C\u002Fp>\u003Cp>Specifically, your hazard analysis for your “Acidified\u002FHigh Acid Fruit and Vegetable Products – Pouches” did not identify patulin as a hazard requiring a preventive control. Patulin is a mycotoxin produced by mold species commonly associated with apples and other fruits, and its presence in apple-containing products is a well-recognized food safety hazard. Your facility manufactures fruit puree baby food, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> baby food pouches containing apple ingredients. However, your “Hazard Analysis Risk Assessment” indicated patulin as having a low likelihood of occurrence in the absence of preventive controls in incoming \u003Cstrong>(b)(4)\u003C\u002Fstrong> ingredients.\u003C\u002Fp>\u003Cp>Preventive controls, such as process controls and supply-chain controls, must be established as appropriate to your facility and your food (see 21 CFR 117.135(c)). Your facility has not established preventive controls like patulin specifications for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> used to manufacture your baby food products. For example, your facility receives Certificates of Analysis (COAs) that include patulin levels for some incoming \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, there is no documentation demonstrating that these COAs are reviewed as part of preventive control measures to significantly minimize or prevent patulin in your baby food products (see 21 CFR 117.135(a)(1)). Additionally, on December 26, 2025, you used \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, to manufacture \u003Cstrong>(b)(4)\u003C\u002Fstrong> Baby Food Pouches, lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>. The COA for this \u003Cstrong>(b)(4)\u003C\u002Fstrong> did not include patulin testing results, and there is no documentation indicating that your firm identified or addressed this deficiency prior to use of the ingredient in production.\u003C\u002Fp>\u003Cp>The significance of patulin as a hazard in your operations is further demonstrated by your firm's February 2026 voluntary recall of \"Tippy Toes\" brand Apple Pear Banana puree due to elevated patulin levels. This recall was initiated after FDA notified your facility of analytical findings from FDA’s Total Diet Study (TDS)\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. A non-regulatory TDS sample of your product detected elevated patulin levels. Following FDA’s notification, your facility conducted internal testing of retained samples from lots your firm determined to be potentially related to the implicated TDS lot. This private lab testing detected patulin at a level of 40 ppb in one lot, prompting the voluntary recall.\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of the violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including applicable FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing within fifteen (15) working days of receipt of this letter of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and provide the time within which you will do so. If you believe your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Marco Esteves, Compliance Officer, via email at Marco.Esteves@fda.hhs.gov. If you have any questions regarding this letter, you may contact Marco Esteves, Compliance Officer, via email at Marco.Esteves@fda.hhs.gov. Please reference 732244 on any submissions and within the subject line of any emails to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, JD MBA\u003Cbr>Director\u003Cbr>Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\u003Cp>________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The TDS is an ongoing FDA program that monitors levels of nutrients and contaminants in foods eaten by people in the United States. As part of the TDS, FDA purchases foods from the same retail outlets that consumers use and prepares them as consumers typically would, providing realistic estimates of contaminant and nutrient levels in the U.S. diet.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nRoy D. Ephgrave\n\nRecipient Title\n\nCEO\n\nIF Co-Pack, LLC dba Initiative Foods\n\n1912 Industrial Way\n\nSanger, CA 93657-9508\n\nUnited States\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nSeptember 29, 2026\nWARNING LETTER\nRe: CMS # 732244\nDear Mr. Ephgrave:\nThe United States Food and Drug Administration (FDA) conducted an inspection of your ready-to-eat (RTE) food manufacturing facility, located at 1912 Industrial Way, Sanger, California from March 31 to April 9, 2026. Your firm manufactures high-acid, acidified, and low-acid canned (LACF) fruit and vegetable baby food products. The inspection revealed significant violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117).\nThe failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP & PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and further information about FDA’s regulations through links in FDA’s home page at http:\u002F\u002Fwww.fda.gov.\nAt the conclusion of the inspection, FDA investigators issued an FDA Form 483 (FDA-483), Inspectional Observations, listing the violations observed at your facility. As of the date of this letter, we have not received a response to the FDA-483 issued to you at the close of the inspection on April 9, 2026. Based on our review of the inspectional findings, FDA is issuing this letter to advise you of our concerns and to provide detailed information describing the findings at your facility.\nYour significant violations were as follows:\nHazard Analysis and Risk-Based Preventive Controls (21 CFR Part 117, Subpart C)\n1. You did not identify and evaluate known or reasonably foreseeable hazards to determine whether they required preventive controls, as required by 21 CFR 117.130(a)(1).\nSpecifically, your hazard analysis for your “Acidified\u002FHigh Acid Fruit and Vegetable Products – Pouches” did not identify patulin as a hazard requiring a preventive control. Patulin is a mycotoxin produced by mold species commonly associated with apples and other fruits, and its presence in apple-containing products is a well-recognized food safety hazard. Your facility manufactures fruit puree baby food, such as (b)(4) baby food pouches containing apple ingredients. However, your “Hazard Analysis Risk Assessment” indicated patulin as having a low likelihood of occurrence in the absence of preventive controls in incoming (b)(4) ingredients.\nPreventive controls, such as process controls and supply-chain controls, must be established as appropriate to your facility and your food (see 21 CFR 117.135(c)). Your facility has not established preventive controls like patulin specifications for your (b)(4) used to manufacture your baby food products. For example, your facility receives Certificates of Analysis (COAs) that include patulin levels for some incoming (b)(4) and (b)(4). However, there is no documentation demonstrating that these COAs are reviewed as part of preventive control measures to significantly minimize or prevent patulin in your baby food products (see 21 CFR 117.135(a)(1)). Additionally, on December 26, 2025, you used (b)(4), lot #(b)(4), to manufacture (b)(4) Baby Food Pouches, lot #(b)(4). The COA for this (b)(4) did not include patulin testing results, and there is no documentation indicating that your firm identified or addressed this deficiency prior to use of the ingredient in production.\nThe significance of patulin as a hazard in your operations is further demonstrated by your firm's February 2026 voluntary recall of \"Tippy Toes\" brand Apple Pear Banana puree due to elevated patulin levels. This recall was initiated after FDA notified your facility of analytical findings from FDA’s Total Diet Study (TDS)1. A non-regulatory TDS sample of your product detected elevated patulin levels. Following FDA’s notification, your facility conducted internal testing of retained samples from lots your firm determined to be potentially related to the implicated TDS lot. This private lab testing detected patulin at a level of 40 ppb in one lot, prompting the voluntary recall.\nThe violations cited in this letter are not intended to be an all-inclusive list of the violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including applicable FDA regulations.\nThis letter notifies you of our concerns and provides you with an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing within fifteen (15) working days of receipt of this letter of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and provide the time within which you will do so. If you believe your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nPlease send your reply to the Food and Drug Administration, Attention: Marco Esteves, Compliance Officer, via email at Marco.Esteves@fda.hhs.gov. If you have any questions regarding this letter, you may contact Marco Esteves, Compliance Officer, via email at Marco.Esteves@fda.hhs.gov. Please reference 732244 on any submissions and within the subject line of any emails to us.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, JD MBA\nDirector\nOffice of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program\n________________________\n1 The TDS is an ongoing FDA program that monitors levels of nutrients and contaminants in foods eaten by people in the United States. As part of the TDS, FDA purchases foods from the same retail outlets that consumers use and prepares them as consumers typically would, providing realistic estimates of contaminant and nutrient levels in the U.S. diet.","IF Co-Pack, LLC dba Initiative Foods","if-co-pack-llc-dba-initiative-foods-732244-09292026","2026-11-10T01:02:16.121874+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fif-co-pack-llc-dba-initiative-foods-732244-09292026","2026-11-17T01:02:03.701861+00:00","2026-11-03","732244","Roy D. Ephgrave","2026-11-10T01:02:51.048+00:00","2026-09-29",{"id":219,"raw":220,"subject":224,"body_html":225,"body_text":226,"firm_name":227,"letter_id":228,"created_at":229,"fei_number":19,"letter_url":230,"updated_at":231,"action_type":22,"case_status":23,"posted_date":232,"marcs_cms_no":233,"product_type":155,"closeout_date":19,"issuing_office":144,"recipient_name":234,"body_fetched_at":235,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":236,"medical_device_id":19,"response_letter_date":19},3399,[221,222,223,144,224,13,13,13],"\u003Ctime datetime=\"2021-04-15T17:00:00Z\">04\u002F15\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-25T04:00:00Z\">03\u002F25\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fikcon-investments-inc-dba-ikcon-medical-609791-03252021\">Ikcon Investments, Inc dba Ikcon Medical\u003C\u002Fa>","Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ricardo Emmanuel Weichsel Upton\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Ikcon Investments, Inc dba Ikcon Medical\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14653 Caminito Lazanja\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Diego\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92127\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@ikconmedical.com\"> info@ikconmedical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: March 25, 2021\u003C\u002Fp>\n\n\u003Cp>TO:&nbsp;\u003C\u002Fp>\n\n\u003Cp>6540 Lusk Blvd Suite C-111\u003Cbr>\nSan Diego, CA 92121\u003C\u002Fp>\n\n\u003Cp>University Center Lane, Suite 400\u003Cbr>\nSan Diego, CA 92122\u003C\u002Fp>\n\n\u003Cp>RE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your websites at the Internet addresses www.ikconmedical.com and www.akcutestshop.com on February 3, 4, and 11, 2021. The FDA has observed that your website, www.akcutestshop.com, offers the “Akcutest COVID-19 Antibody Test” (also referred to as the “Akcutest Kit (25 tests per Kit $20\u002Ftest) COVID-19 Rapid Tests,” “Akcutest Sample Kit (3 tests per Kit $33\u002Ftest) COVID-19 Rapid tests,” and “Akcutest Serological Rapid Test”) (hereafter referred to as “Akcutest Kit”) and the “Lumigenik COVID-19 Antigen Rapid Test” (also referred to as “Lumigenik Sample Kit (3 tests per Kit $50\u002Ftest) COVID-19 Rapid Tests,” “Lumigenik Kit (25 tests per Kit $30\u002Ftest) COVID-19 Rapid Tests,” and “Lumigenik Antigen Rapid Test”) (hereafter referred to as “Lumigenik Kit”) for sale in the United States. Based on our review, these products&nbsp;are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>The Akcutest Kit and the Lumigenik Kit are offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, the products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). The products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described above, you sell a product that is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved, uncleared, and unauthorized product for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>The Akcutest Kit is also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because its labeling is false or misleading. FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to an establishment registration that create an impression of official FDA approval of the establishment or its products are misleading and constitute misbranding. See 21 CFR 807.39. Your websites reference FDA registration (e.g., “FDA registered”), at times incorporating unauthorized use of the FDA logo,\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> alongside information about and photos of the Akcutest Kit. As displayed, such representations imply that FDA has approved, cleared, authorized, or otherwise evaluated the product. As stated above, FDA has not approved, cleared, or authorized the product. Moreover, the “disclaimer” presented, for example, in small font and placed at the very bottom of your websites stating that “[t]his test has not been reviewed by the FDA” could be easily overlooked and does not mitigate the overall impression that FDA has approved, cleared, authorized, or otherwise evaluated the product. We also note that based on our review of FDA’s Establishment Registration &amp; Device Listing Database, an establishment with or including the name “Ikcon” is not registered and no device by the name of “Akcutest” was listed by any establishment. Therefore, statements indicating “FDA registered” also appear to be false. Your firm’s representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your product(s) or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your product(s) as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the product(s) in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to immediately address this matter may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>.Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized product(s) for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\u003Cbr>\n\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Timothy Stenzel, M.D., Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT7: Office of In Vitro Diagnostics and Radiological\u003Cbr>\n&nbsp; &nbsp; Health\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> The FDA logo is for official use by FDA and not for private use on labeling of FDA-regulated products. See FDA Logo Policy (available at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\">https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\u003C\u002Fa>).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Accessible at \u003Ca>https:\u002F\u002Fwww fda.gov\u002Fmedia\u002F135659\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nRicardo Emmanuel Weichsel Upton\n\nRecipient Title\n\nPresident\n\nIkcon Investments, Inc dba Ikcon Medical\n\n14653 Caminito Lazanja\n\nSan Diego, CA 92127\n\nUnited States\n\ninfo@ikconmedical.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDate: March 25, 2021\n\nTO:\n\n6540 Lusk Blvd Suite C-111\n\nSan Diego, CA 92121\n\nUniversity Center Lane, Suite 400\n\nSan Diego, CA 92122\n\nRE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your websites at the Internet addresses www.ikconmedical.com and www.akcutestshop.com on February 3, 4, and 11, 2021. The FDA has observed that your website, www.akcutestshop.com, offers the “Akcutest COVID-19 Antibody Test” (also referred to as the “Akcutest Kit (25 tests per Kit $20\u002Ftest) COVID-19 Rapid Tests,” “Akcutest Sample Kit (3 tests per Kit $33\u002Ftest) COVID-19 Rapid tests,” and “Akcutest Serological Rapid Test”) (hereafter referred to as “Akcutest Kit”) and the “Lumigenik COVID-19 Antigen Rapid Test” (also referred to as “Lumigenik Sample Kit (3 tests per Kit $50\u002Ftest) COVID-19 Rapid Tests,” “Lumigenik Kit (25 tests per Kit $30\u002Ftest) COVID-19 Rapid Tests,” and “Lumigenik Antigen Rapid Test”) (hereafter referred to as “Lumigenik Kit”) for sale in the United States. Based on our review, these products are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nThe Akcutest Kit and the Lumigenik Kit are offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, the products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). The products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described above, you sell a product that is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved, uncleared, and unauthorized product for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nThe Akcutest Kit is also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because its labeling is false or misleading. FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to an establishment registration that create an impression of official FDA approval of the establishment or its products are misleading and constitute misbranding. See 21 CFR 807.39. Your websites reference FDA registration (e.g., “FDA registered”), at times incorporating unauthorized use of the FDA logo,4 alongside information about and photos of the Akcutest Kit. As displayed, such representations imply that FDA has approved, cleared, authorized, or otherwise evaluated the product. As stated above, FDA has not approved, cleared, or authorized the product. Moreover, the “disclaimer” presented, for example, in small font and placed at the very bottom of your websites stating that “[t]his test has not been reviewed by the FDA” could be easily overlooked and does not mitigate the overall impression that FDA has approved, cleared, authorized, or otherwise evaluated the product. We also note that based on our review of FDA’s Establishment Registration & Device Listing Database, an establishment with or including the name “Ikcon” is not registered and no device by the name of “Akcutest” was listed by any establishment. Therefore, statements indicating “FDA registered” also appear to be false. Your firm’s representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”5 provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your product(s) or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your product(s) as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the product(s) in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to immediately address this matter may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products.Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized product(s) for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy Stenzel, M.D., Ph.D.\n\nDirector\n\nOHT7: Office of In Vitro Diagnostics and Radiological\n\nHealth\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n_________________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\n\n4 The FDA logo is for official use by FDA and not for private use on labeling of FDA-regulated products. See FDA Logo Policy (available at: https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy).\n\n5 Accessible at https:\u002F\u002Fwww fda.gov\u002Fmedia\u002F135659\u002Fdownload.","Ikcon Investments, Inc dba Ikcon Medical","ikcon-investments-inc-dba-ikcon-medical-609791-03252021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fikcon-investments-inc-dba-ikcon-medical-609791-03252021","2026-10-26T08:08:57.509369+00:00","2021-04-15","609791","Ricardo Emmanuel Weichsel Upton","2026-08-20T03:11:54.26+00:00","2021-03-25",{"id":238,"raw":239,"subject":243,"body_html":244,"body_text":245,"firm_name":246,"letter_id":247,"created_at":129,"fei_number":19,"letter_url":248,"updated_at":249,"action_type":22,"case_status":23,"posted_date":250,"marcs_cms_no":251,"product_type":26,"closeout_date":19,"issuing_office":123,"recipient_name":252,"body_fetched_at":253,"delivery_method":254,"recipient_title":19,"reference_number":19,"action_taken_date":255,"medical_device_id":19,"response_letter_date":19},816,[240,241,242,123,243,13,13,13],"\u003Ctime datetime=\"2025-06-24T04:00:00Z\">06\u002F24\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-01-16T05:00:00Z\">01\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fyongdae-hwangtae-union-corp-daeryung-696743-01162025\">Yongdae Hwangtae Union Corp Daeryung \u003C\u002Fa>","Seafood HACCP\u002FCGMP for Foods\u002FAdulterated\u002FInsanitary Conditions","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jong Kook Choi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Yongdae Hwangtae Union Corp Daeryung \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>10-30 Wontongro74beon-Gil\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bung-Myeon\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Inje-gun\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gangwon-do\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>24621\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Korea\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Yongdae5978@gmail.com\"> Yongdae5978@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>January 16, 2025\u003C\u002Fp>\u003Cp>Re: #696743\u003C\u002Fp>\u003Cp>Dear Mr. Jong Kook Choi:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your seafood processing facility, Yongdae Hwangtae Union Corp Daeryung 10-30 Wontongro74beon-Gil, Bung-Myeon, Inje, Gangwon Korea (the Republic of) 24621 on June 27-28, 2024. During the inspection, we found that you had serious violations of the Seafood HACCP regulation (21 CFR 123). At the conclusion of the inspection, the FDA investigator issued an FDA-483, Inspectional Observations that lists the observations made at your firm. We acknowledge receipt of your response on July 30, 2024. Your response included promises to make corrections related to environmental monitoring, calibrations of equipment used during manufacturing, and employee training. Our evaluation of your responses revealed they were not adequate, as further described in this letter.\u003C\u002Fp>\u003Cp>In accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your refrigerated and frozen desalted pollack in modified atmosphere packaging products are adulterated, in that they have been prepared, packed, or held under conditions whereby they may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation, and the June 2022 4th Edition of the Fish and Fisheries Products Hazards &amp; Controls Guidance (the Hazards Guide) through links in FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>Your significant deviations are as follows:\u003C\u002Fp>\u003Cp>1. Your finished product of dried pollack is considered a ready-to-eat (RTE) food by FDA because it may appear as a dried RTE food and be eaten without cooking by the consumer. This dried pollack is also considered raw by FDA because it does not receive a verified listericidal thermal treatment to eliminate pathogens (i.e., it is not cooked or dried at cooking temperatures). As a processor of a raw RTE product you must have appropriate sanitation and process controls for pathogen growth and toxin formation throughout processing. These controls should begin after the receipt of frozen pollack from your supplier, and include the \u003Cstrong>(b)(4)\u003C\u002Fstrong> performed at your outdoor \u003Cstrong>(b)(4)\u003C\u002Fstrong> location at the base of a mountain, the refrigerated storage of the dried pollack with unknown water activity in your warehouse, rehydration of the air-dried pollack, pressing and tearing the pollack into strips by hand, \u003Cstrong>(b)(4)\u003C\u002Fstrong> pollack in an oven at \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C (\u003Cstrong>(b)(4)\u003C\u002Fstrong>°F) and reduced oxygen packaging.\u003C\u002Fp>\u003Cp>Your food safety controls for processing in your plant are not adequate as all operations in the manufacturing, processing, packing and hold of food must be conducted in accordance with adequate sanitation principles. Raw materials must be clean and suitable for processing and stored under conditions that will protect from contamination as required by 21 CFR 117.80 (a) and (b). Your firm operates an outdoor \u003Cstrong>(b)(4)\u003C\u002Fstrong> location where pollack is \u003Cstrong>(b)(4)\u003C\u002Fstrong> exposed to the natural environment on \u003Cstrong>(b)(4)\u003C\u002Fstrong> stakes for \u003Cstrong>(b)(4)\u003C\u002Fstrong> months in the winter at ambient temperatures of \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C (\u003Cstrong>(b)(4)\u003C\u002Fstrong>°F). This \u003Cstrong>(b)(4)\u003C\u002Fstrong> process does not protect the pollack that is considered a raw RTE food from contamination with filth including pathogens (e.g., animal poop including birds and insects). The \u003Cstrong>(b)(4)\u003C\u002Fstrong> pollack with unknown water activity is then stored refrigerated in a warehouse until further processing within your processing plant. Your hazard analysis and HACCP must control food safety hazards that can be introduced both within and outside the processing plant environment to comply with 21 CFR 123.6 (a) and (b). Thus, your processing of outdoor air-drying in addition to the processing in your plant must protect the pollack from contamination with biological, chemical, and physical food safety hazards.\u003C\u002Fp>\u003Cp>Additionally, your food safety controls for processing in your plant are not adequate due to the following.\u003C\u002Fp>\u003Cp>2. You must have a HACCP plan that at a minimum, lists the critical limits that must be met, to comply with 21 CFR 123.6 (c)(3). A critical limit is defined in 21 CFR 123.3 (c) as “the maximum or minimum value to which a physical, biological, or chemical parameter must be controlled at a critical control point to prevent, eliminate, or reduce to an acceptable level the occurrence of the identified food safety hazard. However, your firm’s HACCP plan for “Dried Sliced Pollack” dated 2022-08-01 at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> critical control point (CCP) lists a critical limit of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” that is not adequate to control pathogen growth and toxin formation including \u003Cem>Clostridium botulinum\u003C\u002Fem>. Because your RTE dried pollack is intended to be shelf-stable and is in reduced oxygen packaging your critical limit should ensure the finished product achieves a water activity of \u003Cstrong>(b)(4)\u003C\u002Fstrong> or less to control pathogens including \u003Cem>C. botulinum\u003C\u002Fem>. Additionally, because your \u003Cstrong>(b)(4)\u003C\u002Fstrong> temperature is \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C (\u003Cstrong>(b)(4)\u003C\u002Fstrong>°F) which is in the temperature range for unrefrigerated processing \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C (\u003Cstrong>(b)(4)\u003C\u002Fstrong>°F) and not a thermal process that will eliminate pathogens, the cumulative time exposure to temperatures in unrefrigerated processing should not exceed two hours to control pathogen growth and toxin formation other than \u003Cem>C. botulinum\u003C\u002Fem>. The cumulative time exposure for unrefrigerated processing would end once the product achieves \u003Cstrong>(b)(4)\u003C\u002Fstrong> or less water activity. The cumulative time for unrefrigerated processing should include additional processing steps that are performed at ambient air temperatures such as the rehydration, pressing, and tearing of pollack. Your critical limits should list the critical factors as established by a scientific study to achieve a water activity of \u003Cstrong>(b)(4)\u003C\u002Fstrong> or less in the finished product and for the water activity to be achieved within \u003Cstrong>(b)(4)\u003C\u002Fstrong> cumulative hours of unrefrigerated processing. Alternatively, if your \u003Cstrong>(b)(4)\u003C\u002Fstrong> temperature was increased to above \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C (\u003Cstrong>(b)(4)\u003C\u002Fstrong>°F), then the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process would not be considered unrefrigerated processing, and the cumulative time would not be restricted to \u003Cstrong>(b)(4)\u003C\u002Fstrong> hours.\u003C\u002Fp>\u003Cp>3. Because you chose to include a corrective action plan in your HACCP plan, your described corrective actions must be appropriate, to comply with 21 CFR 123.7 (b). Corrective actions are to prevent the distribution of adulterated food into commerce and correct the cause of the deviation. However, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> CCP lists corrective actions of redrying or discarding product without actions to correct the cause of the deviation such as adjustments or repairs to oven or modifications to \u003Cstrong>(b)(4)\u003C\u002Fstrong> procedure. Also redrying should only occur if it does not jeopardize the safety of the product.\u003C\u002Fp>\u003Cp>4. You must conduct or have conducted for you a hazard analysis for each kind of fish and fishery product that you produce to determine whether there are food hazards that are reasonably likely to occur and have a HACCP plan that, at a minimum, lists the food safety hazards that are reasonably likely to occur, to comply with 21 CFR 123.6 (a) and (c) (1). A food safety hazard is defined in 21 CFR Part 123.3 (f) as \"any biological, chemical, or physical property that may cause a food to be unsafe for human consumption.\" However, your firm’s HACCP plan for dried pollack does not list the food safety hazard of undeclared allergens such as finfish (i.e., pollack).\u003C\u002Fp>\u003Cp>Your next response should include your corrective actions, revised HACCP plan with the supporting documentation and at least five days’ worth of CCP and sanitation monitoring in English to demonstrate implementation. For assistance with revising your HACCP plan see FDA’s \u003Cu>Fish and Fishery Products Hazards and Controls\u003C\u002Fu> guidance and for sanitation monitoring see the \u003Cu>Sanitation Control Procedures for Processing Fish and Fishery Products\u003C\u002Fu> document. Also FDA’s Draft Guidance for Industry: \u003Cu>Control of Listeria monocytogenes in Ready-to-Eat Foods\u003C\u002Fu> provides recommendations for RTE food processors.\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific corrections you are performing related to these deviations. If you cannot complete the corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>If you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported fish or fishery products under section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the seafood HACCP regulation is Import Alert 16-120. This alert can be found on FDA’s web site at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fimportalert_25.html.\u003C\u002Fp>\u003Cp>This letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the seafood HACCP regulation (21 CFR Part 123) and the current Good Manufacturing Practice Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117 Subpart B). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\u003C\u002Fp>\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Victoria Palmer, Compliance Officer, Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding any issues in this letter, please contact Victoria Palmer via email at: Victoria.palmer@fda.hhs.gov. Please include reference #696743 on any submissions and within the subject line of any email correspondence to the agency.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, JD, MBA\u003Cbr>Acting Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery and Electronic Mail\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Jong Kook Choi\n\nRecipient Title\n\nPresident\n\nYongdae Hwangtae Union Corp Daeryung\n\n10-30 Wontongro74beon-Gil\n\nBung-Myeon\n\nInje-gun\n\nGangwon-do\n\n24621\n\nSouth Korea\n\nYongdae5978@gmail.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nWARNING LETTER\nJanuary 16, 2025\nRe: #696743\nDear Mr. Jong Kook Choi:\nThe United States Food and Drug Administration (FDA) conducted an inspection of your seafood processing facility, Yongdae Hwangtae Union Corp Daeryung 10-30 Wontongro74beon-Gil, Bung-Myeon, Inje, Gangwon Korea (the Republic of) 24621 on June 27-28, 2024. During the inspection, we found that you had serious violations of the Seafood HACCP regulation (21 CFR 123). At the conclusion of the inspection, the FDA investigator issued an FDA-483, Inspectional Observations that lists the observations made at your firm. We acknowledge receipt of your response on July 30, 2024. Your response included promises to make corrections related to environmental monitoring, calibrations of equipment used during manufacturing, and employee training. Our evaluation of your responses revealed they were not adequate, as further described in this letter.\nIn accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your refrigerated and frozen desalted pollack in modified atmosphere packaging products are adulterated, in that they have been prepared, packed, or held under conditions whereby they may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation, and the June 2022 4th Edition of the Fish and Fisheries Products Hazards & Controls Guidance (the Hazards Guide) through links in FDA's home page at www.fda.gov.\nYour significant deviations are as follows:\n1. Your finished product of dried pollack is considered a ready-to-eat (RTE) food by FDA because it may appear as a dried RTE food and be eaten without cooking by the consumer. This dried pollack is also considered raw by FDA because it does not receive a verified listericidal thermal treatment to eliminate pathogens (i.e., it is not cooked or dried at cooking temperatures). As a processor of a raw RTE product you must have appropriate sanitation and process controls for pathogen growth and toxin formation throughout processing. These controls should begin after the receipt of frozen pollack from your supplier, and include the (b)(4) performed at your outdoor (b)(4) location at the base of a mountain, the refrigerated storage of the dried pollack with unknown water activity in your warehouse, rehydration of the air-dried pollack, pressing and tearing the pollack into strips by hand, (b)(4) pollack in an oven at (b)(4)°C ((b)(4)°F) and reduced oxygen packaging.\nYour food safety controls for processing in your plant are not adequate as all operations in the manufacturing, processing, packing and hold of food must be conducted in accordance with adequate sanitation principles. Raw materials must be clean and suitable for processing and stored under conditions that will protect from contamination as required by 21 CFR 117.80 (a) and (b). Your firm operates an outdoor (b)(4) location where pollack is (b)(4) exposed to the natural environment on (b)(4) stakes for (b)(4) months in the winter at ambient temperatures of (b)(4)°C ((b)(4)°F). This (b)(4) process does not protect the pollack that is considered a raw RTE food from contamination with filth including pathogens (e.g., animal poop including birds and insects). The (b)(4) pollack with unknown water activity is then stored refrigerated in a warehouse until further processing within your processing plant. Your hazard analysis and HACCP must control food safety hazards that can be introduced both within and outside the processing plant environment to comply with 21 CFR 123.6 (a) and (b). Thus, your processing of outdoor air-drying in addition to the processing in your plant must protect the pollack from contamination with biological, chemical, and physical food safety hazards.\nAdditionally, your food safety controls for processing in your plant are not adequate due to the following.\n2. You must have a HACCP plan that at a minimum, lists the critical limits that must be met, to comply with 21 CFR 123.6 (c)(3). A critical limit is defined in 21 CFR 123.3 (c) as “the maximum or minimum value to which a physical, biological, or chemical parameter must be controlled at a critical control point to prevent, eliminate, or reduce to an acceptable level the occurrence of the identified food safety hazard. However, your firm’s HACCP plan for “Dried Sliced Pollack” dated 2022-08-01 at the (b)(4) critical control point (CCP) lists a critical limit of “(b)(4)” that is not adequate to control pathogen growth and toxin formation including Clostridium botulinum. Because your RTE dried pollack is intended to be shelf-stable and is in reduced oxygen packaging your critical limit should ensure the finished product achieves a water activity of (b)(4) or less to control pathogens including C. botulinum. Additionally, because your (b)(4) temperature is (b)(4)°C ((b)(4)°F) which is in the temperature range for unrefrigerated processing (b)(4)°C ((b)(4)°F) and not a thermal process that will eliminate pathogens, the cumulative time exposure to temperatures in unrefrigerated processing should not exceed two hours to control pathogen growth and toxin formation other than C. botulinum. The cumulative time exposure for unrefrigerated processing would end once the product achieves (b)(4) or less water activity. The cumulative time for unrefrigerated processing should include additional processing steps that are performed at ambient air temperatures such as the rehydration, pressing, and tearing of pollack. Your critical limits should list the critical factors as established by a scientific study to achieve a water activity of (b)(4) or less in the finished product and for the water activity to be achieved within (b)(4) cumulative hours of unrefrigerated processing. Alternatively, if your (b)(4) temperature was increased to above (b)(4)°C ((b)(4)°F), then the (b)(4) process would not be considered unrefrigerated processing, and the cumulative time would not be restricted to (b)(4) hours.\n3. Because you chose to include a corrective action plan in your HACCP plan, your described corrective actions must be appropriate, to comply with 21 CFR 123.7 (b). Corrective actions are to prevent the distribution of adulterated food into commerce and correct the cause of the deviation. However, your (b)(4) CCP lists corrective actions of redrying or discarding product without actions to correct the cause of the deviation such as adjustments or repairs to oven or modifications to (b)(4) procedure. Also redrying should only occur if it does not jeopardize the safety of the product.\n4. You must conduct or have conducted for you a hazard analysis for each kind of fish and fishery product that you produce to determine whether there are food hazards that are reasonably likely to occur and have a HACCP plan that, at a minimum, lists the food safety hazards that are reasonably likely to occur, to comply with 21 CFR 123.6 (a) and (c) (1). A food safety hazard is defined in 21 CFR Part 123.3 (f) as \"any biological, chemical, or physical property that may cause a food to be unsafe for human consumption.\" However, your firm’s HACCP plan for dried pollack does not list the food safety hazard of undeclared allergens such as finfish (i.e., pollack).\nYour next response should include your corrective actions, revised HACCP plan with the supporting documentation and at least five days’ worth of CCP and sanitation monitoring in English to demonstrate implementation. For assistance with revising your HACCP plan see FDA’s Fish and Fishery Products Hazards and Controls guidance and for sanitation monitoring see the Sanitation Control Procedures for Processing Fish and Fishery Products document. Also FDA’s Draft Guidance for Industry: Control of Listeria monocytogenes in Ready-to-Eat Foods provides recommendations for RTE food processors.\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific corrections you are performing related to these deviations. If you cannot complete the corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\nIf you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported fish or fishery products under section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the seafood HACCP regulation is Import Alert 16-120. This alert can be found on FDA’s web site at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fimportalert_25.html.\nThis letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the seafood HACCP regulation (21 CFR Part 123) and the current Good Manufacturing Practice Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117 Subpart B). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\nPlease send your reply to the Food and Drug Administration, Attention: Victoria Palmer, Compliance Officer, Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding any issues in this letter, please contact Victoria Palmer via email at: Victoria.palmer@fda.hhs.gov. Please include reference #696743 on any submissions and within the subject line of any email correspondence to the agency.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, JD, MBA\nActing Director, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","Yongdae Hwangtae Union Corp Daeryung","yongdae-hwangtae-union-corp-daeryung-696743-01162025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fyongdae-hwangtae-union-corp-daeryung-696743-01162025","2026-10-26T08:10:36.813524+00:00","2025-06-24","696743","Mr. Jong Kook Choi","2026-08-19T16:39:29.885+00:00","Via Express Delivery and Electronic Mail","2025-01-16",{"id":257,"raw":258,"subject":38,"body_html":263,"body_text":264,"firm_name":265,"letter_id":266,"created_at":150,"fei_number":19,"letter_url":267,"updated_at":268,"action_type":22,"case_status":23,"posted_date":269,"marcs_cms_no":270,"product_type":26,"closeout_date":19,"issuing_office":262,"recipient_name":271,"body_fetched_at":272,"delivery_method":273,"recipient_title":19,"reference_number":19,"action_taken_date":274,"medical_device_id":19,"response_letter_date":19},1441,[259,260,261,262,38,13,13,13],"\u003Ctime datetime=\"2024-05-28T13:20:00Z\">05\u002F28\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-05-09T04:00:00Z\">05\u002F09\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiomic-sciences-llc-dba-ion-intelligence-nature-667601-05092024\">Biomic Sciences, LLC dba ION Intelligence of Nature\u003C\u002Fa>","Division of Human and Animal Food Operations East II","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Zachary Bush\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Biomic Sciences, LLC dba ION Intelligence of Nature\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4351 Seminole Trail\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Charlottesville\u003C\u002Fspan>, \u003Cspan>VA\u003C\u002Fspan> \u003Cspan>22153-2823\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations East II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 9, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS #667601\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Bush,\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 4351 Seminole Trail, Charlottesville, Virginia from June 12 through August 31, 2023. Based on inspectional findings and review of the product labels collected during the inspection, as well as review of your website at www.Intelligenceofnature.com, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection on August 31, 2023, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. We address your responses below, when relevant information from such response(s) pertained to a particular issue.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Human Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>FDA Tested Samples\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>FDA conducted laboratory testing of a lot of ION Intelligence of Nature Sinus Support Nasal Spray drug product and results demonstrate that this drug product is adulterated within the meaning of section 501(a)(1) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. 351(a)(1), in that it consists in whole or in part of any filthy, putrid, or decomposed substance.\u003C\u002Fp>\n\n\u003Cp>FDA laboratory analysis determined that a sample of your ION Intelligence of Nature Sinus Support Nasal Spray drug product was grossly contaminated with microorganisms. This gross contamination is particularly concerning because your drug product is a nasal spray.\u003C\u002Fp>\n\n\u003Cp>FDA laboratory testing of ION Intelligence of Nature Sinus Support Nasal Spray drug product lot 2302081HGA found gross microbial contamination. The individual sample results varied between 510,000 and up to 1,100,000 colony forming units (CFU)\u002FmL for total aerobic microbial count and between 290 and up to 1,100 CFU\u002FmL for total yeast and mold counts. Therefore, this drug product is adulterated under section 501(a)(1) of the Act.\u003C\u002Fp>\n\n\u003Cp>Microorganisms identified included \u003Cem>Microbacterium sp., Fictibacillus sp., Bacillus sp. (primarily B. malikii)\u003C\u002Fem>, and \u003Cem>Paenibacillus sp.\u003C\u002Fem> The high bioburden in conjunction with the route of administration with this drug product poses a high risk of harm to vulnerable patients.\u003C\u002Fp>\n\n\u003Cp>On September 22, 2023, the FDA held a teleconference with you. During the teleconference, you agreed to conduct a voluntary recall of all lots of ION Intelligence of Nature Sinus Support Nasal Spray.\u003C\u002Fp>\n\n\u003Cp>On September 29, 2023, you voluntarily recalled all lots of ION Intelligence of Nature Sinus Support Nasal Spray, ION Sinus, and Restore Sinus Spray products to the consumer level due to microbial contamination identified as \u003Cem>Microbacterium sp., Fictibacillus sp., Bacillus sp.\u003C\u002Fem> (primarily \u003Cem>B. malikii\u003C\u002Fem>), and \u003Cem>Paenibacillus sp\u003C\u002Fem>., as noted on the following FDA website:\u003Cbr>\nhttps:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fbiomic-sciences-issues-voluntary-nationwide-recall-ion-sinus-support-ion-sinus-and-restore-sinus\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The inspection of your facility from June 12 through August 31, 2023, identified significant violations of FDA’s regulations for Current Good Manufacturing Practice (CGMP) for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>1. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(b)).\u003C\u002Fp>\n\n\u003Cp>Your firm released finished drug product without adequate testing for critical microbial attributes (i.e., testing to ensure absence of objectionable microorganisms). Without appropriate testing of each lot of drug product required to be free of objectionable microorganisms prior to release, you did not have scientific evidence that the lots were free of microbial contamination that is objectionable in view of its intended use. Particularly for a drug product that is intended for use as a nasal spray, it is essential that your drug products are tested for microbial contamination to minimize the risk of patient exposure to significant numbers or harmful species of microorganisms, harmful microbial metabolites and\u002For toxins, and drug spoilage or degradation.\u003C\u002Fp>\n\n\u003Cp>You also stated during the inspection that you add \u003Cstrong>(b)(4)\u003C\u002Fstrong> to numerous drug product formulations to control microbial growth. Preservatives are not a substitute for a comprehensive approach to preventing objectionable microorganisms from contaminating your drug product and cannot be relied on to reduce in-process bioburden during manufacturing. Additionally, long term use of medicinal compounds containing \u003Cstrong>(b)(4)\u003C\u002Fstrong> may \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Levels of \u003Cstrong>(b)(4)\u003C\u002Fstrong> exposure that have led to \u003Cstrong>(b)(4)\u003C\u002Fstrong> documented and therefore, it is not possible to establish minimum levels that are safe.\u003C\u002Fp>\n\n\u003Cp>In your September 22, 2023, response, you state that you stopped producing and discontinued sales of the current formulation of ION Intelligence of Nature Sinus Support but plan to market a nasal product in the future. You state that you are revising your written procedures for quality unit (QU) responsibilities, including to specifically establish adequate testing of your finished product and water used in production of your products. You also state that you are revising procedures to ensure all applicable tests impacting the identity, strength, quality, and purity of your products are established and performed.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, clarify whether you plan to resume manufacturing drug products at this facility in the future for marketing in the United States. We request that you notify this office before you market such drug products.\u003C\u002Fp>\n\n\u003Cp>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fp>\n\n\u003Cp>Your firm failed to establish an adequate QU with responsibilities to ensure adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Adequate procedures that are designed to prevent objectionable microbiological contamination of drug products (21 CFR 211.113(a)).\u003C\u002Fli>\n\t\u003Cli>Adequate testing of components with potential for microbiological contamination that is objectionable in view of its intended use (21 CFR 211.84(d)(6)).\u003C\u002Fli>\n\t\u003Cli>Procedures are followed to adequately establish, review, and approve master manufacturing records prior to use (21 CFR 211.100(a)).\u003C\u002Fli>\n\t\u003Cli>Adequate batch records to document the mixing and packaging of your drug product (21 CFR 211.188).\u003C\u002Fli>\n\t\u003Cli>Establishment of an adequate stability program to support expiration dating of your drug products (including microbiological attributes) (21 CFR 211.166(a)).\u003C\u002Fli>\n\t\u003Cli>Adequate documentation for QU review and release of drug product. (21 CFR 211.22(a)).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Additionally, your QU was unaware of the identity of numerous proprietary components used to manufacture many of your drug products, and therefore could not have fulfilled their QU responsibilities to ensure all components meet established specifications for identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. You may refer to FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>Adulterated &amp; Misbranded Dietary Supplements\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Adulterated Low Acid Canned Food Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>The inspection of your facility on June 12 through August 31, 2023, identified serious violations of the Emergency Permit Control regulation Title 21, Code of Federal Regulations (CFR), Part 108 (21 CFR Part 108) and the Thermally Processed Low-Acid Foods Packaged in Hermetically Sealed Containers regulation (21 CFR Part 113). These violations cause your products to be adulterated within the meaning of section 402(a)(4) of the Act, 21 U.S.C. 342(a)(4), in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health.\u003C\u002Fp>\n\n\u003Cp>As a manufacturer of low acid canned food products, you are required to comply with the Act and the Federal regulations relating to the processing of low-acid foods packaged in hermetically sealed containers. The Emergency Permit Control regulations were issued, in part, pursuant to section 404 of the Act, Emergency Permit Control, 21 U.S.C. 344. A temporary emergency permit may be required for thermally processed low-acid foods packaged in hermetically sealed containers whenever a processor has failed to fulfill the requirements of 21 CFR 108.35, including registration and filing of process information, and the mandatory requirements in 21 CFR Parts 113. Regulations specific to the processing of LACF products are described in 21 CFR 108 and 21 CFR 113.\u003C\u002Fp>\n\n\u003Cp>1. You did not register with the FDA as a commercial processor of low-acid foods. A commercial processor of low-acid foods is required, not later than 10 days after first engaging in the manufacture, processing, and packaging of thermally processed low-acid foods in hermetically sealed containers in any state, as defined in section 201(a)(1) of the Act, to register and file a Form FDA 2541 (food canning establishment registration) with the FDA, as required by 21 CFR 108.35(c)(1). However, your firm processes Ion Gut Support, a low-acid food, without registering with the FDA.\u003C\u002Fp>\n\n\u003Cp>2. You must file the scheduled processes with the FDA for each low-acid food in each container size as required by 21 CFR 108.35(c)(2). This filing must occur not later than 60 days after registration and prior to the packing of a new product and include the processing method, type of retort or other thermal processing equipment employed, minimum initial temperatures, times and temperatures of processing, sterilizing value, or other equivalent scientific evidence of process adequacy, critical control factors affecting heat penetration, and source and date of the establishment of the process, for each product in each container size. Specifically, as noted during the inspection, your firm did not file a scheduled process with FDA for your Ion Gut Support product. Further, a scheduled process shall be established by a qualified person who has expert knowledge acquired through appropriate training and experience in the acidification and processing of, as required by 21 CFR 113.83\u003C\u002Fp>\n\n\u003Cp>Your response indicates that you have initiated contact with a process authority, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We acknowledge that you have initiated actions. However, this violation remains uncorrected.\u003C\u002Fp>\n\n\u003Cp>Scheduled process information for low-acid foods processed by retort must be submitted on Form FDA 2541d (Food Process Filing for Low-Acid Retorted Method) and low-acid foods controlled by water activity must be submitted on Form FDA 2541f (Food Process Filing for Water Activity\u002FFormulation Control Method). More information on registration and filing can be found in the publication “Guidance for Industry: Submitting Form FDA 2541 (Food Canning Establishment Registration) and Forms FDA 2541d, FDA 2541e, FDA 2541f, and FDA 2541g (Food Process Filing Forms) to FDA in Electronic or Paper Format” available at http:\u002F\u002Fwww.fda.gov\u002Ffood\u002Fguidanceregulation\u002Fguidancedocumentsregulatoryinformation\u002Fucm309376.htm.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Violations of Dietary Supplement CGMPs\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>The inspection of your facility from June 12 through August 31, 2023, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause your Ion Gut Support dietary supplement to be adulterated within the meaning of section 402(g)(1) of the Act, 21 U.S.C. 342(g)(1), because it has been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of dietary supplement CGMP requirements are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You failed to establish identity specifications for each component you use in the manufacture of a dietary supplement, as required by 21 CFR 111.70(b)(1); component specifications that are necessary to ensure that specifications for the purity, strength, and composition of dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2); and limits on those types of contamination that may adulterate, or that may lead to adulteration, of the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(b)(3).\u003C\u002Fp>\n\n\u003Cp>For your components, you purport to use your Biomic Sciences Component Specification sheets as your specifications for raw components \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used in the manufacture of your Ion Gut Support. However, these specification sheets do not include identity specifications for any of these components, as required by 21 CFR 111.70(b)(1); do not establish component specifications for \u003Cstrong>(b)(4)\u003C\u002Fstrong> or components \u003Cstrong>(b)(4)\u003C\u002Fstrong> that will ensure the purity of your Ion Gut Support, as required by 21 CFR 111.70(b)(2); and do not establish contamination specifications for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as required by 21 CFR 111.70(b)(3). \u003Cstrong>(b)(4)\u003C\u002Fstrong> is susceptible to having contaminants not limited to microorganisms and heavy metals.\u003C\u002Fp>\n\n\u003Cp>We have received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. In your response dated September 22, you state that you are establishing identity component specifications and acceptance criteria using appropriate scientifically valid methods. However, you do not present any supporting evidence for us to evaluate your correction. Your response dated October 31 provides specifications that are for microbial contamination only and does not demonstrate that the requirements of 21 CFR 111.70(b) are met. Your November 15, 2023, and April 24, 2024, responses do not address this citation.\u003C\u002Fp>\n\n\u003Cp>2. You failed to establish product specifications for the identity, strength, and composition of the finished batch of the dietary supplement, as required by 21 CFR 111.70(e). For example, your product label for ION Gut Support lists the content of Humic Extract (from Ancient Soil) in the product as 5 mg; however, you have not established a strength specification for a finished batch of product to ensure that the label claim is met. For each specification you are required to establish and must take specific actions, after they are established, to verify that the specifications are met, as required by 21 CFR 111.73 and 21 CFR 111.75. You must also ensure any tests and examinations you use to determine whether the specifications are met are appropriate, scientifically valid methods, as required by 21 CFR 111.75(h)(1), and you must make and keep records, in accordance with 21 CFR 111.95.\u003C\u002Fp>\n\n\u003Cp>We have received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. Your October 31, 2023, response provided finished product specifications for ION Gut Support (SPC-01). However, the documents you provided do not demonstrate that you have corrected the above-mentioned deficiencies. Your remaining responses did not address this issue.\u003C\u002Fp>\n\n\u003Cp>3. You failed to quarantine components before you used them in the manufacture of a dietary supplement until quality control could conduct the required review and approval of such components, as required per 21 CFR 111.155(c). Specifically, during the inspection, our investigator observed that you did not place \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used in the manufacture of your Ion Gut Support, into quarantine for evaluation and release by Quality Control prior to use. Additionally, you have no records that document you quarantined, sampled, and analyzed select components prior to their use. As an example, you received \u003Cstrong>(b)(4)\u003C\u002Fstrong> from your supplier on January 17, 2022. You did not document the quarantine, sampling, or analysis of this component. You used this component on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to manufacture \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You then used this \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the manufacturing of Ion Gut Support, 8-oz., Lot 2303301HBA, which was released into commerce.\u003C\u002Fp>\n\n\u003Cp>We received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. In your October 31, 2023, response, you state you have established a quarantine area in “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and provided a photograph. However, you did not present any records or evidence that components are being quarantined, sampled, and analyzed in accordance with your written procedure. Your remaining responses did not address this issue. Therefore, your responses fail to demonstrate the sufficiency of your corrective actions.\u003C\u002Fp>\n\n\u003Cp>4. Your batch production record failed to include all the information required under 21 CFR 111.260. Specifically, we reviewed your batch production record for Ion Gut Support and found it failed to contain the following required information:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The date and time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records, such as individual equipment logs, where this information is retained (21 CFR 111.260(c)).\u003C\u002Fli>\n\t\u003Cli>The identity and weight or measurement of water and \u003Cstrong>(b)(4)\u003C\u002Fstrong> components in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> respectively (21 CFR 111.260(e)).\u003C\u002Fli>\n\t\u003Cli>Documentation, at the time of performance, of the manufacture of the batch, including the initials of the person responsible for weighing or measuring each component used in the batch, the initials of the person responsible for verifying the weight or measure of each component used in the batch, the initials of the person responsible for adding the component to the batch, and the initials of the person responsible for verifying the addition of components to the batch (21 CFR 111.260(j)(2)).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We have received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. In your response dated October 31, 2023, you provided the MPR template for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, it does not include all elements as required in 21 CFR 111.260. Your remaining responses did not address this issue.\u003C\u002Fp>\n\n\u003Cp>5. You failed to establish and follow written procedures for calibrating instruments and controls you use in manufacturing or testing a component or dietary supplement, as required by 21 CFR 111.25(a). Specifically, you have not established written procedures for calibrating your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which you use in the manufacturing or testing of your Ion Gut Support.\u003C\u002Fp>\n\n\u003Cp>We have received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. However, none of your responses provided documentation to demonstrate that you have established and followed written procedures for calibrating your&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. Therefore, we cannot evaluate the sufficiency of your corrective actions.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Misbranding of Dietary Supplement Products\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>In addition, we reviewed your product labels collected during the inspection and have determined the Ion Gut Support dietary supplement product you manufacture and distribute is misbranded under section 403 of the Act, 21 U.S.C. 343, because it does not comply with the labeling requirements for dietary supplements. Specifically, we identified the following:\u003C\u002Fp>\n\n\u003Cp>1. Your Ion Gut Support dietary supplement products are misbranded within the meaning of Section 403(i)(2) of the Act, 21 U.S.C. 343(i)(2), in that the product labels fail to declare all the common or usual names of each ingredient used, as required by 21 CFR 101.36 and 21 CFR 101.4.\u003C\u002Fp>\n\n\u003Cp>The Supplement Facts panel of your product identifies “Humic Extract” as the active ingredient with only “Purified water” as the other ingredient. We reviewed and collected your batch production records, which document formulation, of all sizes of your Ion Gut Support product. According to your batch production records, your Ion Gut Support includes the following ingredients: \u003Cstrong>(b)(4) \u003C\u002Fstrong>purified water,\u003Cstrong> (b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Each ingredient must be declared by the common or usual name in descending order of predominance within the ingredient list unless an exemption is provided in 21 CFR 101.100, or a collective (generic) name is provided in 21 CFR 101.4.\u003C\u002Fp>\n\n\u003Cp>In your response, you state your components, other than humic extract,&nbsp;are processing aids to create the extraction. However, you provide no evidence these components are not present in the finished product. Further, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> product (which is a product that consists of: \u003Cstrong>(b)(4)\u003C\u002Fstrong> are added after the extraction process. Thus, they are not processing aids as defined under 21 CFR 101.100(a)(3)(ii). Therefore, your response is inadequate.\u003C\u002Fp>\n\n\u003Cp>2. Your Ion Gut Support products are misbranded under 403(q)(5)(F) of the Act, 21 U.S.C. 343(q)(5)(F), because the presentation of the nutrition information on the labeling of each product label does not comply with 21 CFR 101.36. For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The Supplement Facts label is not enclosed in a box by using hairlines (21 CFR 101.36(e)(2)).\u003C\u002Fli>\n\t\u003Cli>A heavy bar is not placed under the “Serving Per Container” heading (21 CFR 101.36(e)(6)(i)).\u003C\u002Fli>\n\t\u003Cli>A light bar is not placed under the heading “Amount Per Serving” (21 CFR 101.36(e)(7)).\u003C\u002Fli>\n\t\u003Cli>A heavy bar is not placed under the final other ingredient (21 CFR 101.36(e)(6)(iii)).\u003C\u002Fli>\n\t\u003Cli>The title, “Supplement Facts”, and headings are not bolded (21 CFR 101.36(e)(1)).\u003C\u002Fli>\n\t\u003Cli>There is no provision in the regulation for an Other Ingredients list to appear within the Supplement Facts label.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your response, you state you will address items within the Supplement Facts label. However, you do not present sufficient evidence to demonstrate corrections. Therefore, your response is insufficient for us to evaluate corrections.\u003C\u002Fp>\n\n\u003Cp>3. Your Ion Gut Support product is misbranded within the meaning of Section 403(q)(1)(A) of the Act, 21 U.S.C. 343(q)(1)(A), because the Supplement Facts label does not include all intended groups as noted in the label directions. If a product is for persons within more than one group, the percent of Daily Value for each group shall be presented in separate columns. Your product’s Supplement Facts labels do not clearly include all the intended groups with the serving size and nutrition information in separate columns in the Supplement Facts label, as required by 21 CFR 101.36. For example, your Frequently Asked Questions found on your website, https:\u002F\u002Fintelligenceofnature.com\u002Fpages\u002Ffrequently-asked-questions#skin, and the product’s bottle labeling provide directions for use for adults and children under 3; however, both those intended groups are not declared on your product’s Supplement Facts labels.\u003C\u002Fp>\n\n\u003Cp>In your response, you state you will change the directions of use to indicate oral use only and specify the use is for children four years and older. You do not present sufficient evidence to demonstrate corrections. Therefore, your response is inadequate.\u003C\u002Fp>\n\n\u003Cp>4. Your Ion Gut Support product appears to be misbranded within the meaning of Section 403(s)(2)(B) of the Act, 21 U.S.C 343(s)(2)(B), in that the statement of identity provided on the principal display panel is “mineral supplement”, but there is no mineral declared as a dietary ingredient, in accordance with 21 CFR 101.3(g).\u003C\u002Fp>\n\n\u003Cp>In your response dated September 22, 2023, you state you will update your labeling by March 31, 2024. However, you did not present sufficient evidence to demonstrate corrections. Therefore, we cannot evaluate the sufficiency of your corrective actions.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of the receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and time within which you will do so. If you believe that your products are not in violation of the Act, include reasoning and any supportive information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written reply should be directed to Compliance Officer Andrew J. Howard at U.S. Food and Drug Administration, 11155 Dolfield Boulevard, Suite 117, Owings Mills, MD 21117. An emailed response is also acceptable. Files greater than 100 megabytes may be submitted as smaller files in separate emails. If you have any questions regarding this letter, please contact Andrew J. Howard by telephone, at (410) 779-5125, or by email, at Andrew.Howard@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Robin M. Rivers\u003Cbr>\nActing Program Division Director\u003Cbr>\nPhiladephia District Office\u003Cbr>\nHuman &amp; Animal Food East, Division 2\u003Cbr>\nOffice of Regulatory Affairs\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nRobin.Rivers@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>___________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nDr. Zachary Bush\n\nRecipient Title\n\nOwner\n\nBiomic Sciences, LLC dba ION Intelligence of Nature\n\n4351 Seminole Trail\n\nCharlottesville, VA 22153-2823\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East II\n\nUnited States\n\nMay 9, 2024\n\nWARNING LETTER\n\nCMS #667601\n\nDear Dr. Bush,\n\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 4351 Seminole Trail, Charlottesville, Virginia from June 12 through August 31, 2023. Based on inspectional findings and review of the product labels collected during the inspection, as well as review of your website at www.Intelligenceofnature.com, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nAt the conclusion of the inspection on August 31, 2023, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. We address your responses below, when relevant information from such response(s) pertained to a particular issue.\n\nAdulterated Human Drugs\n\nFDA Tested Samples\n\nFDA conducted laboratory testing of a lot of ION Intelligence of Nature Sinus Support Nasal Spray drug product and results demonstrate that this drug product is adulterated within the meaning of section 501(a)(1) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. 351(a)(1), in that it consists in whole or in part of any filthy, putrid, or decomposed substance.\n\nFDA laboratory analysis determined that a sample of your ION Intelligence of Nature Sinus Support Nasal Spray drug product was grossly contaminated with microorganisms. This gross contamination is particularly concerning because your drug product is a nasal spray.\n\nFDA laboratory testing of ION Intelligence of Nature Sinus Support Nasal Spray drug product lot 2302081HGA found gross microbial contamination. The individual sample results varied between 510,000 and up to 1,100,000 colony forming units (CFU)\u002FmL for total aerobic microbial count and between 290 and up to 1,100 CFU\u002FmL for total yeast and mold counts. Therefore, this drug product is adulterated under section 501(a)(1) of the Act.\n\nMicroorganisms identified included Microbacterium sp., Fictibacillus sp., Bacillus sp. (primarily B. malikii), and Paenibacillus sp. The high bioburden in conjunction with the route of administration with this drug product poses a high risk of harm to vulnerable patients.\n\nOn September 22, 2023, the FDA held a teleconference with you. During the teleconference, you agreed to conduct a voluntary recall of all lots of ION Intelligence of Nature Sinus Support Nasal Spray.\n\nOn September 29, 2023, you voluntarily recalled all lots of ION Intelligence of Nature Sinus Support Nasal Spray, ION Sinus, and Restore Sinus Spray products to the consumer level due to microbial contamination identified as Microbacterium sp., Fictibacillus sp., Bacillus sp. (primarily B. malikii), and Paenibacillus sp., as noted on the following FDA website:\n\nhttps:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fbiomic-sciences-issues-voluntary-nationwide-recall-ion-sinus-support-ion-sinus-and-restore-sinus\n\nDrug CGMP Violations\n\nThe inspection of your facility from June 12 through August 31, 2023, identified significant violations of FDA’s regulations for Current Good Manufacturing Practice (CGMP) for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Act, 21 U.S.C. 351(a)(2)(B).\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(b)).\n\nYour firm released finished drug product without adequate testing for critical microbial attributes (i.e., testing to ensure absence of objectionable microorganisms). Without appropriate testing of each lot of drug product required to be free of objectionable microorganisms prior to release, you did not have scientific evidence that the lots were free of microbial contamination that is objectionable in view of its intended use. Particularly for a drug product that is intended for use as a nasal spray, it is essential that your drug products are tested for microbial contamination to minimize the risk of patient exposure to significant numbers or harmful species of microorganisms, harmful microbial metabolites and\u002For toxins, and drug spoilage or degradation.\n\nYou also stated during the inspection that you add (b)(4) to numerous drug product formulations to control microbial growth. Preservatives are not a substitute for a comprehensive approach to preventing objectionable microorganisms from contaminating your drug product and cannot be relied on to reduce in-process bioburden during manufacturing. Additionally, long term use of medicinal compounds containing (b)(4) may (b)(4). Levels of (b)(4) exposure that have led to (b)(4) documented and therefore, it is not possible to establish minimum levels that are safe.\n\nIn your September 22, 2023, response, you state that you stopped producing and discontinued sales of the current formulation of ION Intelligence of Nature Sinus Support but plan to market a nasal product in the future. You state that you are revising your written procedures for quality unit (QU) responsibilities, including to specifically establish adequate testing of your finished product and water used in production of your products. You also state that you are revising procedures to ensure all applicable tests impacting the identity, strength, quality, and purity of your products are established and performed.\n\nIn response to this letter, clarify whether you plan to resume manufacturing drug products at this facility in the future for marketing in the United States. We request that you notify this office before you market such drug products.\n\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour firm failed to establish an adequate QU with responsibilities to ensure adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure:\n\nAdequate procedures that are designed to prevent objectionable microbiological contamination of drug products (21 CFR 211.113(a)).\n\nAdequate testing of components with potential for microbiological contamination that is objectionable in view of its intended use (21 CFR 211.84(d)(6)).\n\nProcedures are followed to adequately establish, review, and approve master manufacturing records prior to use (21 CFR 211.100(a)).\n\nAdequate batch records to document the mixing and packaging of your drug product (21 CFR 211.188).\n\nEstablishment of an adequate stability program to support expiration dating of your drug products (including microbiological attributes) (21 CFR 211.166(a)).\n\nAdequate documentation for QU review and release of drug product. (21 CFR 211.22(a)).\n\nAdditionally, your QU was unaware of the identity of numerous proprietary components used to manufacture many of your drug products, and therefore could not have fulfilled their QU responsibilities to ensure all components meet established specifications for identity, strength, quality, and purity.\n\nYour firm’s quality systems are inadequate. You may refer to FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system1 audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nAdulterated & Misbranded Dietary Supplements\n\nAdulterated Low Acid Canned Food Dietary Supplements\n\nThe inspection of your facility on June 12 through August 31, 2023, identified serious violations of the Emergency Permit Control regulation Title 21, Code of Federal Regulations (CFR), Part 108 (21 CFR Part 108) and the Thermally Processed Low-Acid Foods Packaged in Hermetically Sealed Containers regulation (21 CFR Part 113). These violations cause your products to be adulterated within the meaning of section 402(a)(4) of the Act, 21 U.S.C. 342(a)(4), in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health.\n\nAs a manufacturer of low acid canned food products, you are required to comply with the Act and the Federal regulations relating to the processing of low-acid foods packaged in hermetically sealed containers. The Emergency Permit Control regulations were issued, in part, pursuant to section 404 of the Act, Emergency Permit Control, 21 U.S.C. 344. A temporary emergency permit may be required for thermally processed low-acid foods packaged in hermetically sealed containers whenever a processor has failed to fulfill the requirements of 21 CFR 108.35, including registration and filing of process information, and the mandatory requirements in 21 CFR Parts 113. Regulations specific to the processing of LACF products are described in 21 CFR 108 and 21 CFR 113.\n\n1. You did not register with the FDA as a commercial processor of low-acid foods. A commercial processor of low-acid foods is required, not later than 10 days after first engaging in the manufacture, processing, and packaging of thermally processed low-acid foods in hermetically sealed containers in any state, as defined in section 201(a)(1) of the Act, to register and file a Form FDA 2541 (food canning establishment registration) with the FDA, as required by 21 CFR 108.35(c)(1). However, your firm processes Ion Gut Support, a low-acid food, without registering with the FDA.\n\n2. You must file the scheduled processes with the FDA for each low-acid food in each container size as required by 21 CFR 108.35(c)(2). This filing must occur not later than 60 days after registration and prior to the packing of a new product and include the processing method, type of retort or other thermal processing equipment employed, minimum initial temperatures, times and temperatures of processing, sterilizing value, or other equivalent scientific evidence of process adequacy, critical control factors affecting heat penetration, and source and date of the establishment of the process, for each product in each container size. Specifically, as noted during the inspection, your firm did not file a scheduled process with FDA for your Ion Gut Support product. Further, a scheduled process shall be established by a qualified person who has expert knowledge acquired through appropriate training and experience in the acidification and processing of, as required by 21 CFR 113.83\n\nYour response indicates that you have initiated contact with a process authority, (b)(4). We acknowledge that you have initiated actions. However, this violation remains uncorrected.\n\nScheduled process information for low-acid foods processed by retort must be submitted on Form FDA 2541d (Food Process Filing for Low-Acid Retorted Method) and low-acid foods controlled by water activity must be submitted on Form FDA 2541f (Food Process Filing for Water Activity\u002FFormulation Control Method). More information on registration and filing can be found in the publication “Guidance for Industry: Submitting Form FDA 2541 (Food Canning Establishment Registration) and Forms FDA 2541d, FDA 2541e, FDA 2541f, and FDA 2541g (Food Process Filing Forms) to FDA in Electronic or Paper Format” available at http:\u002F\u002Fwww.fda.gov\u002Ffood\u002Fguidanceregulation\u002Fguidancedocumentsregulatoryinformation\u002Fucm309376.htm.\n\nViolations of Dietary Supplement CGMPs\n\nThe inspection of your facility from June 12 through August 31, 2023, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause your Ion Gut Support dietary supplement to be adulterated within the meaning of section 402(g)(1) of the Act, 21 U.S.C. 342(g)(1), because it has been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\n\nYour significant violations of dietary supplement CGMP requirements are as follows:\n\n1. You failed to establish identity specifications for each component you use in the manufacture of a dietary supplement, as required by 21 CFR 111.70(b)(1); component specifications that are necessary to ensure that specifications for the purity, strength, and composition of dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2); and limits on those types of contamination that may adulterate, or that may lead to adulteration, of the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(b)(3).\n\nFor your components, you purport to use your Biomic Sciences Component Specification sheets as your specifications for raw components (b)(4), used in the manufacture of your Ion Gut Support. However, these specification sheets do not include identity specifications for any of these components, as required by 21 CFR 111.70(b)(1); do not establish component specifications for (b)(4) or components (b)(4) that will ensure the purity of your Ion Gut Support, as required by 21 CFR 111.70(b)(2); and do not establish contamination specifications for (b)(4), as required by 21 CFR 111.70(b)(3). (b)(4) is susceptible to having contaminants not limited to microorganisms and heavy metals.\n\nWe have received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. In your response dated September 22, you state that you are establishing identity component specifications and acceptance criteria using appropriate scientifically valid methods. However, you do not present any supporting evidence for us to evaluate your correction. Your response dated October 31 provides specifications that are for microbial contamination only and does not demonstrate that the requirements of 21 CFR 111.70(b) are met. Your November 15, 2023, and April 24, 2024, responses do not address this citation.\n\n2. You failed to establish product specifications for the identity, strength, and composition of the finished batch of the dietary supplement, as required by 21 CFR 111.70(e). For example, your product label for ION Gut Support lists the content of Humic Extract (from Ancient Soil) in the product as 5 mg; however, you have not established a strength specification for a finished batch of product to ensure that the label claim is met. For each specification you are required to establish and must take specific actions, after they are established, to verify that the specifications are met, as required by 21 CFR 111.73 and 21 CFR 111.75. You must also ensure any tests and examinations you use to determine whether the specifications are met are appropriate, scientifically valid methods, as required by 21 CFR 111.75(h)(1), and you must make and keep records, in accordance with 21 CFR 111.95.\n\nWe have received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. Your October 31, 2023, response provided finished product specifications for ION Gut Support (SPC-01). However, the documents you provided do not demonstrate that you have corrected the above-mentioned deficiencies. Your remaining responses did not address this issue.\n\n3. You failed to quarantine components before you used them in the manufacture of a dietary supplement until quality control could conduct the required review and approval of such components, as required per 21 CFR 111.155(c). Specifically, during the inspection, our investigator observed that you did not place (b)(4) or (b)(4), used in the manufacture of your Ion Gut Support, into quarantine for evaluation and release by Quality Control prior to use. Additionally, you have no records that document you quarantined, sampled, and analyzed select components prior to their use. As an example, you received (b)(4) from your supplier on January 17, 2022. You did not document the quarantine, sampling, or analysis of this component. You used this component on (b)(4), to manufacture (b)(4). You then used this (b)(4) in the manufacturing of Ion Gut Support, 8-oz., Lot 2303301HBA, which was released into commerce.\n\nWe received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. In your October 31, 2023, response, you state you have established a quarantine area in “(b)(4)” and provided a photograph. However, you did not present any records or evidence that components are being quarantined, sampled, and analyzed in accordance with your written procedure. Your remaining responses did not address this issue. Therefore, your responses fail to demonstrate the sufficiency of your corrective actions.\n\n4. Your batch production record failed to include all the information required under 21 CFR 111.260. Specifically, we reviewed your batch production record for Ion Gut Support and found it failed to contain the following required information:\n\nThe date and time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records, such as individual equipment logs, where this information is retained (21 CFR 111.260(c)).\n\nThe identity and weight or measurement of water and (b)(4) components in the (b)(4) and (b)(4) respectively (21 CFR 111.260(e)).\n\nDocumentation, at the time of performance, of the manufacture of the batch, including the initials of the person responsible for weighing or measuring each component used in the batch, the initials of the person responsible for verifying the weight or measure of each component used in the batch, the initials of the person responsible for adding the component to the batch, and the initials of the person responsible for verifying the addition of components to the batch (21 CFR 111.260(j)(2)).\n\nWe have received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. In your response dated October 31, 2023, you provided the MPR template for (b)(4). However, it does not include all elements as required in 21 CFR 111.260. Your remaining responses did not address this issue.\n\n5. You failed to establish and follow written procedures for calibrating instruments and controls you use in manufacturing or testing a component or dietary supplement, as required by 21 CFR 111.25(a). Specifically, you have not established written procedures for calibrating your (b)(4), which you use in the manufacturing or testing of your Ion Gut Support.\n\nWe have received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. However, none of your responses provided documentation to demonstrate that you have established and followed written procedures for calibrating your (b)(4). Therefore, we cannot evaluate the sufficiency of your corrective actions.\n\nMisbranding of Dietary Supplement Products\n\nIn addition, we reviewed your product labels collected during the inspection and have determined the Ion Gut Support dietary supplement product you manufacture and distribute is misbranded under section 403 of the Act, 21 U.S.C. 343, because it does not comply with the labeling requirements for dietary supplements. Specifically, we identified the following:\n\n1. Your Ion Gut Support dietary supplement products are misbranded within the meaning of Section 403(i)(2) of the Act, 21 U.S.C. 343(i)(2), in that the product labels fail to declare all the common or usual names of each ingredient used, as required by 21 CFR 101.36 and 21 CFR 101.4.\n\nThe Supplement Facts panel of your product identifies “Humic Extract” as the active ingredient with only “Purified water” as the other ingredient. We reviewed and collected your batch production records, which document formulation, of all sizes of your Ion Gut Support product. According to your batch production records, your Ion Gut Support includes the following ingredients: (b)(4) purified water, (b)(4).\n\nEach ingredient must be declared by the common or usual name in descending order of predominance within the ingredient list unless an exemption is provided in 21 CFR 101.100, or a collective (generic) name is provided in 21 CFR 101.4.\n\nIn your response, you state your components, other than humic extract, are processing aids to create the extraction. However, you provide no evidence these components are not present in the finished product. Further, the (b)(4) product (which is a product that consists of: (b)(4) are added after the extraction process. Thus, they are not processing aids as defined under 21 CFR 101.100(a)(3)(ii). Therefore, your response is inadequate.\n\n2. Your Ion Gut Support products are misbranded under 403(q)(5)(F) of the Act, 21 U.S.C. 343(q)(5)(F), because the presentation of the nutrition information on the labeling of each product label does not comply with 21 CFR 101.36. For example:\n\nThe Supplement Facts label is not enclosed in a box by using hairlines (21 CFR 101.36(e)(2)).\n\nA heavy bar is not placed under the “Serving Per Container” heading (21 CFR 101.36(e)(6)(i)).\n\nA light bar is not placed under the heading “Amount Per Serving” (21 CFR 101.36(e)(7)).\n\nA heavy bar is not placed under the final other ingredient (21 CFR 101.36(e)(6)(iii)).\n\nThe title, “Supplement Facts”, and headings are not bolded (21 CFR 101.36(e)(1)).\n\nThere is no provision in the regulation for an Other Ingredients list to appear within the Supplement Facts label.\n\nIn your response, you state you will address items within the Supplement Facts label. However, you do not present sufficient evidence to demonstrate corrections. Therefore, your response is insufficient for us to evaluate corrections.\n\n3. Your Ion Gut Support product is misbranded within the meaning of Section 403(q)(1)(A) of the Act, 21 U.S.C. 343(q)(1)(A), because the Supplement Facts label does not include all intended groups as noted in the label directions. If a product is for persons within more than one group, the percent of Daily Value for each group shall be presented in separate columns. Your product’s Supplement Facts labels do not clearly include all the intended groups with the serving size and nutrition information in separate columns in the Supplement Facts label, as required by 21 CFR 101.36. For example, your Frequently Asked Questions found on your website, https:\u002F\u002Fintelligenceofnature.com\u002Fpages\u002Ffrequently-asked-questions#skin, and the product’s bottle labeling provide directions for use for adults and children under 3; however, both those intended groups are not declared on your product’s Supplement Facts labels.\n\nIn your response, you state you will change the directions of use to indicate oral use only and specify the use is for children four years and older. You do not present sufficient evidence to demonstrate corrections. Therefore, your response is inadequate.\n\n4. Your Ion Gut Support product appears to be misbranded within the meaning of Section 403(s)(2)(B) of the Act, 21 U.S.C 343(s)(2)(B), in that the statement of identity provided on the principal display panel is “mineral supplement”, but there is no mineral declared as a dietary ingredient, in accordance with 21 CFR 101.3(g).\n\nIn your response dated September 22, 2023, you state you will update your labeling by March 31, 2024. However, you did not present sufficient evidence to demonstrate corrections. Therefore, we cannot evaluate the sufficiency of your corrective actions.\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of the receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and time within which you will do so. If you believe that your products are not in violation of the Act, include reasoning and any supportive information for our consideration.\n\nYour written reply should be directed to Compliance Officer Andrew J. Howard at U.S. Food and Drug Administration, 11155 Dolfield Boulevard, Suite 117, Owings Mills, MD 21117. An emailed response is also acceptable. Files greater than 100 megabytes may be submitted as smaller files in separate emails. If you have any questions regarding this letter, please contact Andrew J. Howard by telephone, at (410) 779-5125, or by email, at Andrew.Howard@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nRobin M. Rivers\n\nActing Program Division Director\n\nPhiladephia District Office\n\nHuman & Animal Food East, Division 2\n\nOffice of Regulatory Affairs\n\nU.S. Food and Drug Administration\n\nRobin.Rivers@fda.hhs.gov\n\n___________________\n\n1 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Biomic Sciences, LLC dba ION Intelligence of Nature","biomic-sciences-llc-dba-ion-intelligence-nature-667601-05092024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiomic-sciences-llc-dba-ion-intelligence-nature-667601-05092024","2026-10-26T08:08:05.177812+00:00","2024-05-28","667601","Dr. Zachary Bush","2026-08-20T00:03:55.93+00:00","VIA UPS","2024-05-09",{"id":276,"raw":277,"subject":282,"body_html":283,"body_text":284,"firm_name":285,"letter_id":286,"created_at":43,"fei_number":19,"letter_url":287,"updated_at":288,"action_type":22,"case_status":23,"posted_date":289,"marcs_cms_no":290,"product_type":291,"closeout_date":19,"issuing_office":281,"recipient_name":19,"body_fetched_at":292,"delivery_method":293,"recipient_title":19,"reference_number":19,"action_taken_date":294,"medical_device_id":19,"response_letter_date":19},1649,[278,279,280,281,282,13,13,13],"\u003Ctime datetime=\"2024-01-23T14:20:00Z\">01\u002F23\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-12-08T05:00:00Z\">12\u002F08\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchina-first-union-dba-beco-vape-673286-12082023\">China First Union d\u002Fb\u002Fa Beco Vape\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA USPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>China First Union d\u002Fb\u002Fa Beco Vape\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1420 Fifth Avenue, Suite 4200\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Seattle\u003C\u002Fspan>, \u003Cspan>WA\u003C\u002Fspan> \u003Cspan>98101-2375\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@becovape.com\"> info@becovape.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 8, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.becovape.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and are intended for human consumption. Certain tobacco products, including ENDS, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1 and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see, https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fwww.becovape.com revealed that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order, including: Beco Pro Disposable Vape 6000 Puff, Blue Razz; Beco Pro Disposable Vape 6000 Puff, Mango Ice; and Beco Pro Disposable Vape 6000 Puff, Rainbow.\u003C\u002Fp>\n\n\u003Cp>The ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has not received an application requesting marketing authorization for the products listed in this Warning Letter. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW 2302072, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002Fs\u002F\u003Cbr>\nAnn Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS, USPS, and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Vaptio, Inc.\u003Cbr>\n2025 First Avenue, Penthouse A\u003Cbr>\nSeattle, WA 98121-3215\u003Cbr>\ninfo@vaptio.com\u003Cbr>\nbear@vaptio.com\u003Cbr>\nrose.wang@vaptio.com\u003C\u002Fp>\n\n\u003Cp>LPSL Corporate Services\u003Cbr>\n1420 5th Ave Ste 4200\u003Cbr>\nSeattle, WA 98101-2375\u003C\u002Fp>\n\n\u003Cp>China First union\u003Cbr>\nAttn: Damien Bove\u003Cbr>\nAdact Medical US LLC\u003Cbr>\n848 Brickell Avenue, Penthouse 5\u003Cbr>\nMiami, FL 33131\u003Cbr>\nsales@adactmedicalus.com\u003C\u002Fp>\n\n\u003Cp>Shenzhen First Union Technology Co., Ltd.\u003Cbr>\nmarketing@chinafirstunion.com\u003Cbr>\nsales@chinafirstunion.com\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc.\u003Cbr>\nabuse@shopify.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA USPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nChina First Union d\u002Fb\u002Fa Beco Vape\n\n1420 Fifth Avenue, Suite 4200\n\nSeattle, WA 98101-2375\n\nUnited States\n\ninfo@becovape.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nDecember 8, 2023\n\nWARNING LETTER\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.becovape.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and are intended for human consumption. Certain tobacco products, including ENDS, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1 and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see, https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fwww.becovape.com revealed that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order, including: Beco Pro Disposable Vape 6000 Puff, Blue Razz; Beco Pro Disposable Vape 6000 Puff, Mango Ice; and Beco Pro Disposable Vape 6000 Puff, Rainbow.\n\nThe ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nFDA has not received an application requesting marketing authorization for the products listed in this Warning Letter. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nIt is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW 2302072, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002Fs\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS, USPS, and Electronic Mail\n\ncc:\n\nVaptio, Inc.\n\n2025 First Avenue, Penthouse A\n\nSeattle, WA 98121-3215\n\ninfo@vaptio.com\n\nbear@vaptio.com\n\nrose.wang@vaptio.com\n\nLPSL Corporate Services\n\n1420 5th Ave Ste 4200\n\nSeattle, WA 98101-2375\n\nChina First union\n\nAttn: Damien Bove\n\nAdact Medical US LLC\n\n848 Brickell Avenue, Penthouse 5\n\nMiami, FL 33131\n\nsales@adactmedicalus.com\n\nShenzhen First Union Technology Co., Ltd.\n\nmarketing@chinafirstunion.com\n\nsales@chinafirstunion.com\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nShopify, Inc.\n\nabuse@shopify.com","China First Union d\u002Fb\u002Fa Beco Vape","china-first-union-dba-beco-vape-673286-12082023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchina-first-union-dba-beco-vape-673286-12082023","2026-10-26T08:08:14.792935+00:00","2024-01-23","673286","Tobacco","2026-08-20T00:22:01.509+00:00","VIA USPS and Electronic Mail","2023-12-08",{"id":296,"raw":297,"subject":282,"body_html":301,"body_text":302,"firm_name":303,"letter_id":304,"created_at":229,"fei_number":19,"letter_url":305,"updated_at":306,"action_type":22,"case_status":23,"posted_date":307,"marcs_cms_no":308,"product_type":291,"closeout_date":19,"issuing_office":281,"recipient_name":19,"body_fetched_at":309,"delivery_method":310,"recipient_title":19,"reference_number":19,"action_taken_date":307,"medical_device_id":19,"response_letter_date":19},3450,[298,299,300,281,282,13,13,13],"\u003Ctime datetime=\"2021-03-19T13:46:00Z\">03\u002F19\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-19T04:00:00Z\">03\u002F19\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvapor-outlet-inc-dba-union-hills-vape-shop-613760-03192021\">Vapor Outlet Inc d\u002Fb\u002Fa Union Hills Vape Shop\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Vapor Outlet Inc d\u002Fb\u002Fa Union Hills Vape Shop\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1905 West Union Hills Drive, Suite B.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Phoenix\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85027-5230\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:UHVAPE@gmail.com\"> UHVAPE@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Choukeir:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Little Town Vaping d\u002Fb\u002Fa Swamp Vapor New Iberia manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have premarket authorization. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States UH Vape CTCM 120ml 3mg e-liquid product without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)) Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with 864 products listed with FDA. It is your responsibility to ensure that your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to adequately address this matter may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your corrective actions, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2100095, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Lillian Ortega at \u003Cspan>(240) 402-9041\u003Ca>\u003C\u002Fa>\u003C\u002Fspan> or Lillian.Ortega@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nVapor Outlet Inc d\u002Fb\u002Fa Union Hills Vape Shop\n\n1905 West Union Hills Drive, Suite B.\n\nPhoenix, AZ 85027-5230\n\nUnited States\n\nUHVAPE@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nWARNING LETTER\n\nDear Mr. Choukeir:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Little Town Vaping d\u002Fb\u002Fa Swamp Vapor New Iberia manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have premarket authorization. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States UH Vape CTCM 120ml 3mg e-liquid product without a marketing authorization order.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)) Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with 864 products listed with FDA. It is your responsibility to ensure that your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to adequately address this matter may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your corrective actions, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2100095, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Lillian Ortega at (240) 402-9041 or Lillian.Ortega@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Vapor Outlet Inc d\u002Fb\u002Fa Union Hills Vape Shop","vapor-outlet-inc-dba-union-hills-vape-shop-613760-03192021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvapor-outlet-inc-dba-union-hills-vape-shop-613760-03192021","2026-10-26T08:10:24.699935+00:00","2021-03-19","613760","2026-08-20T03:16:03.914+00:00","VIA UPS and Electronic Mail",{"id":312,"raw":313,"subject":282,"body_html":317,"body_text":318,"firm_name":319,"letter_id":320,"created_at":150,"fei_number":19,"letter_url":321,"updated_at":322,"action_type":22,"case_status":23,"posted_date":323,"marcs_cms_no":324,"product_type":291,"closeout_date":19,"issuing_office":281,"recipient_name":19,"body_fetched_at":325,"delivery_method":310,"recipient_title":19,"reference_number":326,"action_taken_date":327,"medical_device_id":19,"response_letter_date":19},1091,[314,315,316,281,282,13,13,13],"\u003Ctime datetime=\"2025-01-15T05:00:00Z\">01\u002F15\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-01-08T05:00:00Z\">01\u002F08\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmidwest-goods-inc-dba-midwest-distribution-and-midwest-distribution-illinois-696454-01082025\">Midwest Goods Inc., d\u002Fb\u002Fa Midwest Distribution and Midwest Distribution Illinois\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2401093\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Midwest Goods Inc., d\u002Fb\u002Fa Midwest Distribution and Midwest Distribution Illinois\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1001 Foster Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bensenville\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60106\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 08, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Midwest Goods Inc., d\u002Fb\u002Fa Midwest Distribution and Midwest Distribution Illinois sells and\u002For distributes e-liquid products to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\">https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States the following e-liquid products that lack a marketing authorization order: MR FOG BUBBLE GANG BLUE RASPBERRY 100mL 12mg\u002FmL.\u003C\u002Fp>\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of products that received marketing granted orders, please visit our website: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\">https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, ER2401093, in your response and direct your response to the following address:\u003C\u002Fp>\u003Cp>DEM-WL Response, Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;&nbsp;\u003Cbr>10903 New Hampshire Avenue&nbsp;&nbsp;\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nER2401093\n\nProduct:\n\nTobacco\n\nRecipient:\n\nMidwest Goods Inc., d\u002Fb\u002Fa Midwest Distribution and Midwest Distribution Illinois\n\n1001 Foster Avenue\n\nBensenville, IL 60106\n\nUnited States\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nJanuary 08, 2025\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Midwest Goods Inc., d\u002Fb\u002Fa Midwest Distribution and Midwest Distribution Illinois sells and\u002For distributes e-liquid products to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you offer for sale or distribution to customers in the United States the following e-liquid products that lack a marketing authorization order: MR FOG BUBBLE GANG BLUE RASPBERRY 100mL 12mg\u002FmL.\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act.\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, ER2401093, in your response and direct your response to the following address:\nDEM-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products","Midwest Goods Inc., d\u002Fb\u002Fa Midwest Distribution and Midwest Distribution Illinois","midwest-goods-inc-dba-midwest-distribution-and-midwest-distribution-illinois-696454-01082025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmidwest-goods-inc-dba-midwest-distribution-and-midwest-distribution-illinois-696454-01082025","2026-10-26T08:09:25.415485+00:00","2025-01-15","696454","2026-08-19T17:04:31.508+00:00","ER2401093","2025-01-08",16,{"510k":330,"classification":331,"enforcement":332,"event":333,"event_backfill":334,"pma":335,"warning_letter":336},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]